felodipine has been researched along with Blood Pressure, High in 420 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to analyze the effect of felodipine combined with enalapril in the treatment of patients with essential hypertension and coronary artery disease." | 9.51 | Efficacy of felodipine and enalapril in the treatment of essential hypertension with coronary artery disease and the effect on levels of Salusin-β, Apelin, and PON1 gene expression in patients. ( Jin, F; Zhang, J; Zhang, W; Zhou, H, 2022) |
| "Lercanidipine hydrochloride and felodipine sustained-release tablets comparison for the treatment of patients with mild-to-moderate primary hypertension." | 9.20 | Lercanidipine hydrochloride versus felodipine sustained-release for mild-to-moderate hypertension: a multi-center, randomized clinical trial. ( Dai, Q; Gong, J; Jin, H; Lu, X; Peng, J; Wang, B; Wang, H; Wu, Y; Xu, M; Xu, X; Yan, J; Zhang, M; Zhao, S, 2015) |
| "To assess the efficacy and safety of aranidipine versus retard-released felodipine in Chinese patients with mild-to-moderate essential hypertension." | 9.17 | [Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension]. ( Chen, L; Jiao, Y; Jin, H; Ke, YN; Li, DY; Liu, MX; Wang, BY; Wang, L; Wang, Y; Yang, HY; Zhao, XL; Zheng, JT, 2013) |
| "org: NCT01238705) in 160 women (18-60 years) with mild or moderate hypertension, randomized to a once-daily treatment with felodipine combined with irbesartan or metoprolol for 48 weeks." | 9.16 | Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. ( Bai, F; Lin, X; Ma, R; Xu, D; Yang, L; Yu, J; Zhao, F, 2012) |
| "To evaluate the impact of age on the pharmacokinetics and blood pressure (BP) responses of a dihydropyridine (DHP) with large versus small first-pass metabolism in hypertensive subjects, younger (n = 28) and older (n = 35) patients with hypertension were randomized to placebo, felodipine-ER 5 mg/d, or amlodipine 5 mg/d." | 9.14 | Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension. ( Coletta, E; Leenen, FH, 2010) |
| "This multicenter, open-label, single-arm trial assessed the efficacy of the combination of amlodipine 10 mg and valsartan 160 mg to provide additional blood pressure reduction and tolerability in patients with moderate hypertension not adequately responding to the combination of ramipril 5 mg and felodipine 5 mg." | 9.13 | Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination. ( Borbas, E; Handrock, R; Klebs, S; Schaetzl, R; Trenkwalder, P, 2008) |
| "To evaluate the efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination each with Metoprolol, Lisinopril or Hydrochlorothiazide in the 12 weeks treatment of mild to moderate essential hypertension in China." | 9.12 | [Efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination therapy in the treatment of mild to moderate essential hypertension in China]. ( Chen, YY; Liu, HL; Shen, FR; Sun, NL; Tao, J; Wu, HY; Xiang, XP; Yu, ZQ; Zhang, FC; Zhang, L; Zhang, WZ; Zhao, JA, 2007) |
| "To compare efficacy and tolerability of felodipine based antihypertensive therapy with those of standard hospital treatment of hypertension." | 9.11 | [Efficacy and tolerability of felodipine based antihypertensive therapy in hospitalized patients with hypertension]. ( Bagmanova, NKh; Kobalava, ZhD; Kotovskaia, IuV; Mil'to, AS; Plavunov, NF; Riabova, AV, 2004) |
| "Aim of this study was to compare the effect of valsartan and felodipine on blood pressure (BP), plasma leptin (L), insulin sensitivity and plasma norepinephrine (NE) in obese hypertensive patients." | 9.11 | Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2005) |
| "To assess, by smoothness index (SI), distribution of the antihypertensive effect of extended-release (ER) felodipine over 24 hours in elderly patients with hypertension." | 9.10 | Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. ( Ansuini, R; Antonicelli, R; Gesuita, R; Giovanni, DC; Mori, A; Omboni, S; Paciaroni, E; Parati, G, 2002) |
| "In this multicentre, double-blind, parallel-group study, 120 out-patients with mild to moderate primary hypertension were randomised, after a 4-week single-blind placebo run-in period, to a combination tablet of felodipine-metoprolol 5/50 mg (Logimax, Mobloc, Astra) once daily or enalapril 10 mg once daily." | 9.09 | Improved efficacy with maintained tolerability in the treatment of primary hypertension. Comparison between the felodipine-metoprolol combination tablet and monotherapy with enalapril. Swedish Multicentre Group. ( Andersson, OK, 1999) |
| "Sitting blood pressures (BP), heart rate, body weight, adverse reactions, and serum biochemistry were assessed in 70 patients with isolated systolic hypertension (34 treated with felodipine ER and 36 slow-release diltiazem [diltiazem SR] for 10 weeks)." | 9.09 | Comparison of clinical efficacy and adverse effects between extended-release felodipine and slow-release diltiazem in patients with isolated systolic hypertension. ( Chern, MS; Lin, FC; Wu, D, 1999) |
| "Out of 245 randomized outpatients (90 men, 155 women) with uncomplicated mild-to-moderate primary hypertension and mean sitting diastolic blood pressure (DBP) 95-115 mmHg inclusive, 212 (102 on felodipine-metoprolol, 110 on amlodipine) were eligible for analysis." | 9.09 | Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension. Lorraine General Physician Investigators Group. ( Boivin, JM; Zannad, F, 1999) |
| "This 12-week, open-label, multicenter study assessed the efficacy and safety of losartan/hydrochlorothiazide (HCTZ), alone or in combination with other antihypertensive agents, in the treatment of patients with severe systemic hypertension." | 9.09 | Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. ( Aurup, P; Goldberg, A; Oparil, S; Snavely, D, 2001) |
| " To compare the effects of active treatment compared with placebo on blood pressure, left ventricular hypertrophy, and quality of life among older stage 1 isolated systolic hypertensive patients, a randomized, double-blind, parallel-group, multicenter clinical trial comparing felodipine (2." | 9.09 | One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. ( Black, HR; DeQuattro, V; Elliott, WJ; Frishman, WH; Hwang, CT; Klibaner, MI; Liebson, PR; Montoro, R; Ruff, DA; Schleman, MM; Strom, JA; Weber, MA; Zhang, D, 2001) |
| "The anti-hypertensive efficacy and safety of extended-release (ER) felodipine (5, 10 or 20 mg) and amlodipine (5 or 10 mg) once daily were compared in patients with mild to moderate essential hypertension in a double-blind, double-dummy, randomised, comparative study." | 9.08 | Comparative effects of amlodipine and felodipine ER on office and ambulatory blood pressure in patients with mild to moderate hypertension. Danish Multicentre Group. ( Høegholm, A; Nielsen, PE; Rasmussen, E; Wiinberg, N, 1995) |
| " The medication of 39 patients with hypertension was changed from once-daily diltiazem hydrochloride (Cardizem CD) or nifedipine (Procardia XL) to felodipine (Plendil)." | 9.08 | Felodipine as an alternative to more expensive calcium antagonists in mild to moderate hypertension. ( Horwhat, JD; Landry, FJ; Pinski, L; Tomich, D, 1996) |
| "The aim of the study was to evaluate the efficacy over 1 year of of felodipine ER 5 and 10 mg once daily (od) in 12 Caucasian patients with left ventricular hypertrophy secondary to primary hypertension." | 9.08 | The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension. ( Boydak, B; Killiçcioglu, B; Nalbantgil, I; Onder, R; Terzioglu, E; Yilmaz, H, 1996) |
| "To compare the efficacy and tolerance of felodipine-ER and nifedipine OROS, both once daily, in the treatment of mild-to-moderate uncomplicated arterial hypertension (AH)." | 9.08 | [Multicenter comparative study of felodipine-ER and nifedipine-OROS in the treatment of mild-to-moderate arterial hypertension]. ( Armaganijan, D; Batlouni, M; Castro, I; Chaves Junior, Hde C; Leite Luna, R; Nobre, F; Pereira da Cunha, C; Silveira Sbissa, A, 1996) |
| "Both felodipine ER and nifedipine Retard are effective "add-on' drugs in patients with monotherapy-resistant hypertension." | 9.08 | Calcium antagonists, a useful additional therapy in treatment resistant hypertension: comparison of felodipine ER and nifedipine Retard by 24-h ambulatory blood pressure monitoring. ( Breed, JG; Dees, A; Kremer Hovinga, T; Meems, L; Puister, SM; Verstappen, VM, 1997) |
| "This multicenter, placebo-controlled, double-blind trial of factorial design evaluated the safety and efficacy of combination treatment with the angiotensin-converting enzyme inhibitor, enalapril, and the vascular selective calcium antagonist felodipine extended release (ER) in patients with essential hypertension." | 9.08 | Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. ( Cutler, NR; Davis, PJ; Gradman, AH; Robbins, JA; Weiss, RJ; Wood, BC, 1997) |
| "To study the effectiveness of felodipine in the treatment of essential hypertension in subjects older than 64 years old." | 9.08 | [Felodipine in the treatment of essential arterial hypertension in elderly patients]. ( Fasce, E; Fasce, M; Peña, L, 1996) |
| "Sitting blood pressure (BP), heart rate, body weight, adverse reaction and serum biochemistry were assessed in 70 patients with mild-moderate essential hypertension treated either with felodipine ER (37 patients), or atenolol (33 patients) for 10 weeks." | 9.08 | Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension. ( Chern, MS; Lin, FC; Wu, D, 1997) |
| "To evaluate the 24 h antihypertensive efficacy and duration of action of felodipine extended release (ER) in comparison with two other long acting dihydropyridine calcium antagonists, amlodipine and nifedipine gastrointestinal therapeutic system (GITS), in patients with mild to moderate essential hypertension substantiated by ambulatory blood pressure (BP) monitoring." | 9.08 | Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study. ( Archambault, F; Jewell, D; Lacourcière, Y; Lefebvre, J; Poirier, L; Reed, CV, 1998) |
| "To compare 8 weeks of monotherapy using either felodipine extended release (ER) or a conventional diuretic therapy, triamterene/hydrochlorothiazide (HCTZ), in elderly patients with systolic hypertension." | 9.08 | Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group. ( McClennen, W; Wilson, T, 1998) |
| "The SILVER (Study of Irbesartan in Left VEntricular hypertrophy Regression) trial is designed to test the hypothesis that the newly developed angiontensin-II receptor antagonist, irbesartan, will produce a greater reduction in left ventricular (LV) mass than felodipine ER, in a population of hypertensive patients defined by seated diastolic blood pressure (SeDBP) in the range 95-115 mmHg or seated systolic blood pressure (SeSBP) in the range 160-200 mm Hg." | 9.08 | Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression. ( Agabiti Rosei, E; Bregman, B; Brudi, P; Clairefond, P; Cohen, A; Dubourg, O; Gosse, P; Guéret, P; Williams, B, 1998) |
| "The efficacy and safety of nisoldipine CC and felodipine were compared in a multicentre, randomised, double-blind, trial in patients with mild-to-moderate hypertension (n = 229)." | 9.08 | A comparison of nisoldipine coat-core and felodipine in the treatment of mild-to-moderate hypertension. ( Hoglund, C; Hutchinson, HG, 1998) |
| "Efficacy, tolerability, and optimal doses of felodipine ER (FER) and diltiazem SR (DSR), given as monotherapy, were evaluated in patients with mild or moderate primary hypertension." | 9.07 | Efficacy and tolerability of felodipine ER and diltiazem SR as monotherapy in primary hypertension: a double-blind randomized study. ( Almkvist, H; Berglund, L; Björnsson, T; Fagher, B; Henningsen, N; Honkavaara, M; Naukkarinen, V; Nordenström, P; Sillanpää, J; Thulin, T, 1994) |
| "This study compared the efficacy and tolerability of monotherapy with felodipine and enalapril in patients with essential hypertension using a double-blind randomised crossover design." | 9.07 | Comparison of felodipine and enalapril monotherapy in essential hypertension. ( Dufek, A; Watts, RW; Wing, LM, 1993) |
| "Using a randomised double-blind crossover design with Latin square allocation of treatments in 20 subjects (7 male, 13 female-ages: 61-87 years) with systolic hypertension, we investigated the efficacy and tolerability of once daily felodipine (extended release) 5-20 mg, enalapril 5-20 mg and their combination compared with placebo in four treatment phases each of 6 weeks duration." | 9.07 | Mono- and combination therapy with felodipine or enalapril in elderly patients with systolic hypertension. ( Bune, AJ; Chalmers, JP; Russell, AE; Tonkin, AL; Watts, RW; West, MJ; Wing, LM, 1994) |
| "This study compared with placebo the efficacy and tolerability of optimised doses of felodipine 5-20 mg daily, metoprolol 50-200 mg daily and their combination in subjects 60 years or over with isolated systolic hypertension." | 9.07 | Felodipine, metoprolol and their combination compared with placebo in isolated systolic hypertension in the elderly. ( Bune, AJ; Chalmers, JP; Russell, AE; Tonkin, AL; West, MJ; Wing, LM, 1994) |
| "The aim of this study was to compare the tolerability and efficacy of isradipine and felodipine in the treatment of mild-moderate hypertension." | 9.07 | A comparison of isradipine and felodipine in Australian patients with hypertension: focus on ankle oedema. The Physician's Study Group. ( Cutler, SA; Hammond, JJ, 1993) |
| "In a double-blind cross-over study, the arterial changes produced by hydrochlorothiazide were compared with those observed after the calcium antagonist felodipine in 16 patients with mild to moderate systemic hypertension." | 9.07 | Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. ( Asmar, RG; Benetos, A; Chaouche-Teyara, K; Raveau-Landon, CM; Safar, ME, 1993) |
| "Twenty patients with mild to moderate hypertension took part in this study consisting of a two-week placebo treatment period, followed by treatment with an extended-release calcium channel blocker, felodipine-ER (5 to 20 mg once daily) for 12 weeks." | 9.07 | Effect of felodipine-ER on blood pressure, platelet function, and rheological properties in hypertension. ( Chou, TZ; Ding, YA; Lee, KW, 1993) |
| "The objective of this study was to compare the tolerability of isradipine and felodipine in patients with mild-to-moderate hypertension." | 9.07 | A multicenter comparison of isradipine and felodipine in the treatment of mild-to-moderate hypertension. The Physician's Study Group. ( Cutler, SA; Hammond, JJ, 1993) |
| "The antihypertensive effects of lisinopril 10-20 mg once daily and felodipine (extended release formulation) 5-10 mg once daily were compared in a double-blind, parallel group study of eight weeks duration involving 219 patients with mild to moderate hypertension." | 9.07 | Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group. ( Jensen, HA, 1992) |
| "We have studied the efficacy and tolerability of felodipine plus a beta-adrenoceptor blocker in 79 patients with essential hypertension previously treated with a combination of three or more anti-hypertensive agents, one of which was a beta-adrenoceptor blocker." | 9.07 | Felodipine in combination with a beta-adrenoceptor blocker as an effective substitute for triple therapy in severe hypertension. The Australian Felodipine Multicentre Study Group. ( Agar, J; Aldons, P; Atkins, PF; Frewin, DB; Jackson, B; Karrasch, J; O'Sullivan, EF; Singh, BB; Wilson, LL; Wyndham, RN, 1991) |
| "A double-blind, parallel-group study was performed to assess the antihypertensive effects and tolerability of felodipine and hydrochlorothiazide (HCT) in black patients with mild to moderate uncomplicated hypertension [entry supine diastolic blood pressure (DBP) of 96-116 mm Hg]." | 9.06 | Comparison of felodipine and hydrochlorothiazide for the treatment of mild to moderate hypertension in black Africans. ( Leary, WP; Maharaj, B, 1990) |
| "Studies were performed in nine patients with essential hypertension to explore the effect of the calcium antagonist felodipine on the exercise-induced responses of the sympathetic and renin-angiotensin-aldosterone systems as well as of blood pressure and heart rate." | 9.06 | Catecholamines, renin-angiotensin-aldosterone, and cardiovascular response during exercise following acute and long-term calcium antagonism with felodipine in essential hypertension. ( Hökfelt, B; Hulthén, UL; Katzman, PL, 1987) |
| "The role of felodipine, a new calcium antagonist, in monotherapy for mild and moderate hypertension was investigated in a placebo-controlled double-blind study of 109 patients from 13 centres." | 9.06 | Monotherapy with felodipine, a new calcium antagonist, in mild and moderate hypertension. ( Barnes, PC; Bowles, RM; Comerford, MB; Ginks, SE; Ginks, WR; Goves, JR; Grabau, WJ; Hamilton, DV; Malcolm, JP; Rajaratnam, DV, 1987) |
| "To assess the duration of the antihypertensive effect of the dihydropiridine calcium antagonist felodipine in conventional (C-F) and slow-release (ER-F) formulations, 12 patients with essential hypertension underwent ambulatory blood pressure monitoring (ABPM) at the end of a 2-week treatment period with C-F 5 mg b." | 9.06 | Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild-to-moderate hypertension. ( Benemio, G; Boldrini, F; Gatteschi, C; Guerrieri, M; Pollavini, G; Porcellati, C; Verdecchia, P, 1989) |
| "The efficacy and tolerability of felodipine and prazosin were compared in a double-blind randomised parallel group study of 100 patients with moderately severe essential hypertension, treated concomitantly with a beta-blocking drug." | 9.06 | Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study. ( Anderson, A; Gibson, J; Jackson, B; Morgan, TO, 1987) |
| "The role of felodipine, a new calcium antagonist, as monotherapy in mild and moderate hypertension (supine diastolic blood pressure between 95 and 100mm Hg: phase V) was investigated in a placebo-controlled, double-blind study of 109 patients from 13 centres using 3 different doses." | 9.06 | Felodipine, a new calcium antagonist, as monotherapy in mild or moderate hypertension. Cooperative study group. ( , 1987) |
| " The antihypertensive efficacy of two different doses of the calcium antagonist felodipine was evaluated in patients with hypertension persisting despite beta-adrenoceptor blocker therapy." | 9.06 | Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group. ( , 1988) |
| "Studies were performed in 10 male patients with untreated essential hypertension, WHO grade I-II, aged 25-62 years, to explore the acute (single dose) and long-term (8 weeks) effects of felodipine on sympathetic activity--evaluated by plasma and urinary catecholamines--as related to blood pressure, heart rate and the activity in the renin-angiotensin-aldosterone system." | 9.06 | Effects of the calcium antagonist felodipine on the sympathetic and renin-angiotensin-aldosterone systems in essential hypertension. ( Hökfelt, B; Hulthén, UL; Katzman, PL, 1988) |
| "Eighty one patients with uncomplicated hypertension who required additional antihypertensive medication (diastolic Phase V [dBP] greater than or equal to 95 mm Hg) after 4 weeks treatment with hydrochlorothiazide (HCTZ) 25 mg o." | 9.06 | A comparison of felodipine and propranolol as additions to hydrochlorothiazide in the treatment of hypertension. ( Carle, WK; Latta, D; Lees, CT; Lough, JR; Peers, EM; Pender, J; Richardson, PD; Ross, JR; Sefton, S, 1988) |
| "To investigate the use of felodipine in severe hypertension 2 separate studies were carried out." | 9.06 | The use of felodipine in the treatment of severe hypertension. ( Muir, AL; Wathen, CG, 1987) |
| "In a double-blind cross-over study, the effect on blood pressure (BP), heart rate (HR) and plasma noradrenaline concentration (pNA) of placebo or felodipine given in addition to hydrochlorothiazide was studied in 12 male patients with essential hypertension, not satisfactorily controlled with the diuretic alone." | 9.06 | Treatment of essential hypertension with felodipine in combination with a diuretic. ( Elmfeldt, D; Hedner, T; Samuelsson, O; Sjögren, E, 1986) |
| "In a group of 15 men with severe hypertension in a double-blind crossover trial, the new calcium antagonist felodipine has been shown to lower blood pressure as effectively as minoxidil when used in combination with a beta-blocker and a loop diuretic." | 9.05 | Felodipine can replace minoxidil in the treatment of refractory hypertension. ( Forret, EA; Hill, TW; MacLeod, D; Muir, AL; Tucker, L; Wathen, CG, 1985) |
| "The aim of this study was to compare the new vasodilator felodipine with nifedipine in 18 patients with poorly controlled hypertension." | 9.05 | Comparative trial of felodipine and nifedipine in refractory hypertension. ( Aberg, H; Lindsjö, M; Mörlin, B, 1985) |
| "This review attempts to evaluate the benefit-risk balance of felodipine in the treatment of hypertension." | 8.77 | Aspects on the benefit-risk balance of felodipine in hypertension. ( Elmfeldt, D; Westerling, S, 1987) |
| "In newly diagnosed patients with hypertension, lercanidipine was superior to nifedipine in the six-year period when the analyzed endpoint was stroke." | 7.85 | Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study. ( Cheng, KC; Cheng, KH; Cheng, KY; Lai, WT; Lee, CW; Yang, YH, 2017) |
| "Sorafenib, an orally active multi-kinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC), is primarily metabolized both via cytochrome P450 3A4 isoform (CYP3A4) and UGT1A9." | 7.77 | Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. ( Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Tod, M, 2011) |
| "To evaluate the curative effects of slow releasing felodipine on mild to moderate primary hypertension and its influence on the pulse wave velocity of slow of the patients." | 7.74 | [Curative effects on mild to moderate primary hypertension and influence on pulse wave velocity of slow releasing felodipine]. ( Jing, S; Sun, NL, 2008) |
| "The objective of the present study was to evaluate the efficacy and safety of a therapeutic interchange between high-dose calcium channel blocker therapy and a fixed-dose combination of amlodipine/ benazepril (Lotrel; Novartis Pharmaceuticals, USA) in patients with moderate to severe hypertension." | 7.71 | Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension. ( Faulkner, M; Hilleman, DE; Reyes, AP; Wurdeman, RL, 2001) |
| "Felodipine is a second-generation dihydropyridine calcium antagonist used to treat mild to moderate arterial hypertension." | 7.70 | Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension. ( Arrigucci, S; Bicchi, M; Cappelli, R; Forconi, S; Righi, GA; Vedovini, G, 1998) |
| "We present results from a Swedish retrospective cost-effectiveness analysis of felodipine-metoprolol (Logimax) and enalapril in hypertension." | 7.70 | Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension. ( Andersson, F; Andersson, OK; Kartman, B, 1998) |
| "The efficacy and tolerability of felodipine, in a low dose of 5-10 mg daily was assessed in 32 patients with mild-to-moderate hypertension, aged 53 +/- 11 years." | 7.69 | Efficacy of low felodipine dose monotherapy in mild-to-moderate hypertension: a comparison between office and ambulatory blood pressure monitoring. ( Bernheim, J; Korzets, Z; Podjarny, E, 1996) |
| "All clinical studies of at least 1 week's duration with felodipine in patients with hypertension were included in a safety analysis." | 7.69 | Overview of the safety of felodipine based on clinical trials in patients with hypertension. ( Elmfeldt, D; Elvelin, L; Niklasson, A; Olsson, G; Welin, L, 1997) |
| "We report three cases of felodipine use in pregnancy by women with chronic hypertension." | 7.69 | Felodipine use in pregnancy. Report of three cases. ( Casele, HL; Gratton, R; Laifer, SA; Prieto, JA; Windley, KC, 1997) |
| "We sought to characterize the effects of the nonselective Ca2+ channel antagonist, verapamil, and the vascular-selective Ca2+ channel antagonist, felodipine, on obese, hypertensive, heart failure-prone, female SHHF/Mcc-fa(cp) rats." | 7.69 | Verapamil accelerates the transition to heart failure in obese, hypertensive, female SHHF/Mcc-fa(cp) rats. ( Altschuld, RA; Hensley, J; Hoepf, TM; Hohl, CM; McCune, SA; Park, S; Radin, MJ, 1997) |
| "To evaluate whether a spontaneous increase in cerebral blood flow (CBF) could be observed in subjects with severe hypertension and to study the effect of a calcium antagonist, felodipine, on blood pressure and CBF after acute and chronic administration." | 7.68 | Cerebral blood flow in patients with severe hypertension, and acute and chronic effects of felodipine. ( Elmqvist, D; Fagher, B; Grabowski, M; Johansson, BB; Ryding, E; Thulin, T, 1993) |
| "Felodipine, a dihydropyridine calcium antagonist, was used to treat eight patients with severe uncontrolled hypertension: five had essential hypertension, two had renovascular disease, and one chronic pyelonephritis." | 7.68 | Long-term effects of felodipine on blood pressure and renal hemodynamics in severe hypertension. ( Aurell, M; Granérus, G; Herlitz, H, 1990) |
| "Twenty-three patients with severe hypertension and impaired renal function were included in an open study of the efficacy and tolerance of felodipine treatment over 6 months." | 7.68 | Felodipine in the treatment of patients with severe hypertension and impaired renal function. ( Bengtsson, U; Danielsson, B; Elmfeldt, D; Hardlund, JH; Larsson, R; Lindsjö, MK; Moberg, L; Sjöström, PA, 1990) |
| " The combination of nitrendipine plus enalapril was also examined in ischemic failure and in rats with spontaneous hypertension." | 7.67 | Enalapril in experimental hypertension and acute heart failure: comparison with calcium channel blockers. ( Adkins, E; Emmert, S; Ludden, CT; Ribeiro, LG; Seymour, AA; Sweet, CS, 1986) |
| "Felodipine (Plendil), a new drug, has been used in the treatment of five patients with refractory essential hypertension (WHO II-III)." | 7.67 | Effect of felodipine in refractory hypertension. ( Ekeroth, M; Ostman, J; Seideman, P, 1988) |
| "A dose titration study was performed using felodipine, a new calcium antagonist, in Chinese patients with essential hypertension inadequately controlled by metoprolol alone (DBP greater than 95 mmHg)." | 7.67 | The effects of combining felodipine and metoprolol in moderate to severe hypertension--a one year study. ( Chow, J, 1988) |
| "Studies were performed to explore the effect of calcium antagonism with felodipine for 8 weeks on glucose homeostasis and serum lipids in 8 patients with essential hypertension." | 7.67 | Unchanged insulin secretion and glucose tolerance but increased insulin clearance during long-term calcium antagonism with felodipine in essential hypertension. ( Hökfelt, B; Hulthén, UL; Katzman, PL, 1987) |
| "The effect of 8 weeks' treatment with the dihydropyridine calcium antagonist felodipine on glucoregulatory hormone response following insulin-induced hypoglycaemia was evaluated in 7 patients with essential hypertension, WHO grade I-II." | 7.67 | Glucoregulatory hormone response to insulin-induced hypoglycaemia following long-term calcium antagonism with felodipine in patients with essential hypertension. ( Hökfelt, B; Hulthén, UL; Katzman, PL, 1987) |
| "The calcium antagonist, felodipine, was used to treat 21 patients with severe uncontrolled hypertension: 13 had renoparenchymatous hypertension, 5 essential hypertension and 3 renovascular hypertension." | 7.67 | Clinical evaluation of felodipine in patients with refractory hypertension. ( Aurell, M; Björck, S; Granérus, G; Herlitz, H; Nyberg, G, 1987) |
| "The effect of 8 weeks treatment with the calcium antagonist felodipine--a new long-acting dihydropyridine derivative--in a dose of 10 mg twice daily was studied in 10 male patients with essential hypertension, WHO grade I-II, aged 25-62 years." | 7.67 | The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension. ( Hökfelt, B; Hulthén, UL; Katzman, PL, 1986) |
| "Oral administration of felodipine to 10 patients with mild essential hypertension acutely reduced systemic vascular resistance (SVR) by 40% after 30 min." | 7.67 | Acute haemodynamic and humoral responses to felodipine and metoprolol in mild hypertension. ( Amery, A; Fagard, R; Lijnen, P; Moerman, E; Staessen, J, 1987) |
| "Felodipine is a new dihydropyridine calcium antagonist, and in hypertension it is a much more effective "third-line" drug than hydralazine." | 7.67 | Felodipine compared to nifedipine as "third-line drug" in resistant hypertension. ( Maclean, D; Mitchell, ET; Readman, AS, 1986) |
| "The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker." | 6.79 | The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. ( Chen, W; Fang, H; Liu, X; Xu, W, 2014) |
| "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment." | 6.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| " There is a need for efficacious, safe, and well-tolerated antihypertensive agents with a once-a-day dosing regimen in children and adolescents." | 6.71 | Clinical trial of extended-release felodipine in pediatric essential hypertension. ( Frank, R; Klibaner, M; Mahan, JD; Matoo, TK; Portman, R; Restaino, I; Tou, C; Trachtman, H, 2003) |
| " Amlodipine seems to be more effective than felodipine when the drugs are compared in the same dose, with regard to the effect on clinic BP 24 h after dosing and to ambulatory BP during the night." | 6.69 | Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension. ( Brodin, U; Isaksson, H; Ohman, KP; Ostergren, J; Schwan, A, 1998) |
| " Each patient received 50 mg of losartan or 5 mg of felodipine ER once daily, and the dosage was adjusted to double the initial level at week 6 if necessary." | 6.69 | Comparison of antihypertensive efficacy and tolerability of losartan and extended-release felodipine in patients with mild to moderate hypertension. ( Cherng, WJ; Hsieh, IC; Hung, KC; Hung, MJ; Lin, FC; Wang, CH; Wen, MS; Wu, D, 1999) |
| " Drug dosage was determined in an initial stepped-care titration phase lasting six weeks." | 6.69 | Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension. ( De Rosa, ML; Della Guardia, D; Giordano, A; Lionetti, F; Maddaluno, G; Marsicani, N; Vigorito, C, 1999) |
| "Amlodipine has potential advantages in children since it can be dissolved into a liquid preparation and has a long elimination half-life, allowing for once-daily administration." | 6.69 | A randomized prospective crossover trial of amlodipine in pediatric hypertension. ( Arbus, GS; Blowey, D; Khattak, S; Koren, G; Lyszkiewicz, DA; Rogan, JW, 2000) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 6.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| "To characterize the population dose-response and concentration-response relationships of felodipine and to investigate the influence of patient variables on these relationships." | 6.68 | Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. ( Sambol, NC; Wade, JR, 1995) |
| "Felodipine was well tolerated." | 6.67 | Extended-release felodipine in patients with mild to moderate hypertension. Felodipine ER Dose-Response Study Group. ( Faison, EP; Goldberg, AI; Irvin, JD; Lipschutz, K; Nelson, EB; Shapiro, DA; Weber, MA, 1994) |
| " Altogether, 251 hypertensive patients with a diastolic blood pressure greater than 95 mm Hg after 4 weeks of treatment with placebo in combination with metoprolol CR 100 mg were randomized to four parallel groups." | 6.67 | Optimal felodipine dose when combined with metoprolol in arterial hypertension: a Swedish multicenter study within primary health care. Swedish General Practitioner Felodipine Study Group. ( Bengtsson, C; Brun, J; Fröberg, L; Kronmann, P; Olsson, LB; Scherstén, B; Skoog, P; Tibblin, G; Tygesen, G, 1990) |
| "Felodipine ER once daily was as effective and tolerable as plain tablets b." | 6.67 | Felodipine extended-release tablets once daily are equivalent to plain tablets twice daily in treating hypertension. Dutch Hospital Multicentre Group. ( Hart, W; Westberg, B, 1990) |
| " Plasma noradrenaline concentration increased after both acute and chronic administration (p less than 0." | 6.67 | Beta-adrenergic receptors and reflex tachycardia after single and repeated felodipine administration in essential hypertension. ( Baldi, G; Bertora, P; Bevilacqua, M; Chebat, E; Norbiato, G; Peruzzi, E; Renesto, E; Sardina, M; Savonitto, S; Vago, T, 1991) |
| "Treatment with felodipine ER over 2 weeks increased sympathetic outflow as indicated by elevated plasma norepinephrine levels, whereas plasma epinephrine was mainly unaffected, as were plasma renin and aldosterone levels." | 6.67 | Catecholamines and the renin-angiotensin-aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension. ( Binner, L; Gabrielsen, F; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991) |
| "5 h after dosing with HCTZ, which was not significantly lower." | 6.67 | Comparison of once daily felodipine 10 mg ER and hydrochlorothiazide 25 mg in the treatment of mild to moderate hypertension. ( Binner, L; Hehr, R; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991) |
| "Hydrochlorothiazide treatment was accompanied by a decrease in serum potassium and an increase in serum uric acid." | 6.67 | The efficacy and tolerability of long-term felodipine treatment in hypertension. The Scandinavian Multicenter Group. ( Ibsen, H; Westberg, B, 1990) |
| "Felodipine Er, 10 mg, was given once daily for 2 weeks, and after another wash-out period of 1 week, patients were switched to 25 mg HCTZ, once daily, and vice versa." | 6.67 | Effects of felodipine ER and hydrochlorothiazide on blood rheology in essential hypertension--a randomized, double-blind, crossover study. ( Binner, L; Ernst, E; Hehr, R; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991) |
| "Felodipine (Plendil) is a once daily antihypertensive calcium antagonist." | 6.67 | Felodipine as monotherapy in Asian patients with mild to moderate hypertension. ( Tan, AT; Woo, BY; Yeoh, TK, 1990) |
| "1." | 6.67 | Felodipine ER formulation in the treatment of mild hypertension: efficacy and tolerability vs placebo. ( Bossini, A; Cagli, V; Cavallotti, G; Di Veroli, C, 1990) |
| "Felodipine-ER once daily is an effective antihypertensive drug for patients who require therapy in addition to a beta-blocker; the tolerability in this study was good, and a starting dose greater than 10 mg once daily is not indicated." | 6.66 | A dose-finding, placebo-controlled study on extended-release felodipine once daily in treatment of hypertension. ( Barnes, P; Cambell, LM; Goves, JR; Lees, CT; McCullagh, A; Richardson, PD; Ross, JR; Timerick, SJ, 1989) |
| "Felodipine alone was sufficient to control blood pressure in 90% of patients, while 50% of patients who were receiving diuretic therapy required a second agent for control." | 6.66 | Cardiovascular-risk reduction: initial diuretic therapy compared with calcium-antagonist (felodipine) therapy for primary hypertension. ( Bruce, A; Jennings, GL; Sudhir, K, 1989) |
| "The felodipine treated patients experienced more ankle swelling and flushing than those in the hydralazine group who experienced more headache and minor gastro-intestinal upset." | 6.66 | Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension. Cooperative Study Group. ( , 1986) |
| "Felodipine is an effective antihypertensive agent when used with metoprolol." | 6.66 | Hormonal and blood pressure responses to tilting in beta-blocked essential hypertension treated with felodipine or prazosin. ( Jackson, B; Johnston, CI; McGrath, BP, 1987) |
| " The ramipril/felodipine ER combination is as well tolerated as ramipril or felodipine ER monotherapy administered at the same dosages, and is better tolerated than felodipine ER monotherapy given at twice the dosage used in the combination." | 6.43 | Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension. ( Cvetković, RS; Plosker, GL, 2005) |
| " In one study that titrated dosages to effect, fewer felodipine/metoprolol than felodipine or metoprolol monotherapy recipients required dosage increases to achieve BP control (45 vs 60 and 67%, respectively)." | 6.41 | Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension. ( Haria, M; Markham, A; Plosker, GL, 2000) |
| " In patients with congestive heart failure, chronic dosing with felodipine produces a persistent reduction in vascular resistance and an increase in cardiac output, both at rest and during exercise." | 6.38 | Treatment of hypertension with felodipine in patients with concomitant diseases. ( Gradman, AH, 1993) |
| "The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects, and dosage of felodipine and isradipine are reviewed." | 6.38 | Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. ( Symes, LR; Walton, T, 1993) |
| "Felodipine is a new calcium antagonist that was developed aiming particularly at reduction in vascular resistance-without any decrease in heart pump function." | 6.38 | Hemodynamic effects of felodipine in hypertension: a review. ( Lund-Johansen, P, 1990) |
| "Felodipine has a dose-related effect on diastolic BP whether given alone or with a beta-blocker." | 6.38 | Dose-plasma concentration--effect relationship of felodipine in essential hypertension: a review. ( Reid, JL, 1990) |
| "Felodipine does not cause orthostatic hypotension since it has no effect in clinical doses on venous smooth muscle." | 6.37 | Felodipine in hypertension--a review. ( Elmfeldt, D; Hedner, T; Westerling, S, 1987) |
| "Felodipine is a dihydropyridine calcium antagonist which selectively relaxes vascular smooth muscle." | 6.37 | Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. ( Ellrodt, AG; Langley, MS; Monk, JP; Saltiel, E, 1988) |
| " All patients were randomly assigned to take aspirin 75 mg/day or placebo, and patients in the aspirin group had a 15% lower rate of major cardiovascular events and myocardial infarctions than did patients who received placebo." | 6.19 | Aggressive blood pressure lowering is safe, but benefit is still hard to prove. ( Pohl, MA; Vidt, DG, 1999) |
| "Felodipine, a dihydropyridine calcium-channel antagonist, significantly reduces systolic and diastolic blood pressure (BP) in patients with hypertension and has been associated with beneficial hemodynamic effects in patients with chronic stable angina pectoris or congestive heart failure (CHF)." | 6.16 | Felodipine: a new dihydropyridine calcium-channel antagonist. ( Lopez, LM; Yedinak, KC, 1991) |
| " This impelled us to improve its solubility, bioavailability, and pharmacodynamic properties through the Nanocrystal (NC) approach." | 5.72 | Appraisal of Felodipine Nanocrystals for Solubility Enhancement and Pharmacodynamic Parameters on Cadmium Chloride Induced Hypertension in Rats. ( Maurya, P; Pandey, P; Saraf, SA; Singh, S; Sonkar, A, 2022) |
| "This study aimed to analyze the effect of felodipine combined with enalapril in the treatment of patients with essential hypertension and coronary artery disease." | 5.51 | Efficacy of felodipine and enalapril in the treatment of essential hypertension with coronary artery disease and the effect on levels of Salusin-β, Apelin, and PON1 gene expression in patients. ( Jin, F; Zhang, J; Zhang, W; Zhou, H, 2022) |
| "Felodipine has a protective effect on the myocardium and kidney as evidenced by decreased perivascular inflammation, myocardial necrosis and fibrosis." | 5.36 | Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats. ( Franco, M; Janicki, JS; Matsubara, BB; Matsubara, LS, 2010) |
| "Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure." | 5.29 | Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. ( Lund-Johansen, P; Omvik, P, 1993) |
| "Felodipine appears to be a highly potent, well tolerated drug and offers a substitute treatment for severe hypertensives refractory to other vasodilators." | 5.29 | Felodipine in the treatment of severe refractory hypertension. ( Carroll, J; Grossman, E; Katz, A; Nussinovitch, N; Rachima, C; Rosenthal, T; Shamiss, A, 1996) |
| "When felodipine was given as single drug to 14 previously untreated hypertensives in a single-blind manner, BP was rapidly reduced by about 15% while HR increased by 25%." | 5.27 | Short-term effects of felodipine, a new dihydropyridine, in hypertension. ( Aberg, H; Andersson, O; Bengtsson, C; Elmfeldt, D; Haglund, K; Hedner, T; Ostman, J; Seideman, P; Sjöberg, KH; Strömgren, E, 1984) |
| "Felodipine, a new dihydropyridine, was given to 58 hypertensive patients in combination with an adrenergic beta-receptor antagonist and a diuretic agent." | 5.27 | Long term experience of felodipine in combination with beta-blockade and diuretics in refractory hypertension. ( Collste, P; Danielsson, M; Elmfeldt, D; Feleke, E; Gelin, A; Hedner, T; Rydén, L, 1985) |
| "075 mg/kg) of felodipine in combination with the beta-blocker and diuretic." | 5.27 | Felodipine in combination with a beta-blocker and a diuretic in chronic treatment of patients with refractory primary hypertension. ( Andersson, OK; Granérus, G; Hedner, T, 1987) |
| "The objective of this study was to compare the effectiveness of lercanidipine with felodipine in patients with mild-to-moderate hypertension on day-to-day home blood pressure variability." | 5.22 | Effects of lercanidipine hydrochloride versus felodipine sustained-release on day-to-day home blood pressure variability. ( Dai, Q; Gong, J; Jin, H; Lu, X; Peng, J; Wang, B; Wang, H; Wu, Y; Xu, M; Xu, X; Yan, J; Zhang, M; Zhao, S, 2016) |
| "Lercanidipine hydrochloride and felodipine sustained-release tablets comparison for the treatment of patients with mild-to-moderate primary hypertension." | 5.20 | Lercanidipine hydrochloride versus felodipine sustained-release for mild-to-moderate hypertension: a multi-center, randomized clinical trial. ( Dai, Q; Gong, J; Jin, H; Lu, X; Peng, J; Wang, B; Wang, H; Wu, Y; Xu, M; Xu, X; Yan, J; Zhang, M; Zhao, S, 2015) |
| "To assess the efficacy and safety of aranidipine versus retard-released felodipine in Chinese patients with mild-to-moderate essential hypertension." | 5.17 | [Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension]. ( Chen, L; Jiao, Y; Jin, H; Ke, YN; Li, DY; Liu, MX; Wang, BY; Wang, L; Wang, Y; Yang, HY; Zhao, XL; Zheng, JT, 2013) |
| "org: NCT01238705) in 160 women (18-60 years) with mild or moderate hypertension, randomized to a once-daily treatment with felodipine combined with irbesartan or metoprolol for 48 weeks." | 5.16 | Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. ( Bai, F; Lin, X; Ma, R; Xu, D; Yang, L; Yu, J; Zhao, F, 2012) |
| "We examined the effects of ARB administration on hyperinsulinemia-associated capillary density by measuring baseline skin capillary density, capillary density during reactive hyperemia (hyperemic capillary recruitment), and capillary density during venous congestion in 17 hypertensive individuals in the basal state, during a hyperinsulinemic euglycemic clamp, and during a hyperinsulinemic clamp with acute ARB administration (600 mg irbesartan), acute calcium channel blockade (CCB; 10mg felodipine ER), as a control for the reduction in blood pressure, or placebo." | 5.15 | Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals. ( de Leeuw, PW; Houben, AJ; Jonk, AM; Schaper, NC; Serné, EH; Smulders, YM; Stehouwer, CD, 2011) |
| "To evaluate the impact of age on the pharmacokinetics and blood pressure (BP) responses of a dihydropyridine (DHP) with large versus small first-pass metabolism in hypertensive subjects, younger (n = 28) and older (n = 35) patients with hypertension were randomized to placebo, felodipine-ER 5 mg/d, or amlodipine 5 mg/d." | 5.14 | Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension. ( Coletta, E; Leenen, FH, 2010) |
| "This multicenter, open-label, single-arm trial assessed the efficacy of the combination of amlodipine 10 mg and valsartan 160 mg to provide additional blood pressure reduction and tolerability in patients with moderate hypertension not adequately responding to the combination of ramipril 5 mg and felodipine 5 mg." | 5.13 | Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination. ( Borbas, E; Handrock, R; Klebs, S; Schaetzl, R; Trenkwalder, P, 2008) |
| "To evaluate the efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination each with Metoprolol, Lisinopril or Hydrochlorothiazide in the 12 weeks treatment of mild to moderate essential hypertension in China." | 5.12 | [Efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination therapy in the treatment of mild to moderate essential hypertension in China]. ( Chen, YY; Liu, HL; Shen, FR; Sun, NL; Tao, J; Wu, HY; Xiang, XP; Yu, ZQ; Zhang, FC; Zhang, L; Zhang, WZ; Zhao, JA, 2007) |
| "To compare efficacy and tolerability of felodipine based antihypertensive therapy with those of standard hospital treatment of hypertension." | 5.11 | [Efficacy and tolerability of felodipine based antihypertensive therapy in hospitalized patients with hypertension]. ( Bagmanova, NKh; Kobalava, ZhD; Kotovskaia, IuV; Mil'to, AS; Plavunov, NF; Riabova, AV, 2004) |
| "Aim of this study was to compare the effect of valsartan and felodipine on blood pressure (BP), plasma leptin (L), insulin sensitivity and plasma norepinephrine (NE) in obese hypertensive patients." | 5.11 | Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2005) |
| "To assess, by smoothness index (SI), distribution of the antihypertensive effect of extended-release (ER) felodipine over 24 hours in elderly patients with hypertension." | 5.10 | Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. ( Ansuini, R; Antonicelli, R; Gesuita, R; Giovanni, DC; Mori, A; Omboni, S; Paciaroni, E; Parati, G, 2002) |
| "In this multicentre, double-blind, parallel-group study, 120 out-patients with mild to moderate primary hypertension were randomised, after a 4-week single-blind placebo run-in period, to a combination tablet of felodipine-metoprolol 5/50 mg (Logimax, Mobloc, Astra) once daily or enalapril 10 mg once daily." | 5.09 | Improved efficacy with maintained tolerability in the treatment of primary hypertension. Comparison between the felodipine-metoprolol combination tablet and monotherapy with enalapril. Swedish Multicentre Group. ( Andersson, OK, 1999) |
| " the level of blood pressure associated with the lowest incidence of major cardiovascular events such as fatal and non-fatal stroke and myocardial infarction and other cardiovascular mortality); and (2) to assess the effect of a low dose of acetylsalicylic acid (aspirin) compared with placebo on major cardiovascular events." | 5.09 | The Hypertension Optimal Treatment study and the importance of lowering blood pressure. ( Hansson, L, 1999) |
| "Sitting blood pressures (BP), heart rate, body weight, adverse reactions, and serum biochemistry were assessed in 70 patients with isolated systolic hypertension (34 treated with felodipine ER and 36 slow-release diltiazem [diltiazem SR] for 10 weeks)." | 5.09 | Comparison of clinical efficacy and adverse effects between extended-release felodipine and slow-release diltiazem in patients with isolated systolic hypertension. ( Chern, MS; Lin, FC; Wu, D, 1999) |
| "Out of 245 randomized outpatients (90 men, 155 women) with uncomplicated mild-to-moderate primary hypertension and mean sitting diastolic blood pressure (DBP) 95-115 mmHg inclusive, 212 (102 on felodipine-metoprolol, 110 on amlodipine) were eligible for analysis." | 5.09 | Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension. Lorraine General Physician Investigators Group. ( Boivin, JM; Zannad, F, 1999) |
| " Patients with uncomplicated essential hypertension (diastolic blood pressure between 95 and 110 mm Hg at the end of a 4-week run-in period) were randomly allocated to a double-blind, 12-week treatment with either a combination tablet of felodipine and metoprolol (Logimax), 5/50 mg daily (n = 321), enalapril, 10 mg daily (n = 321), or placebo (n = 304), with the possibility of doubling the dose after 4 or 8 weeks of treatment if needed (diastolic blood pressure remaining >90 mm Hg)." | 5.09 | Felodipine-metoprolol combination tablet: a valuable option to initiate antihypertensive therapy? ( Dahlöf, B; Detry, JM; Gundersen, T; Hosie, J; Januszewicz, W; Lindström, CJ; Magometschnigg, D; Puig, JG; Safar, M; Tanser, P; Toutouzas, P; Waeber, B, 1999) |
| "The aim of the study was to identify the most appropriate dosage combination of ramipril and felodipine ER (an extended release tablet) for mild-to-moderate hypertension." | 5.09 | Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER. ( Bauer, B; Massaro, J; Scholze, J, 1999) |
| "To assess drug prescription patterns and medical resource consumption in an elderly population in Quebec receiving amlodipine or felodipine for the treatment of hypertension." | 5.09 | Patterns of amlodipine and felodipine use in an elderly Quebec population. ( LeLorier, J; Sheehy, O, 2000) |
| "The aim of this study was to compare the chronic effects of four dihydropyridine calcium antagonists with different pharmacologic characteristics, amlodipine, felodipine, lacidipine and manidipine,on blood pressure (BP), heart rate (HR) and plasma norepinephrine (NE) levels in patients with mild to moderate essential hypertension." | 5.09 | Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. ( Corradi, L; Fogari, R; Malalamani, GD; Mugellini, A; Preti, P; Zoppi, A, 2000) |
| "This 12-week, open-label, multicenter study assessed the efficacy and safety of losartan/hydrochlorothiazide (HCTZ), alone or in combination with other antihypertensive agents, in the treatment of patients with severe systemic hypertension." | 5.09 | Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. ( Aurup, P; Goldberg, A; Oparil, S; Snavely, D, 2001) |
| " To compare the effects of active treatment compared with placebo on blood pressure, left ventricular hypertrophy, and quality of life among older stage 1 isolated systolic hypertensive patients, a randomized, double-blind, parallel-group, multicenter clinical trial comparing felodipine (2." | 5.09 | One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. ( Black, HR; DeQuattro, V; Elliott, WJ; Frishman, WH; Hwang, CT; Klibaner, MI; Liebson, PR; Montoro, R; Ruff, DA; Schleman, MM; Strom, JA; Weber, MA; Zhang, D, 2001) |
| " Twenty five unmedicated patients with primary hypertension were randomised to initial therapy with either the calcium antagonist, felodipine, or a diuretic and doses titrated to achieve similar levels of blood pressure (BP)." | 5.08 | Assessment of effects of two anti-hypertensive regimens on overall cardiovascular risk. ( Jennings, GL; Korner, P; Laufer, E; Reid, C; Sudhir, K, 1995) |
| "The anti-hypertensive efficacy and safety of extended-release (ER) felodipine (5, 10 or 20 mg) and amlodipine (5 or 10 mg) once daily were compared in patients with mild to moderate essential hypertension in a double-blind, double-dummy, randomised, comparative study." | 5.08 | Comparative effects of amlodipine and felodipine ER on office and ambulatory blood pressure in patients with mild to moderate hypertension. Danish Multicentre Group. ( Høegholm, A; Nielsen, PE; Rasmussen, E; Wiinberg, N, 1995) |
| "The anti-hypertensive efficacy and safety of extended-release (ER) felodipine (5, 10 or 20 mg) and amlodipine (5 or 10 mg) once daily were compared in patients with mild-to-moderate essential hypertension in a double-blind, double-dummy, randomised, comparative study." | 5.08 | Office and ambulatory blood pressure: a comparison between amlodipine and felodipine ER. Danish Multicentre Group. ( Høegholm, A; Nielsen, PE; Rasmussen, E; Wiinberg, N, 1995) |
| "The effects on blood pressure (BP) and heart rate (HR), at rest and during bicycle exercise, of the vascular selective calcium antagonist felodipine, the cardio-selective beta-blocker metoprolol, and of the two drugs in combination, were assessed in a double-blind, three-way cross-over study comprising 23 patients with essential, mild to moderate hypertension." | 5.08 | Effects of felodipine, metoprolol and their combination on blood pressure at rest and during exercise and on volume regulatory hormones in hypertensive patients. ( Elmfeldt, DB; Gordon, RD; Klemm, SA; Tunny, TJ; Wicks, JR, 1995) |
| " The medication of 39 patients with hypertension was changed from once-daily diltiazem hydrochloride (Cardizem CD) or nifedipine (Procardia XL) to felodipine (Plendil)." | 5.08 | Felodipine as an alternative to more expensive calcium antagonists in mild to moderate hypertension. ( Horwhat, JD; Landry, FJ; Pinski, L; Tomich, D, 1996) |
| "This study was performed to assess whether a new formulation of felodipine extended release (FER) tablets with a 9 mm diameter is similar to the presently used 11 mm diameter FER formulation with respect to antihypertensive effect and tolerability in patients with essential hypertension." | 5.08 | Clinical equivalence of two tablet formulations of felodipine. A placebo-controlled study of 24-hour blood pressure control and tolerability. ( Elmfeldt, DB; McGrath, BP; Watts, RW, 1995) |
| "We assessed the 24-h antihypertensive efficacy of an extended-release (ER) 10-mg formulation of the dihydropyridine felodipine in mild-to-moderate essential hypertension [World Health Organization (WHO) stage I-II]." | 5.08 | Twenty-four-hour antihypertensive efficacy of felodipine 10 mg extended-release: the Italian inter-university study. ( Barsotti, A; Bentivoglio, M; Campa, PP; Collauto, F; Corea, L; Irace, L; Jacono, A; Monti, F; Pannarale, G; Puddu, PE; Trevi, G, 1996) |
| "The aim of the study was to evaluate the efficacy over 1 year of of felodipine ER 5 and 10 mg once daily (od) in 12 Caucasian patients with left ventricular hypertrophy secondary to primary hypertension." | 5.08 | The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension. ( Boydak, B; Killiçcioglu, B; Nalbantgil, I; Onder, R; Terzioglu, E; Yilmaz, H, 1996) |
| "To compare the efficacy and tolerance of felodipine-ER and nifedipine OROS, both once daily, in the treatment of mild-to-moderate uncomplicated arterial hypertension (AH)." | 5.08 | [Multicenter comparative study of felodipine-ER and nifedipine-OROS in the treatment of mild-to-moderate arterial hypertension]. ( Armaganijan, D; Batlouni, M; Castro, I; Chaves Junior, Hde C; Leite Luna, R; Nobre, F; Pereira da Cunha, C; Silveira Sbissa, A, 1996) |
| "A multinational, double-blind, randomised study was conducted to investigate the efficacy and safety of a low-dose combination of the angiotensin converting enzyme inhibitor, ramipril, and the calcium antagonist, felodipine ER, in 642 patients with mild to moderate hypertension [supine diastolic blood pressure (DBP) = 95-115 mm Hg]." | 5.08 | Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy. ( Bauer, B; Poisson, P; Rangoonwala, B; Schueler, E, 1996) |
| "Both felodipine ER and nifedipine Retard are effective "add-on' drugs in patients with monotherapy-resistant hypertension." | 5.08 | Calcium antagonists, a useful additional therapy in treatment resistant hypertension: comparison of felodipine ER and nifedipine Retard by 24-h ambulatory blood pressure monitoring. ( Breed, JG; Dees, A; Kremer Hovinga, T; Meems, L; Puister, SM; Verstappen, VM, 1997) |
| "This multicenter, placebo-controlled, double-blind trial of factorial design evaluated the safety and efficacy of combination treatment with the angiotensin-converting enzyme inhibitor, enalapril, and the vascular selective calcium antagonist felodipine extended release (ER) in patients with essential hypertension." | 5.08 | Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. ( Cutler, NR; Davis, PJ; Gradman, AH; Robbins, JA; Weiss, RJ; Wood, BC, 1997) |
| "To study the effectiveness of felodipine in the treatment of essential hypertension in subjects older than 64 years old." | 5.08 | [Felodipine in the treatment of essential arterial hypertension in elderly patients]. ( Fasce, E; Fasce, M; Peña, L, 1996) |
| "Sitting blood pressure (BP), heart rate, body weight, adverse reaction and serum biochemistry were assessed in 70 patients with mild-moderate essential hypertension treated either with felodipine ER (37 patients), or atenolol (33 patients) for 10 weeks." | 5.08 | Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension. ( Chern, MS; Lin, FC; Wu, D, 1997) |
| "In an open study, 16 patients with moderate essential hypertension were treated with 5 or 10 mg felodipine daily for 3 months." | 5.08 | Rest and effort hemodynamic responses during prolonged treatment with felodipine, 24-h blood pressure monitoring, and echocardiographic changes. ( Schwartz, J; Tobar, R; Zimlichman, R, 1997) |
| "To evaluate the 24 h antihypertensive efficacy and duration of action of felodipine extended release (ER) in comparison with two other long acting dihydropyridine calcium antagonists, amlodipine and nifedipine gastrointestinal therapeutic system (GITS), in patients with mild to moderate essential hypertension substantiated by ambulatory blood pressure (BP) monitoring." | 5.08 | Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study. ( Archambault, F; Jewell, D; Lacourcière, Y; Lefebvre, J; Poirier, L; Reed, CV, 1998) |
| "To compare 8 weeks of monotherapy using either felodipine extended release (ER) or a conventional diuretic therapy, triamterene/hydrochlorothiazide (HCTZ), in elderly patients with systolic hypertension." | 5.08 | Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group. ( McClennen, W; Wilson, T, 1998) |
| ") infusion of two dihydropyridine calcium channel blockers (either nifedipine or felodipine) in 122 patients, of whom 63 were diagnosed as hypertensive emergencies and 59 as hypertensive crisis, who had not reacted adequately (diastolic blood pressure <115 mmHg) to 5 mg of nifedipine PO." | 5.08 | A comparison of the antihypertensive efficacy and safety of felodipine IV and nifedipine IV in patients with hypertensive crisis or emergency not responding to oral nifedipine. ( Bohm, R; Erley, CM; Koch, HH; Nast, HP; Risler, T; Stein, G; Wetzchewald, D, 1998) |
| "The SILVER (Study of Irbesartan in Left VEntricular hypertrophy Regression) trial is designed to test the hypothesis that the newly developed angiontensin-II receptor antagonist, irbesartan, will produce a greater reduction in left ventricular (LV) mass than felodipine ER, in a population of hypertensive patients defined by seated diastolic blood pressure (SeDBP) in the range 95-115 mmHg or seated systolic blood pressure (SeSBP) in the range 160-200 mm Hg." | 5.08 | Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression. ( Agabiti Rosei, E; Bregman, B; Brudi, P; Clairefond, P; Cohen, A; Dubourg, O; Gosse, P; Guéret, P; Williams, B, 1998) |
| "In an open trial, the antihypertensive efficacy of felodipine and its effects on lipid metabolism were investigated in 117 Nordic patients with mild to moderate essential hypertension and hyperlipidaemia." | 5.08 | Effects of felodipine ER, a dihydropyridine calcium antagonist, on blood pressure and serum lipids. ( Degen, A; Lorenz, H; Reuter, MK; Smith, N; Verho, M; Verho, P, 1998) |
| "The efficacy and safety of nisoldipine CC and felodipine were compared in a multicentre, randomised, double-blind, trial in patients with mild-to-moderate hypertension (n = 229)." | 5.08 | A comparison of nisoldipine coat-core and felodipine in the treatment of mild-to-moderate hypertension. ( Hoglund, C; Hutchinson, HG, 1998) |
| "This study compared the antihypertensive efficacy and tolerability of a combination tablet containing the vascular-selective calcium antagonist felodipine and the beta1-selective adrenergic antagonist metoprolol, with a combination tablet of captopril-hydrochlorothiazide in a randomized, double-blind trial involving 109 patients with mild to moderate hypertension." | 5.08 | Combination therapy with felodipine and metoprolol compared with captopril and hydrochlorothiazide. German MC Study Group. ( Klein, G, 1998) |
| "Efficacy, tolerability, and optimal doses of felodipine ER (FER) and diltiazem SR (DSR), given as monotherapy, were evaluated in patients with mild or moderate primary hypertension." | 5.07 | Efficacy and tolerability of felodipine ER and diltiazem SR as monotherapy in primary hypertension: a double-blind randomized study. ( Almkvist, H; Berglund, L; Björnsson, T; Fagher, B; Henningsen, N; Honkavaara, M; Naukkarinen, V; Nordenström, P; Sillanpää, J; Thulin, T, 1994) |
| "This study compared the efficacy and tolerability of monotherapy with felodipine and enalapril in patients with essential hypertension using a double-blind randomised crossover design." | 5.07 | Comparison of felodipine and enalapril monotherapy in essential hypertension. ( Dufek, A; Watts, RW; Wing, LM, 1993) |
| "Using a randomised double-blind crossover design with Latin square allocation of treatments in 20 subjects (7 male, 13 female-ages: 61-87 years) with systolic hypertension, we investigated the efficacy and tolerability of once daily felodipine (extended release) 5-20 mg, enalapril 5-20 mg and their combination compared with placebo in four treatment phases each of 6 weeks duration." | 5.07 | Mono- and combination therapy with felodipine or enalapril in elderly patients with systolic hypertension. ( Bune, AJ; Chalmers, JP; Russell, AE; Tonkin, AL; Watts, RW; West, MJ; Wing, LM, 1994) |
| "This study compared with placebo the efficacy and tolerability of optimised doses of felodipine 5-20 mg daily, metoprolol 50-200 mg daily and their combination in subjects 60 years or over with isolated systolic hypertension." | 5.07 | Felodipine, metoprolol and their combination compared with placebo in isolated systolic hypertension in the elderly. ( Bune, AJ; Chalmers, JP; Russell, AE; Tonkin, AL; West, MJ; Wing, LM, 1994) |
| "The aim of this study was to compare the tolerability and efficacy of isradipine and felodipine in the treatment of mild-moderate hypertension." | 5.07 | A comparison of isradipine and felodipine in Australian patients with hypertension: focus on ankle oedema. The Physician's Study Group. ( Cutler, SA; Hammond, JJ, 1993) |
| "In a double-blind cross-over study, the arterial changes produced by hydrochlorothiazide were compared with those observed after the calcium antagonist felodipine in 16 patients with mild to moderate systemic hypertension." | 5.07 | Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. ( Asmar, RG; Benetos, A; Chaouche-Teyara, K; Raveau-Landon, CM; Safar, ME, 1993) |
| "Twenty patients with mild to moderate hypertension took part in this study consisting of a two-week placebo treatment period, followed by treatment with an extended-release calcium channel blocker, felodipine-ER (5 to 20 mg once daily) for 12 weeks." | 5.07 | Effect of felodipine-ER on blood pressure, platelet function, and rheological properties in hypertension. ( Chou, TZ; Ding, YA; Lee, KW, 1993) |
| "The objective of this study was to compare the tolerability of isradipine and felodipine in patients with mild-to-moderate hypertension." | 5.07 | A multicenter comparison of isradipine and felodipine in the treatment of mild-to-moderate hypertension. The Physician's Study Group. ( Cutler, SA; Hammond, JJ, 1993) |
| "The effect of three calcium entry blockers--verapamil, nifedipine and felodipine--on diuresis, natriuresis, the renin-aldosterone axis, and atrial natriuretic peptide (ANP) levels was studied in 30 previously untreated patients with mild to moderate essential hypertension." | 5.07 | The role of atrial natriuretic peptide in the diuretic effect of Ca2+ entry blockers. ( Ezra, D; Peleg, E; Rosenthal, T; Shamiss, A, 1993) |
| "The antihypertensive effects of lisinopril 10-20 mg once daily and felodipine (extended release formulation) 5-10 mg once daily were compared in a double-blind, parallel group study of eight weeks duration involving 219 patients with mild to moderate hypertension." | 5.07 | Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group. ( Jensen, HA, 1992) |
| "Twenty patients whose systemic hypertension was not controlled with chronic beta-blocker therapy were studied to evaluate the acute (first dose), short-term (4 weeks) and chronic (6 to 12 months) effects of the calcium antagonist felodipine on blood pressure (BP), left ventricular (LV) anatomy and function and on plasma norepinephrine." | 5.07 | Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. ( Holliwell, DL; Leenen, FH, 1992) |
| "Six men with borderline hypertension took felodipine 5 mg with water, grapefruit juice, or orange juice." | 5.07 | Interaction of citrus juices with felodipine and nifedipine. ( Arnold, JM; Bailey, DG; Munoz, C; Spence, JD, 1991) |
| "We have studied the efficacy and tolerability of felodipine plus a beta-adrenoceptor blocker in 79 patients with essential hypertension previously treated with a combination of three or more anti-hypertensive agents, one of which was a beta-adrenoceptor blocker." | 5.07 | Felodipine in combination with a beta-adrenoceptor blocker as an effective substitute for triple therapy in severe hypertension. The Australian Felodipine Multicentre Study Group. ( Agar, J; Aldons, P; Atkins, PF; Frewin, DB; Jackson, B; Karrasch, J; O'Sullivan, EF; Singh, BB; Wilson, LL; Wyndham, RN, 1991) |
| "A double-blind, parallel-group study was performed to assess the antihypertensive effects and tolerability of felodipine and hydrochlorothiazide (HCT) in black patients with mild to moderate uncomplicated hypertension [entry supine diastolic blood pressure (DBP) of 96-116 mm Hg]." | 5.06 | Comparison of felodipine and hydrochlorothiazide for the treatment of mild to moderate hypertension in black Africans. ( Leary, WP; Maharaj, B, 1990) |
| "To investigate the hypotensive and hemodynamic effects of plain and extended-release (ER) formulations of felodipine added to a diuretic in the treatment of moderate essential hypertension, we studied 18 patients in a randomized, double-blind, cross-over study." | 5.06 | Hemodynamic interactions between diuretics and calcium antagonists in the treatment of hypertensive patients. ( Cavallotti, G; de Divitiis, O; Di Somma, S; Liguori, V; Petitto, M; Savonitto, S, 1990) |
| "Eighteen patients with non-insulin dependent diabetes mellitus and hypertension were treated during two 4 week periods with the calcium antagonist felodipine or placebo in a double-blind, randomised, cross-over study." | 5.06 | Effects of felodipine on atrial natriuretic peptide in hypertensive non-insulin dependent diabetes mellitus. ( Brown, J; Capewell, S; Collier, A; Hajducka, C; Jeffrey, RF; Lee, MR, 1990) |
| "The antihypertensive effect of felodipine, a new calcium antagonist with dihydropyridine structure, was investigated in 25 patients with essential hypertension that was not controlled on standard triple therapy (a beta-blocker, a diuretic, and a vasodilator)." | 5.06 | Antihypertensive effects and pharmacokinetics of felodipine combined with a beta-blocker and a diuretic. ( Elmfeldt, D; Hedner, T; Sjögren, E, 1987) |
| "Studies were performed in nine patients with essential hypertension to explore the effect of the calcium antagonist felodipine on the exercise-induced responses of the sympathetic and renin-angiotensin-aldosterone systems as well as of blood pressure and heart rate." | 5.06 | Catecholamines, renin-angiotensin-aldosterone, and cardiovascular response during exercise following acute and long-term calcium antagonism with felodipine in essential hypertension. ( Hökfelt, B; Hulthén, UL; Katzman, PL, 1987) |
| "The role of felodipine, a new calcium antagonist, in monotherapy for mild and moderate hypertension was investigated in a placebo-controlled double-blind study of 109 patients from 13 centres." | 5.06 | Monotherapy with felodipine, a new calcium antagonist, in mild and moderate hypertension. ( Barnes, PC; Bowles, RM; Comerford, MB; Ginks, SE; Ginks, WR; Goves, JR; Grabau, WJ; Hamilton, DV; Malcolm, JP; Rajaratnam, DV, 1987) |
| "Felodipine was compared with prazosin in patients with essential hypertension whose blood pressure was not controlled by a beta-blocking drug." | 5.06 | Felodipine compared to prazosin as additional therapy to a beta-blocking drug. ( Bune, A; Chalmers, J; Heath, W; Jackson, B; Johnston, C; Mashford, ML; McGrath, B; West, M; Westwood, B; Wing, L, 1987) |
| "In a double-blind randomized study, hydralazine (n = 59) or the new dihydropyridine calcium antagonist felodipine (n = 61) was added to previous treatment with beta-adrenoceptor blocking agents in a group of 120 patients with essential hypertension." | 5.06 | Antihypertensive effect of felodipine or hydralazine when added to beta-blocker therapy. ( Dahlöf, B; Gudbrandsson, T; Hansson, L; Hellsing, T; Kullman, S; Kuylenstierna, J; Leppert, J; Möller, B; Skogström, K; Svensson, A, 1988) |
| " Felodipine is a highly selective dihydropyridine calcium antagonist effective in the treatment of hypertension." | 5.06 | A trial of the calcium antagonist felodipine in hypertensive type 2 diabetic patients. ( Capewell, S; Clarke, BF; Collier, A; Collier, R; Hajducka, C; Matthews, D; Muir, AL, 1989) |
| "To assess the duration of the antihypertensive effect of the dihydropiridine calcium antagonist felodipine in conventional (C-F) and slow-release (ER-F) formulations, 12 patients with essential hypertension underwent ambulatory blood pressure monitoring (ABPM) at the end of a 2-week treatment period with C-F 5 mg b." | 5.06 | Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild-to-moderate hypertension. ( Benemio, G; Boldrini, F; Gatteschi, C; Guerrieri, M; Pollavini, G; Porcellati, C; Verdecchia, P, 1989) |
| "The efficacy and tolerability of felodipine and prazosin were compared in a double-blind randomised parallel group study of 100 patients with moderately severe essential hypertension, treated concomitantly with a beta-blocking drug." | 5.06 | Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study. ( Anderson, A; Gibson, J; Jackson, B; Morgan, TO, 1987) |
| "The role of felodipine, a new calcium antagonist, as monotherapy in mild and moderate hypertension (supine diastolic blood pressure between 95 and 100mm Hg: phase V) was investigated in a placebo-controlled, double-blind study of 109 patients from 13 centres using 3 different doses." | 5.06 | Felodipine, a new calcium antagonist, as monotherapy in mild or moderate hypertension. Cooperative study group. ( , 1987) |
| " The antihypertensive efficacy of two different doses of the calcium antagonist felodipine was evaluated in patients with hypertension persisting despite beta-adrenoceptor blocker therapy." | 5.06 | Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group. ( , 1988) |
| "Studies were performed in 10 male patients with untreated essential hypertension, WHO grade I-II, aged 25-62 years, to explore the acute (single dose) and long-term (8 weeks) effects of felodipine on sympathetic activity--evaluated by plasma and urinary catecholamines--as related to blood pressure, heart rate and the activity in the renin-angiotensin-aldosterone system." | 5.06 | Effects of the calcium antagonist felodipine on the sympathetic and renin-angiotensin-aldosterone systems in essential hypertension. ( Hökfelt, B; Hulthén, UL; Katzman, PL, 1988) |
| "Eighty one patients with uncomplicated hypertension who required additional antihypertensive medication (diastolic Phase V [dBP] greater than or equal to 95 mm Hg) after 4 weeks treatment with hydrochlorothiazide (HCTZ) 25 mg o." | 5.06 | A comparison of felodipine and propranolol as additions to hydrochlorothiazide in the treatment of hypertension. ( Carle, WK; Latta, D; Lees, CT; Lough, JR; Peers, EM; Pender, J; Richardson, PD; Ross, JR; Sefton, S, 1988) |
| "To investigate the use of felodipine in severe hypertension 2 separate studies were carried out." | 5.06 | The use of felodipine in the treatment of severe hypertension. ( Muir, AL; Wathen, CG, 1987) |
| "In a double-blind parallel-group study 133 patients with mild to moderate essential hypertension were randomised to felodipine 5mg twice daily or Moduretic mite every morning after a run-in placebo period of 1 to 2 weeks." | 5.06 | Felodipine versus Moduretic. A double-blind parallel-group multicentre study. ( Flygt, G; Krönig, B, 1987) |
| "In a double-blind cross-over study, the effect on blood pressure (BP), heart rate (HR) and plasma noradrenaline concentration (pNA) of placebo or felodipine given in addition to hydrochlorothiazide was studied in 12 male patients with essential hypertension, not satisfactorily controlled with the diuretic alone." | 5.06 | Treatment of essential hypertension with felodipine in combination with a diuretic. ( Elmfeldt, D; Hedner, T; Samuelsson, O; Sjögren, E, 1986) |
| "The influence of acute and chronic treatment with felodipine on ambulatory intra-arterial blood pressure, certain cardiac reflexes, and plasma renin activity was studied in nine patients with essential hypertension." | 5.06 | Felodipine, blood pressure, and cardiovascular reflexes in hypertensive humans. ( Littler, WA; Mace, PJ; Smith, SA, 1986) |
| "In a group of 15 men with severe hypertension in a double-blind crossover trial, the new calcium antagonist felodipine has been shown to lower blood pressure as effectively as minoxidil when used in combination with a beta-blocker and a loop diuretic." | 5.05 | Felodipine can replace minoxidil in the treatment of refractory hypertension. ( Forret, EA; Hill, TW; MacLeod, D; Muir, AL; Tucker, L; Wathen, CG, 1985) |
| "The aim of this study was to compare the new vasodilator felodipine with nifedipine in 18 patients with poorly controlled hypertension." | 5.05 | Comparative trial of felodipine and nifedipine in refractory hypertension. ( Aberg, H; Lindsjö, M; Mörlin, B, 1985) |
| " Extended-release nifedipine and amlodipine are the two most commonly used oral CCAs in the management of pediatric hypertension." | 4.83 | A review of calcium channel antagonists in the treatment of pediatric hypertension. ( Sahney, S, 2006) |
| "The plasma concentration versus antihypertensive effect relationship for the calcium antagonist felodipine was investigated in 67 patients with hypertension and 21 healthy subjects by use of the Emax model." | 4.78 | Plasma concentration--effect relationships for felodipine: a meta analysis. ( Blychert, E; Edgar, B; Elmfeldt, D; Hedner, T, 1992) |
| "This review attempts to evaluate the benefit-risk balance of felodipine in the treatment of hypertension." | 4.77 | Aspects on the benefit-risk balance of felodipine in hypertension. ( Elmfeldt, D; Westerling, S, 1987) |
| "The aim of the current study was to assess the association between 3 different calcium channel blockers (CCBs) (nifedipine, amlodipine and felodipine) and gingival overgrowth in patients with a diagnosis of severe refractory hypertension." | 3.88 | Influence of 3 calcium channel blockers on gingival overgrowth in a population of severe refractory hypertensive patients. ( de Souza, RC; Ferreira, DC; Fischer, RG; Gonçalves, LS; Vidal, F, 2018) |
| "In newly diagnosed patients with hypertension, lercanidipine was superior to nifedipine in the six-year period when the analyzed endpoint was stroke." | 3.85 | Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study. ( Cheng, KC; Cheng, KH; Cheng, KY; Lai, WT; Lee, CW; Yang, YH, 2017) |
| "Sorafenib, an orally active multi-kinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC), is primarily metabolized both via cytochrome P450 3A4 isoform (CYP3A4) and UGT1A9." | 3.77 | Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. ( Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Tod, M, 2011) |
| "Felodipine is a vascular-selective, dihydropyridine calcium antagonist previously investigated as a conventional tablet formulation administered twice daily." | 3.77 | Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. ( Faulds, D; Todd, PA, 1992) |
| "In 102 patients with high risk (52 patients with history of myocardial infarction, 50 patients with history of cerebral stroke within previous 6-48 months) arterial hypertension (AH) we studied clinical efficacy on angiotensin converting enzyme inhibitor (ACEI) lisinopril, calcium antagonist felodipine, and nonselective - -blocker carvedilol in dependence on salt sensitivity of AH." | 3.76 | [Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt]. ( Babkin, AP; Gladkikh, VV; Gulaia, GI; Pershukov, IV, 2010) |
| "To evaluate the curative effects of slow releasing felodipine on mild to moderate primary hypertension and its influence on the pulse wave velocity of slow of the patients." | 3.74 | [Curative effects on mild to moderate primary hypertension and influence on pulse wave velocity of slow releasing felodipine]. ( Jing, S; Sun, NL, 2008) |
| "Electron paramagnetic resonance (EPR) spectroscopy was used to investigate the gamma-radiation damage in the crystalline powder form of nine calcium channel blockers from the 1,4-dihydropyridine derivatives, which are in clinical use for treatment of arteria hypertension and ischemic heart disease." | 3.74 | The effect of ionizing radiation of 1,4-dihydropyridine derivatives in the solid state. ( Mielcarek, J; Naskrent, M, 2007) |
| "Valsartan or Plendil could prevent the development of salt-sensitive hypertension induced by sensory denervation and the overloading of intracellular [Ca(2+)](i), which indicated that salt-sensitive hypertension induced by sensory nerve degeneration might be related to renin-angiotensin-aldosterone system (RAAS) and the over loading intracellular [Ca(2+)](i), and might be more closely to RAAS." | 3.73 | [The effect and mechanism of felodipine and valsartan on a novel salt-sensitive hypertensive rat induced by sensory denervation]. ( Han, YF; Ou, BR; Su, CJ, 2005) |
| "Two hundred eighty-three men who were taking amlodipine to manage hypertension." | 3.72 | Evaluation of a therapeutic conversion from amlodipine to felodipine. ( Manzo, BA; Matalka, MS; Ravnan, SL, 2003) |
| " This study was designed to determine the effects of aging and AT-1 receptor blockade (losartan 30 mg/kg/day beginning at 8 weeks of age) on NO system in this model." | 3.71 | Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR. ( Kivlighn, S; Ni, ZN; Shahinfar, S; Vaziri, ND; Wang, XQ, 2002) |
| "The objective of the present study was to evaluate the efficacy and safety of a therapeutic interchange between high-dose calcium channel blocker therapy and a fixed-dose combination of amlodipine/ benazepril (Lotrel; Novartis Pharmaceuticals, USA) in patients with moderate to severe hypertension." | 3.71 | Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension. ( Faulkner, M; Hilleman, DE; Reyes, AP; Wurdeman, RL, 2001) |
| "Felodipine is a second-generation dihydropyridine calcium antagonist used to treat mild to moderate arterial hypertension." | 3.70 | Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension. ( Arrigucci, S; Bicchi, M; Cappelli, R; Forconi, S; Righi, GA; Vedovini, G, 1998) |
| "We present results from a Swedish retrospective cost-effectiveness analysis of felodipine-metoprolol (Logimax) and enalapril in hypertension." | 3.70 | Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension. ( Andersson, F; Andersson, OK; Kartman, B, 1998) |
| "Both enalapril and felodipine ameliorated adverse cardiovascular effects of hypertension in the aged SHRs within 12 weeks, as demonstrated by reduced arterial pressure, diminished left ventricular mass, and improved coronary hemodynamics." | 3.70 | Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. ( Frohlich, ED; Susic, D; Varagic, J, 1999) |
| " Twenty-three patients with moderate essential hypertension were studied before and during acute (10 patients) and chronic (21 patients) treatment with a dihydropyridine calcium antagonist (nifedipine, nicardipine or felodipine) as monotherapy in a dose titrated to produce a fall in mean cuff pressure of at least 10%." | 3.70 | The effects of acute and chronic dihydropyridine calcium antagonist therapy on baroreflex sensitivity: a re-analysis using the sequence method. ( Jordan, PJ; Littler, WA; Stallard, TJ; Vaile, JC, 2000) |
| " This study showed that hypertension induced increments the content of malondialdehyde (MDA) by 55% and 38% as well as the activity of glutathione peroxidase (GSH-Px) by 26% and 23% in heart and kidney, respectively, accompanied by reductions in the activity of myocardial superoxide dismutase (SOD) from 3." | 3.70 | Pumpkin-seed oil modulates the effect of felodipine and captopril in spontaneously hypertensive rats. ( Abd El-Fattah, AA; El-Sayed, MI; Zuhair, HA, 2000) |
| "One hundred patients with hypertension who were receiving amlodipine." | 3.70 | Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers. ( Beckey, NP; Korman, L; Parra, D, 2000) |
| "Eleven men with mild to moderate primary hypertension were studied at rest and during mental stress before and during intravenous infusion of the calcium antagonist felodipine." | 3.69 | Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. ( Hjemdahl, P; Kahan, T; Lindqvist, M; Melcher, A, 1994) |
| "The effects of long-term monotherapy with felodipine, a calcium antagonist, on blood pressure, glucose tolerance, and serum lipid profiles were prospectively investigated in 51 hypertensive patients: 13 with normal glucose tolerance and 38 with glucose intolerance." | 3.69 | Felodipine therapy may not alter glucose and lipid metabolism in hypertensives. Felodipine Multicenter Prospective Study Group in Japan. ( Hariya, Y; Ishii, J; Katayama, S; Kitamoto, K; Nagasawa, K; Nagasawa, T; Ohyama, Y; Sato, R; Shionoiri, H; Takizawa, T, 1994) |
| "The efficacy and tolerability of felodipine, in a low dose of 5-10 mg daily was assessed in 32 patients with mild-to-moderate hypertension, aged 53 +/- 11 years." | 3.69 | Efficacy of low felodipine dose monotherapy in mild-to-moderate hypertension: a comparison between office and ambulatory blood pressure monitoring. ( Bernheim, J; Korzets, Z; Podjarny, E, 1996) |
| "All clinical studies of at least 1 week's duration with felodipine in patients with hypertension were included in a safety analysis." | 3.69 | Overview of the safety of felodipine based on clinical trials in patients with hypertension. ( Elmfeldt, D; Elvelin, L; Niklasson, A; Olsson, G; Welin, L, 1997) |
| "We report three cases of felodipine use in pregnancy by women with chronic hypertension." | 3.69 | Felodipine use in pregnancy. Report of three cases. ( Casele, HL; Gratton, R; Laifer, SA; Prieto, JA; Windley, KC, 1997) |
| "We sought to characterize the effects of the nonselective Ca2+ channel antagonist, verapamil, and the vascular-selective Ca2+ channel antagonist, felodipine, on obese, hypertensive, heart failure-prone, female SHHF/Mcc-fa(cp) rats." | 3.69 | Verapamil accelerates the transition to heart failure in obese, hypertensive, female SHHF/Mcc-fa(cp) rats. ( Altschuld, RA; Hensley, J; Hoepf, TM; Hohl, CM; McCune, SA; Park, S; Radin, MJ, 1997) |
| "To evaluate whether a spontaneous increase in cerebral blood flow (CBF) could be observed in subjects with severe hypertension and to study the effect of a calcium antagonist, felodipine, on blood pressure and CBF after acute and chronic administration." | 3.68 | Cerebral blood flow in patients with severe hypertension, and acute and chronic effects of felodipine. ( Elmqvist, D; Fagher, B; Grabowski, M; Johansson, BB; Ryding, E; Thulin, T, 1993) |
| "Felodipine, a dihydropyridine calcium antagonist, was used to treat eight patients with severe uncontrolled hypertension: five had essential hypertension, two had renovascular disease, and one chronic pyelonephritis." | 3.68 | Long-term effects of felodipine on blood pressure and renal hemodynamics in severe hypertension. ( Aurell, M; Granérus, G; Herlitz, H, 1990) |
| "Twenty-three patients with severe hypertension and impaired renal function were included in an open study of the efficacy and tolerance of felodipine treatment over 6 months." | 3.68 | Felodipine in the treatment of patients with severe hypertension and impaired renal function. ( Bengtsson, U; Danielsson, B; Elmfeldt, D; Hardlund, JH; Larsson, R; Lindsjö, MK; Moberg, L; Sjöström, PA, 1990) |
| " The combination of nitrendipine plus enalapril was also examined in ischemic failure and in rats with spontaneous hypertension." | 3.67 | Enalapril in experimental hypertension and acute heart failure: comparison with calcium channel blockers. ( Adkins, E; Emmert, S; Ludden, CT; Ribeiro, LG; Seymour, AA; Sweet, CS, 1986) |
| "A study has been performed in thirteen patients with essential hypertension, WHO Class I-II, and a diastolic blood pressure greater than or equal to 95 mmHg, on beta-blocker (metoprolol or atenolol) monotherapy, who were also given felodipine 10 mg b." | 3.67 | Haemodynamic effects and pharmacokinetics of felodipine at rest and during exercise in hypertensive patients treated with metoprolol or atenolol. ( Bengtsson-Hasselgren, B; Elmfeldt, D; Moberg, L; Rönn, O, 1989) |
| "The acute hemodynamic and pharmacokinetic interactions between the vasodilating/diuretic drugs ethanol and felodipine, a 1,4-dihydropyridine calcium entry blocker, were assessed in 10 patients with untreated borderline hypertension." | 3.67 | Ethanol enhances the hemodynamic effects of felodipine. ( Arnold, JM; Bailey, DG; Bayliff, CD; Edgar, B; Spence, JD, 1989) |
| "The effects of small doses of felodipine (10 mg twice daily) on blood pressure, renal function and sodium and water balance were studied in 11 patients with arterial hypertension." | 3.67 | Renal and antihypertensive effects of felodipine in hypertensive patients. ( Cuspidi, C; Fruscio, M; Gradnik, R; Leonetti, G; Rupoli, L; Sampieri, L; Terzoli, L; Zanchetti, A, 1985) |
| "Felodipine (Plendil), a new drug, has been used in the treatment of five patients with refractory essential hypertension (WHO II-III)." | 3.67 | Effect of felodipine in refractory hypertension. ( Ekeroth, M; Ostman, J; Seideman, P, 1988) |
| "A dose titration study was performed using felodipine, a new calcium antagonist, in Chinese patients with essential hypertension inadequately controlled by metoprolol alone (DBP greater than 95 mmHg)." | 3.67 | The effects of combining felodipine and metoprolol in moderate to severe hypertension--a one year study. ( Chow, J, 1988) |
| "Studies were performed to explore the effect of calcium antagonism with felodipine for 8 weeks on glucose homeostasis and serum lipids in 8 patients with essential hypertension." | 3.67 | Unchanged insulin secretion and glucose tolerance but increased insulin clearance during long-term calcium antagonism with felodipine in essential hypertension. ( Hökfelt, B; Hulthén, UL; Katzman, PL, 1987) |
| "The effect of 8 weeks' treatment with the dihydropyridine calcium antagonist felodipine on glucoregulatory hormone response following insulin-induced hypoglycaemia was evaluated in 7 patients with essential hypertension, WHO grade I-II." | 3.67 | Glucoregulatory hormone response to insulin-induced hypoglycaemia following long-term calcium antagonism with felodipine in patients with essential hypertension. ( Hökfelt, B; Hulthén, UL; Katzman, PL, 1987) |
| "Oral administration of felodipine to 10 patients with mild essential hypertension acutely reduced the brachial artery pressure by 15/13mm Hg." | 3.67 | Effects of felodipine and metoprolol on blood pressure, plasma renin, angiotensin II, aldosterone and catecholamines in hypertensive patients. ( Amery, A; De Schaepdryver, A; Fagard, R; Lijnen, P; Moerman, E; Staessen, J, 1987) |
| "The calcium antagonist, felodipine, was used to treat 21 patients with severe uncontrolled hypertension: 13 had renoparenchymatous hypertension, 5 essential hypertension and 3 renovascular hypertension." | 3.67 | Clinical evaluation of felodipine in patients with refractory hypertension. ( Aurell, M; Björck, S; Granérus, G; Herlitz, H; Nyberg, G, 1987) |
| "The effect of 8 weeks treatment with the calcium antagonist felodipine--a new long-acting dihydropyridine derivative--in a dose of 10 mg twice daily was studied in 10 male patients with essential hypertension, WHO grade I-II, aged 25-62 years." | 3.67 | The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension. ( Hökfelt, B; Hulthén, UL; Katzman, PL, 1986) |
| "Oral administration of felodipine to 10 patients with mild essential hypertension acutely reduced systemic vascular resistance (SVR) by 40% after 30 min." | 3.67 | Acute haemodynamic and humoral responses to felodipine and metoprolol in mild hypertension. ( Amery, A; Fagard, R; Lijnen, P; Moerman, E; Staessen, J, 1987) |
| "Felodipine is a new dihydropyridine calcium antagonist, and in hypertension it is a much more effective "third-line" drug than hydralazine." | 3.67 | Felodipine compared to nifedipine as "third-line drug" in resistant hypertension. ( Maclean, D; Mitchell, ET; Readman, AS, 1986) |
| "The antihypertensive and vasodilator effects of felodipine, a new calcium antagonist of the dihydropyridine group, were examined in 15 patients with moderate to severe hypertension." | 3.67 | Effect of felodipine and metoprolol on muscle and skin arteries in hypertensive patients. ( Clement, DL; De Pue, NY, 1985) |
| "The new calcium antagonist felodipine with a pronounced arteriolar dilating capacity was used to treat 11 patients with severe hypertension resistant to treatment (4 with essential hypertension, 5 with renoparechymatous hypertension, 2 with renovascular hypertension)." | 3.67 | Renal effects of felodipine in hypertensive patients with reduced renal function. ( Aurell, M; Björck, S; Granérus, G; Herlitz, H, 1985) |
| "The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker." | 2.79 | The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. ( Chen, W; Fang, H; Liu, X; Xu, W, 2014) |
| "Hypertension is a major risk factor for vascular disease, yet blood pressure (BP) control is unsatisfactory low, partly due to side-effects." | 2.77 | Antihypertensive effect of low-frequency transcutaneous electrical nerve stimulation (TENS) in comparison with drug treatment. ( Manhem, K; Mannheimer, C; Mourtzinis, G; Silverdal, J; Stener-Victorin, E, 2012) |
| "When felodipine was compared to placebo, the benefit of a lower SBP/DBP caused by felodipine was evident in the no-add-on patients (hazard ratio 0." | 2.77 | Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: is adding drugs always beneficial? ( Liu, L; Tang, X; Wang, Y; Zanchetti, A; Zhang, X; Zhang, Y, 2012) |
| " The morning dosage was titrated if the goal blood pressure was not achieved." | 2.74 | [Impact of antihypertensive medication timing on degree and stability of blood pressure lowering in patients with essential hypertension]. ( Bai, B; Cui, TQ; Hou, JN; Jiang, LS; Mu, CL; Zhao, CP, 2009) |
| "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment." | 2.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| " Amlodipine did not affect cardiac function in the young, and with chronic dosing decreased the heart rate by 3-5 bpm and the cardiac index by 0." | 2.72 | Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients: amlodipine versus felodipine extended release. ( Coletta, E; Leenen, FH; White, R, 2006) |
| "Despite efforts to diagnose and treat hypertension effectively, the goal of lowering blood pressure (BP) levels is rarely achieved, as treatment is often initiated with a single antihypertensive agent." | 2.72 | Initiation of hypertension treatment with a fixed-dose combination or its monocomponents -- does it really matter? ( Bida, M; Dörffel, Y; Hansen, A; Juncken, D; Rangoonwala, B; Ritz, A; Schnitker, J; Scholze, J, 2006) |
| " There is a need for efficacious, safe, and well-tolerated antihypertensive agents with a once-a-day dosing regimen in children and adolescents." | 2.71 | Clinical trial of extended-release felodipine in pediatric essential hypertension. ( Frank, R; Klibaner, M; Mahan, JD; Matoo, TK; Portman, R; Restaino, I; Tou, C; Trachtman, H, 2003) |
| "Enalapril was started at 10 mg/day, felodipine-ER at 5 mg/day and nifedipine-GITS at 30 mg/day, all once daily." | 2.70 | Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril. ( Joyner, CD; Leenen, FH; Myers, MG; Toal, CB, 2002) |
| "Felodipine was the basic drug used." | 2.70 | Reduction in diastolic blood pressure and cardiovascular mortality in nondiabetic hypertensive patients. A reanalysis of the HOT study. ( Andrade, J; Lopes, AA; Noblat, AC; Silveira, MA, 2001) |
| " The cardinal questions to be answered were: (1) the relationship between three targeted diastolic pressures (< or = 90, < or = 85 and < or = 80 mm Hg, respectively) and cardiovascular morbidity and mortality rates among hypertensives; and (2) the effect of low dosage aspirin (75 mg daily) on morbidity and mortality rates, compared with a placebo." | 2.69 | [The Hypertension Optimal Treatment (HOT) study: results of 12-month therapy related to age]. ( Kolloch, RE; Rahn, KH, 1998) |
| " Amlodipine seems to be more effective than felodipine when the drugs are compared in the same dose, with regard to the effect on clinic BP 24 h after dosing and to ambulatory BP during the night." | 2.69 | Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension. ( Brodin, U; Isaksson, H; Ohman, KP; Ostergren, J; Schwan, A, 1998) |
| "Felodipine-treated patients decreased on the 36th month, but remained over 80%." | 2.69 | [The Hypertension Optimal Treatment Study: efficacy and tolerability on the 36th month]. ( Baguet, JP; Benkritly, A; Herpin, D; Mallion, JM; Tremel, F, 1998) |
| "The primary aim of this double-blind, parallel group trial was to compare incidence of newly occurring vasodilatory adverse events in elderly patients treated with recommended once-daily doses of felodipine extended release (ER) or amlodipine." | 2.69 | Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. ( Aldons, PM; Burgess, ED; Girerd, X; Morgan, TO; Rehn, L; Schaefer, RM; Singh, GP; Tilvis, R, 1998) |
| " Each patient received 50 mg of losartan or 5 mg of felodipine ER once daily, and the dosage was adjusted to double the initial level at week 6 if necessary." | 2.69 | Comparison of antihypertensive efficacy and tolerability of losartan and extended-release felodipine in patients with mild to moderate hypertension. ( Cherng, WJ; Hsieh, IC; Hung, KC; Hung, MJ; Lin, FC; Wang, CH; Wen, MS; Wu, D, 1999) |
| "Obesity is a significant risk factor for hypertension and the cardiovascular sequelae of hypertension." | 2.69 | The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. ( Adair, CT; Anderson, DC; Cameron, ME; Jones, DW; King, NS; Miller, ME; Willoughby, DL; Wofford, MR, 1999) |
| " Drug dosage was determined in an initial stepped-care titration phase lasting six weeks." | 2.69 | Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension. ( De Rosa, ML; Della Guardia, D; Giordano, A; Lionetti, F; Maddaluno, G; Marsicani, N; Vigorito, C, 1999) |
| "Amlodipine has potential advantages in children since it can be dissolved into a liquid preparation and has a long elimination half-life, allowing for once-daily administration." | 2.69 | A randomized prospective crossover trial of amlodipine in pediatric hypertension. ( Arbus, GS; Blowey, D; Khattak, S; Koren, G; Lyszkiewicz, DA; Rogan, JW, 2000) |
| " A secondary aim was to relate the efficacy of the free and fixed combinations with pharmacokinetic profiles." | 2.69 | The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients. ( Elliott, HL; Hosie, J; MacDonald, TM; McLay, JS, 2000) |
| " At the end of the dosing interval, felodipine lowered office DBP (mm Hg) by -18 +/- 12/14 +/- 1 compared to -14 +/- 2/11 +/- 1 for nifedipine (P < or = ." | 2.68 | Differential effects of felodipine and nifedipine on 24-h blood pressure and left ventricular mass. ( Leenen, FH; Myers, MG; Tanner, J, 1995) |
| "Losartan was shown to have a smooth antihypertensive profile throughout the 24 h period following dosing, which mirrors the diurnal variability of blood pressure." | 2.68 | Efficacy and safety of losartan. ( Goldberg, A; Sweet, C, 1995) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 2.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| "To characterize the population dose-response and concentration-response relationships of felodipine and to investigate the influence of patient variables on these relationships." | 2.68 | Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. ( Sambol, NC; Wade, JR, 1995) |
| "Felodipine was remarkably well tolerated, and most of the patients were able to continue this drug regimen." | 2.68 | Hypertension optimal treatment: the Israeli HOT Study Group. Hypertension Optimal Treatment. ( Rosenthal, T, 1996) |
| "Only felodipine ER 5 mg has a significant reducing effect on BP load during day and night time." | 2.68 | Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life. ( van der Pol, GA; van Ree, JW, 1996) |
| " Significant differences were found between all principal pharmacokinetic variables, when comparing the 2 treatments after both single and repeated dosing." | 2.68 | Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients. ( Jacobsen, IA; Videbaek, LM, 1997) |
| " Further dosage adjustments are made in accordance with a set protocol." | 2.67 | The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. ( Hansson, L; Zanchetti, A, 1994) |
| "Felodipine was well tolerated." | 2.67 | Extended-release felodipine in patients with mild to moderate hypertension. Felodipine ER Dose-Response Study Group. ( Faison, EP; Goldberg, AI; Irvin, JD; Lipschutz, K; Nelson, EB; Shapiro, DA; Weber, MA, 1994) |
| " After 12 weeks of active treatment, reductions in supine systolic/diastolic blood pressure 24 h after dosing were 20/14, 13/10 and 11/8 mmHg with felodipine-metoprolol, felodipine and metoprolol, respectively." | 2.67 | Antihypertensive efficacy and tolerability of a new once-daily felodipine-metoprolol combination compared with each component alone. The Swedish/UK Study Group. ( Dahlöf, B; Hosie, J, 1993) |
| " as basic antihypertensive treatment with the addition of a beta-blocker or an ACE-inhibitor in a second step, with further predetermined increments in dosage as required in order to obtain the randomized therapeutic goal." | 2.67 | The Hypertension Optimal Treatment Study (the HOT Study). ( , 1993) |
| "and felodipine PT b." | 2.67 | Antihypertensive effect and tolerability of felodipine extended release (ER) tablets in comparison with felodipine plain tablets (PT) and placebo in hypertensives on a diuretic. Canadian Study Group. ( Carruthers, SG; Vint-Reed, C, 1993) |
| "Felodipine was completely absorbed from an oral solution (OS), as well as from the conventional (CT) and extended release (ER) tablets." | 2.67 | Felodipine pharmacokinetics and plasma concentration vs effect relationships. ( Blychert, E, 1992) |
| " For a majority of hypertensive patients the adequacy of blood pressure control and the simplicity of once daily dosing will favour the extended release tablet given once daily." | 2.67 | Twenty-four hour blood pressure profiles in hypertensive patients following various formulations and dosage regimens of felodipine. ( Blychert, E; Frisén, M; Karlsson, O; Rydén, L, 1992) |
| " The absolute bioavailability of felodipine ER was 22%." | 2.67 | Plasma concentration-effect relationships of intravenous and extended-release oral felodipine in hypertensive patients. ( Blychert, E; Dahlöf, C; Elmfeldt, D; Hedner, T, 1990) |
| " Altogether, 251 hypertensive patients with a diastolic blood pressure greater than 95 mm Hg after 4 weeks of treatment with placebo in combination with metoprolol CR 100 mg were randomized to four parallel groups." | 2.67 | Optimal felodipine dose when combined with metoprolol in arterial hypertension: a Swedish multicenter study within primary health care. Swedish General Practitioner Felodipine Study Group. ( Bengtsson, C; Brun, J; Fröberg, L; Kronmann, P; Olsson, LB; Scherstén, B; Skoog, P; Tibblin, G; Tygesen, G, 1990) |
| "Felodipine ER once daily was as effective and tolerable as plain tablets b." | 2.67 | Felodipine extended-release tablets once daily are equivalent to plain tablets twice daily in treating hypertension. Dutch Hospital Multicentre Group. ( Hart, W; Westberg, B, 1990) |
| " Plasma noradrenaline concentration increased after both acute and chronic administration (p less than 0." | 2.67 | Beta-adrenergic receptors and reflex tachycardia after single and repeated felodipine administration in essential hypertension. ( Baldi, G; Bertora, P; Bevilacqua, M; Chebat, E; Norbiato, G; Peruzzi, E; Renesto, E; Sardina, M; Savonitto, S; Vago, T, 1991) |
| "Treatment with felodipine ER over 2 weeks increased sympathetic outflow as indicated by elevated plasma norepinephrine levels, whereas plasma epinephrine was mainly unaffected, as were plasma renin and aldosterone levels." | 2.67 | Catecholamines and the renin-angiotensin-aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension. ( Binner, L; Gabrielsen, F; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991) |
| "5 h after dosing with HCTZ, which was not significantly lower." | 2.67 | Comparison of once daily felodipine 10 mg ER and hydrochlorothiazide 25 mg in the treatment of mild to moderate hypertension. ( Binner, L; Hehr, R; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991) |
| " The pharmacokinetic characteristics and reduction in diastolic BP were similar to those in hypertensive patients with normal renal function and in uremic patients who were not treated with dialysis." | 2.67 | Pharmacokinetics of felodipine in chronic hemodialysis patients. ( Aberg, J; Buur, T; Larsson, R; Regårdh, CG, 1991) |
| "Hydrochlorothiazide treatment was accompanied by a decrease in serum potassium and an increase in serum uric acid." | 2.67 | The efficacy and tolerability of long-term felodipine treatment in hypertension. The Scandinavian Multicenter Group. ( Ibsen, H; Westberg, B, 1990) |
| "Felodipine Er, 10 mg, was given once daily for 2 weeks, and after another wash-out period of 1 week, patients were switched to 25 mg HCTZ, once daily, and vice versa." | 2.67 | Effects of felodipine ER and hydrochlorothiazide on blood rheology in essential hypertension--a randomized, double-blind, crossover study. ( Binner, L; Ernst, E; Hehr, R; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991) |
| "Felodipine (Plendil) is a once daily antihypertensive calcium antagonist." | 2.67 | Felodipine as monotherapy in Asian patients with mild to moderate hypertension. ( Tan, AT; Woo, BY; Yeoh, TK, 1990) |
| " The dosage of felodipine or nifedipine was doubled if seated diastolic blood pressure exceeded 95 mmHg, 2 or 4 weeks after randomisation." | 2.67 | Control of blood pressure in hypertensive patients with felodipine extended release or nifedipine retard. ( Littler, WA, 1990) |
| "1." | 2.67 | Felodipine ER formulation in the treatment of mild hypertension: efficacy and tolerability vs placebo. ( Bossini, A; Cagli, V; Cavallotti, G; Di Veroli, C, 1990) |
| " The rate of absorption increased in the order extended-release tablets, conventional tablets, solution." | 2.67 | Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets. ( Blychert, E; Edgar, B; Lidman, K; Wingstrand, K, 1990) |
| "Felodipine-ER once daily is an effective antihypertensive drug for patients who require therapy in addition to a beta-blocker; the tolerability in this study was good, and a starting dose greater than 10 mg once daily is not indicated." | 2.66 | A dose-finding, placebo-controlled study on extended-release felodipine once daily in treatment of hypertension. ( Barnes, P; Cambell, LM; Goves, JR; Lees, CT; McCullagh, A; Richardson, PD; Ross, JR; Timerick, SJ, 1989) |
| "Felodipine alone was sufficient to control blood pressure in 90% of patients, while 50% of patients who were receiving diuretic therapy required a second agent for control." | 2.66 | Cardiovascular-risk reduction: initial diuretic therapy compared with calcium-antagonist (felodipine) therapy for primary hypertension. ( Bruce, A; Jennings, GL; Sudhir, K, 1989) |
| "Felodipine was generally well tolerated." | 2.66 | Antihypertensive effects of felodipine compared with placebo. ( Elmfeldt, D; Hedner, T, 1985) |
| "The felodipine treated patients experienced more ankle swelling and flushing than those in the hydralazine group who experienced more headache and minor gastro-intestinal upset." | 2.66 | Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension. Cooperative Study Group. ( , 1986) |
| "Felodipine is an effective antihypertensive agent when used with metoprolol." | 2.66 | Hormonal and blood pressure responses to tilting in beta-blocked essential hypertension treated with felodipine or prazosin. ( Jackson, B; Johnston, CI; McGrath, BP, 1987) |
| " Blood pressure was significantly reduced during the dosage interval of felodipine (12 h)." | 2.66 | Glucose tolerance in hypertensive patients during treatment with the calcium antagonist, felodipine. ( Elmfeldt, D; Hedner, T; Sjögren, E; Smith, U; Von Schenck, H, 1987) |
| " The ramipril/felodipine ER combination is as well tolerated as ramipril or felodipine ER monotherapy administered at the same dosages, and is better tolerated than felodipine ER monotherapy given at twice the dosage used in the combination." | 2.43 | Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension. ( Cvetković, RS; Plosker, GL, 2005) |
| " In one study that titrated dosages to effect, fewer felodipine/metoprolol than felodipine or metoprolol monotherapy recipients required dosage increases to achieve BP control (45 vs 60 and 67%, respectively)." | 2.41 | Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension. ( Haria, M; Markham, A; Plosker, GL, 2000) |
| "1%) were the most commonly reported clinical adverse experiences in patients treated with losartan." | 2.39 | Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| "Felodipine is a highly vascular selective calcium entry blocker, with a vascular selectivity ratio greater than 100, as shown experimentally." | 2.39 | Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. ( Cheng, CP; Elvelin, L; Little, WC; Nordlander, M, 1995) |
| " In patients with congestive heart failure, chronic dosing with felodipine produces a persistent reduction in vascular resistance and an increase in cardiac output, both at rest and during exercise." | 2.38 | Treatment of hypertension with felodipine in patients with concomitant diseases. ( Gradman, AH, 1993) |
| "The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects, and dosage of felodipine and isradipine are reviewed." | 2.38 | Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. ( Symes, LR; Walton, T, 1993) |
| "Felodipine appears to lower blood pressure effectively in the elderly patient with few, generally mild, adverse effects." | 2.38 | Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients. ( DeQuattro, V, 1992) |
| "Felodipine is a new calcium antagonist with vascular selectivity." | 2.38 | Vascular selectivity of felodipine: clinical experience. ( Sheridan, DJ; Thomas, P, 1990) |
| "Felodipine is a new calcium antagonist that was developed aiming particularly at reduction in vascular resistance-without any decrease in heart pump function." | 2.38 | Hemodynamic effects of felodipine in hypertension: a review. ( Lund-Johansen, P, 1990) |
| "Felodipine has a dose-related effect on diastolic BP whether given alone or with a beta-blocker." | 2.38 | Dose-plasma concentration--effect relationship of felodipine in essential hypertension: a review. ( Reid, JL, 1990) |
| "Felodipine is a dihydropyridine that blocks the slow entry channel for calcium." | 2.38 | A review of the antihypertensive effects of felodipine alone or in combination. ( Morgan, TO, 1990) |
| "Felodipine is a calcium antagonist that has potentially beneficial effects in angina pectoris and congestive heart failure." | 2.38 | The safety of felodipine. ( Lorimer, AR; Pringle, SD, 1990) |
| "Felodipine does not cause orthostatic hypotension since it has no effect in clinical doses on venous smooth muscle." | 2.37 | Felodipine in hypertension--a review. ( Elmfeldt, D; Hedner, T; Westerling, S, 1987) |
| "Felodipine is a dihydropyridine calcium antagonist which selectively relaxes vascular smooth muscle." | 2.37 | Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. ( Ellrodt, AG; Langley, MS; Monk, JP; Saltiel, E, 1988) |
| " This impelled us to improve its solubility, bioavailability, and pharmacodynamic properties through the Nanocrystal (NC) approach." | 1.72 | Appraisal of Felodipine Nanocrystals for Solubility Enhancement and Pharmacodynamic Parameters on Cadmium Chloride Induced Hypertension in Rats. ( Maurya, P; Pandey, P; Saraf, SA; Singh, S; Sonkar, A, 2022) |
| " These findings may apply to drugs administered as a single dosage form or in separate dosage forms and hence need to be well controlled to assure effective treatments and patient safety." | 1.56 | Insights into Dissolution and Solution Chemistry of Multidrug Formulations of Antihypertensive Drugs. ( Alhalaweh, A; Bergström, CAS; El Sayed, M, 2020) |
| "Objective of the present investigation was to enhance the bioavailability of felodipine by targeting the M cells of Peyer's patches using PLGA nanoparticles (NPs)." | 1.40 | Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design. ( Joshi, G; Sawant, K; Shah, U, 2014) |
| "Felodipine has a protective effect on the myocardium and kidney as evidenced by decreased perivascular inflammation, myocardial necrosis and fibrosis." | 1.36 | Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats. ( Franco, M; Janicki, JS; Matsubara, BB; Matsubara, LS, 2010) |
| "Felodipine was given to patients in group A after levothyroxine was administered, resulting in normalization of blood pressure and a significant decrease of aortic stiffness index (P <." | 1.31 | Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. ( Dernellis, J; Panaretou, M, 2002) |
| "Ramipril or felodipine treatments did not significantly affect the heart rate, either alone or in combination." | 1.30 | Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats. ( Karppanen, H; Laakso, J; Malmberg, L; Mervaala, EM; Teräväinen, TL; Vapaatalo, H, 1997) |
| "Arterial hypertension is a cardinal precursor of congestive heart failure, and diastolic dysfunction is the most frequent mechanism for it." | 1.30 | [Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999) |
| "Because hypertension is a risk factor for stroke, and because severe BP elevation may increase oedema and the risk of haemorrhage, acute antihypertensive therapy might seem reasonable." | 1.29 | [Reducing hypertension may worsen symptoms of acute apoplexy]. ( Garde, E; Jørgensen, HS; Lassen, NA; Olsen, TS, 1995) |
| "Felodipine was equally effective at both time points." | 1.29 | Time-dependent efficacy of antihypertensive agents in spontaneously hypertensive rats. ( Janssen, BJ; Oosting, J; Struyker-Boudier, HA; Tyssen, CM, 1993) |
| " Systolic and diastolic blood pressures were significantly lowered with long-term administration of felodipine (from 159 +/- 12/105 +/- 5 to 141 +/- 11/87 +/- 7 mm Hg, p = 0." | 1.29 | Scintigraphic evaluation of the short- and long-term renal effects of oral felodipine using technetium-99m-mercaptoacetyl triglycine. ( Bekdik, C; Erbas, B; Erbengi, G; Oram, E; Ozdemir, O; Ugur, O; Varoglu, E, 1993) |
| "Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure." | 1.29 | Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. ( Lund-Johansen, P; Omvik, P, 1993) |
| "Felodipine appears to be a highly potent, well tolerated drug and offers a substitute treatment for severe hypertensives refractory to other vasodilators." | 1.29 | Felodipine in the treatment of severe refractory hypertension. ( Carroll, J; Grossman, E; Katz, A; Nussinovitch, N; Rachima, C; Rosenthal, T; Shamiss, A, 1996) |
| " The in vitro dissociation constant (Kd) of felodipine to the calcium channel in the heart of rats was determined, and was compared to the in vivo dissociation constant (Kd,calc) estimated by the pharmacodynamic analysis of the concentration-effect data in Japanese essential hypertensive patients obtained from literature." | 1.29 | In vitro-in vivo correlation of pharmacodynamics of felodipine in essential hypertensive patients based on an ion-channel binding model. ( Iga, T; Kotaki, H; Nakajima, Y; Sawada, Y; Shimada, S; Yamamoto, K, 1996) |
| "The results confirm that effective treatment of hypertension significantly reduced basal [Ca2+]i in platelets but raise doubts whether elevated basal [Ca2+]i is necessarily the sole mechanism by which the sensitivity of platelets to aggregatory agents is increased in hypertension." | 1.28 | Treatment of hypertension induces a fall in platelet basal cytoplasmic calcium concentration without influencing platelet aggregation. ( Baig, MW; Davies, JA; Lees, AD; Orchard, MA; Perrins, EJ; Prentice, CR; Wilson, J, 1992) |
| "This felodipine effect was stronger and longer lasting than the nifedipine one." | 1.28 | [Antihypertensive effect of felodipine, a new calcium antagonist]. ( Hayashi, S; Inoue, T; Inukai, T; Nakao, K; Odagiri, N; Omosu, M; Ono, T; Sakaguchi, S, 1992) |
| " The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS)." | 1.28 | Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ( Aberg, J; Gelin, A; Karlberg, BE; Larsson, R; Regårdh, CG, 1990) |
| "Felodipine treatment produced a significant decrease in blood pressure in SHRSP (control SHRSP: 240 +/- 7 mmHg, n = 6; felodipine-treated SHRSP: 164 +/- 8 mmHg, n = 5, P less than 0." | 1.28 | Effect of felodipine on blood pressure and vascular reactivity in stroke-prone spontaneously hypertensive rats. ( Bruner, CA; Webb, RC, 1989) |
| "When felodipine was given as single drug to 14 previously untreated hypertensives in a single-blind manner, BP was rapidly reduced by about 15% while HR increased by 25%." | 1.27 | Short-term effects of felodipine, a new dihydropyridine, in hypertension. ( Aberg, H; Andersson, O; Bengtsson, C; Elmfeldt, D; Haglund, K; Hedner, T; Ostman, J; Seideman, P; Sjöberg, KH; Strömgren, E, 1984) |
| "Enalapril treatment (5 mg/kg/day, n = 11) or felodipine (30 mg/kg/day, n = 11) reduced systolic blood pressure to a comparable degree." | 1.27 | Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat. ( Cubela, R; Debrevi, L; Jackson, B; Johnston, CI; Whitty, M, 1987) |
| "Felodipine, a new dihydropyridine, was given to 58 hypertensive patients in combination with an adrenergic beta-receptor antagonist and a diuretic agent." | 1.27 | Long term experience of felodipine in combination with beta-blockade and diuretics in refractory hypertension. ( Collste, P; Danielsson, M; Elmfeldt, D; Feleke, E; Gelin, A; Hedner, T; Rydén, L, 1985) |
| "075 mg/kg) of felodipine in combination with the beta-blocker and diuretic." | 1.27 | Felodipine in combination with a beta-blocker and a diuretic in chronic treatment of patients with refractory primary hypertension. ( Andersson, OK; Granérus, G; Hedner, T, 1987) |
| " Cmax (17 nmol/L), Cmin (5 nmol/L) and AUC (82 nmol/L." | 1.27 | Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ( Edgar, B; Gabrielsson, M; Landahl, S; Larsson, M; Lernfelt, B; Lundborg, P; Regårdh, CG, 1988) |
| "The felodipine-induced increase of heart rate (HR) persisted for 90 min, but the increase of stroke volume was only transient." | 1.27 | The use of Doppler echocardiography to assess the acute haemodynamic response to felodipine and metoprolol in hypertensive patients. ( Amery, A; Fagard, R; Staessen, J, 1987) |
| "Felodipine was acutely administered by a constant infusion, 1." | 1.27 | Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ( Collste, P; Edgar, B; Haglund, K; Regårdh, CG, 1987) |
| " Following long term administration of felodipine cardiac output remained elevated owing to an increase in stroke volume." | 1.27 | Haemodynamic effects of short and long term administration of felodipine in spontaneously hypertensive rats. ( Nordlander, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 101 (24.05) | 18.7374 |
| 1990's | 217 (51.67) | 18.2507 |
| 2000's | 67 (15.95) | 29.6817 |
| 2010's | 32 (7.62) | 24.3611 |
| 2020's | 3 (0.71) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, W | 1 |
| Zhang, J | 1 |
| Jin, F | 1 |
| Zhou, H | 1 |
| El Sayed, M | 1 |
| Alhalaweh, A | 1 |
| Bergström, CAS | 1 |
| Maurya, P | 1 |
| Pandey, P | 1 |
| Singh, S | 2 |
| Sonkar, A | 1 |
| Saraf, SA | 1 |
| Vidal, F | 1 |
| de Souza, RC | 1 |
| Ferreira, DC | 1 |
| Fischer, RG | 1 |
| Gonçalves, LS | 1 |
| Elhebir, ES | 1 |
| Hughes, JD | 1 |
| Hilmi, SC | 1 |
| Yang, L | 2 |
| Yu, J | 3 |
| Ma, R | 2 |
| Zhao, F | 3 |
| Lin, X | 2 |
| Liu, P | 1 |
| Hu, H | 2 |
| Bai, F | 3 |
| Shah, U | 1 |
| Joshi, G | 1 |
| Sawant, K | 1 |
| Jiao, Y | 1 |
| Chen, L | 1 |
| Zheng, JT | 1 |
| Ke, YN | 1 |
| Wang, Y | 2 |
| Yang, HY | 1 |
| Jin, H | 3 |
| Zhao, XL | 1 |
| Liu, MX | 1 |
| Wang, L | 1 |
| Wang, BY | 1 |
| Li, DY | 1 |
| Fang, H | 1 |
| Chen, W | 1 |
| Liu, X | 1 |
| Xu, W | 1 |
| Wu, Y | 2 |
| Xu, M | 2 |
| Wang, H | 3 |
| Xu, X | 2 |
| Zhao, S | 2 |
| Zhang, M | 2 |
| Yan, J | 2 |
| Wang, B | 2 |
| Gong, J | 2 |
| Lu, X | 2 |
| Peng, J | 2 |
| Dai, Q | 2 |
| Navadiya, K | 1 |
| Tiwari, S | 1 |
| Khan, YH | 1 |
| Sarriff, A | 1 |
| Adnan, AS | 1 |
| Khan, AH | 1 |
| Malhi, TH | 1 |
| Jummaat, F | 1 |
| Seravalle, G | 2 |
| Brambilla, G | 1 |
| Pizzalla, DP | 1 |
| Casati, A | 1 |
| Riva, M | 1 |
| Cuspidi, C | 3 |
| Bombelli, M | 1 |
| Mancia, G | 2 |
| Grassi, G | 2 |
| Cheng, KH | 1 |
| Cheng, KC | 1 |
| Cheng, KY | 1 |
| Yang, YH | 1 |
| Lee, CW | 1 |
| Lai, WT | 1 |
| Thongsri, T | 1 |
| Goldberg, AI | 4 |
| Dunlay, MC | 2 |
| Sweet, CS | 4 |
| Runikhina, NK | 1 |
| Tkacheva, ON | 1 |
| Ageev, FT | 1 |
| Deev, AD | 1 |
| Trenkwalder, P | 4 |
| Schaetzl, R | 1 |
| Borbas, E | 1 |
| Handrock, R | 1 |
| Klebs, S | 1 |
| Jing, S | 1 |
| Sun, NL | 2 |
| Musikhina, NA | 1 |
| Iuferova, OV | 1 |
| Gapon, LI | 1 |
| Makhneva, EA | 1 |
| Belikova, EA | 1 |
| Petelina, TI | 1 |
| Todosiĭchuk, VV | 1 |
| Al-Niaimi, F | 1 |
| Lyon, C | 1 |
| Mu, CL | 1 |
| Zhao, CP | 1 |
| Hou, JN | 1 |
| Jiang, LS | 1 |
| Cui, TQ | 1 |
| Bai, B | 1 |
| Rybczynska, A | 1 |
| Jurska-Jasko, A | 1 |
| Boblewski, K | 1 |
| Lehmann, A | 1 |
| Orlewska, C | 1 |
| Matsubara, BB | 1 |
| Franco, M | 1 |
| Janicki, JS | 1 |
| Matsubara, LS | 1 |
| Zhang, Y | 6 |
| Zhang, X | 4 |
| Liu, L | 4 |
| Zanchetti, A | 10 |
| Gomo, C | 1 |
| Coriat, R | 1 |
| Faivre, L | 1 |
| Mir, O | 1 |
| Ropert, S | 1 |
| Billemont, B | 1 |
| Dauphin, A | 1 |
| Tod, M | 1 |
| Goldwasser, F | 1 |
| Blanchet, B | 1 |
| Fomin, VV | 1 |
| Leenen, FH | 5 |
| Coletta, E | 2 |
| Xu, D | 2 |
| Liu, PJ | 1 |
| Guo, XY | 1 |
| Chang, P | 1 |
| Li, XL | 1 |
| Chen, XH | 1 |
| Shen, XP | 1 |
| Babkin, AP | 1 |
| Gladkikh, VV | 1 |
| Pershukov, IV | 1 |
| Gulaia, GI | 1 |
| Chen, J | 1 |
| Li, J | 1 |
| Wang, ZR | 1 |
| Jonk, AM | 1 |
| Houben, AJ | 1 |
| Schaper, NC | 1 |
| de Leeuw, PW | 2 |
| Serné, EH | 1 |
| Smulders, YM | 1 |
| Stehouwer, CD | 1 |
| Csiki, Z | 1 |
| Garai, I | 1 |
| Shemirani, AH | 1 |
| Papp, G | 1 |
| Zsori, KS | 1 |
| Andras, C | 1 |
| Zeher, M | 1 |
| Drapkina, OM | 1 |
| Ashikhmin, IaI | 1 |
| Silverdal, J | 2 |
| Mourtzinis, G | 1 |
| Stener-Victorin, E | 1 |
| Mannheimer, C | 1 |
| Manhem, K | 1 |
| Doumas, M | 1 |
| Anyfanti, P | 1 |
| Lazaridis, N | 1 |
| Tang, X | 1 |
| Stein, C | 1 |
| Méa Plentz, RD | 1 |
| Antonicelli, R | 1 |
| Omboni, S | 1 |
| Giovanni, DC | 1 |
| Ansuini, R | 1 |
| Mori, A | 1 |
| Gesuita, R | 1 |
| Parati, G | 1 |
| Paciaroni, E | 1 |
| Vaziri, ND | 2 |
| Wang, XQ | 2 |
| Ni, ZN | 1 |
| Kivlighn, S | 1 |
| Shahinfar, S | 1 |
| Morgan, TO | 8 |
| Anderson, A | 9 |
| Myers, MG | 2 |
| Joyner, CD | 1 |
| Toal, CB | 1 |
| Turri, C | 1 |
| Bolla, G | 2 |
| Jönsson, B | 1 |
| Hansson, L | 6 |
| Stålhammar, NO | 1 |
| Trachtman, H | 1 |
| Frank, R | 1 |
| Mahan, JD | 1 |
| Portman, R | 1 |
| Restaino, I | 1 |
| Matoo, TK | 1 |
| Tou, C | 1 |
| Klibaner, M | 2 |
| Blivin, SJ | 1 |
| Pippins, J | 1 |
| Annis, LG | 1 |
| Lyons, F | 1 |
| Miczke, A | 1 |
| Pupek-Musialik, D | 1 |
| Cymerys, M | 1 |
| Bryl, W | 1 |
| Kujawska-Łuczak, M | 1 |
| Bogdański, P | 1 |
| Kotchen, TA | 1 |
| Mansour, G | 1 |
| Mansour, AJ | 1 |
| Manzo, BA | 1 |
| Matalka, MS | 1 |
| Ravnan, SL | 1 |
| Zervoudaki, A | 1 |
| Economou, E | 1 |
| Pitsavos, C | 1 |
| Vasiliadou, K | 1 |
| Aggeli, C | 1 |
| Tsioufis, K | 1 |
| Toutouza, M | 1 |
| Stefanadis, C | 1 |
| Toutouzas, P | 3 |
| Kotovskaia, IuV | 1 |
| Bagmanova, NKh | 1 |
| Mil'to, AS | 1 |
| Riabova, AV | 1 |
| Plavunov, NF | 1 |
| Kobalava, ZhD | 1 |
| Han, YF | 1 |
| Su, CJ | 1 |
| Ou, BR | 1 |
| Mann, S | 1 |
| Fogari, R | 2 |
| Derosa, G | 1 |
| Zoppi, A | 2 |
| Rinaldi, A | 1 |
| Lazzari, P | 1 |
| Fogari, E | 1 |
| Mugellini, A | 2 |
| Preti, P | 2 |
| Cvetković, RS | 1 |
| Plosker, GL | 2 |
| Dahlöf, B | 6 |
| Degl' Innocenti, A | 1 |
| Elmfeldt, D | 17 |
| Puig, JG | 2 |
| Gundersen, T | 2 |
| Hosie, J | 7 |
| Januszewicz, W | 2 |
| Lindström, CJ | 2 |
| Magometschnigg, D | 2 |
| Tanser, P | 2 |
| Waeber, B | 3 |
| Wiklund, I | 3 |
| Kjeldsen, SE | 1 |
| Westheim, AS | 1 |
| Os, I | 1 |
| Liu, G | 1 |
| Li, W | 1 |
| White, R | 1 |
| Handler, J | 1 |
| Scholze, J | 3 |
| Bida, M | 1 |
| Hansen, A | 1 |
| Juncken, D | 1 |
| Rangoonwala, B | 2 |
| Ritz, A | 1 |
| Schnitker, J | 1 |
| Dörffel, Y | 1 |
| Ridderstråle, W | 1 |
| Ulfhammer, E | 1 |
| Jern, S | 1 |
| Hrafnkelsdóttir, T | 1 |
| Frishman, WH | 2 |
| Hainer, JW | 1 |
| Sugg, J | 1 |
| Bremer, T | 1 |
| Man, A | 1 |
| Kask, K | 1 |
| Diamond, C | 1 |
| Modeliard, SS | 1 |
| Serot, JM | 1 |
| Mansour, J | 1 |
| Achard, JM | 1 |
| Fournier, A | 1 |
| Naskrent, M | 1 |
| Mielcarek, J | 1 |
| Karotsis, AK | 1 |
| Symeonidis, A | 1 |
| Mastorantonakis, SE | 1 |
| Stergiou, GS | 1 |
| Sahney, S | 1 |
| Grimm, E | 1 |
| Herrmann, D | 1 |
| Unger, T | 1 |
| Kintscher, U | 1 |
| Soucek, M | 1 |
| Plachý, M | 1 |
| Vetchy, D | 1 |
| Vetcha, M | 1 |
| Rabiskova, M | 1 |
| Gryczova, E | 1 |
| Bartosikova, L | 1 |
| Chen, YY | 1 |
| Zhang, WZ | 1 |
| Wu, HY | 1 |
| Zhang, L | 1 |
| Yu, ZQ | 1 |
| Zhang, FC | 1 |
| Xiang, XP | 1 |
| Liu, HL | 1 |
| Shen, FR | 1 |
| Tao, J | 1 |
| Zhao, JA | 1 |
| Song, H | 1 |
| Bao, W | 1 |
| An, G | 1 |
| Feng, J | 1 |
| Wang, R | 1 |
| An, F | 1 |
| Herlitz, H | 4 |
| Aurell, M | 4 |
| Conradson, T | 1 |
| Lundin, SA | 1 |
| Hallbäck-Nordlander, MI | 1 |
| Andersson, O | 1 |
| Bengtsson, C | 4 |
| Haglund, K | 3 |
| Hedner, T | 13 |
| Seideman, P | 2 |
| Sjöberg, KH | 1 |
| Strömgren, E | 1 |
| Aberg, H | 2 |
| Ostman, J | 2 |
| Mulvany, MJ | 2 |
| Korsgaard, N | 1 |
| Nyborg, N | 1 |
| Tanner, J | 1 |
| Mayet, J | 3 |
| Stanton, AV | 1 |
| Sinclair, AM | 1 |
| MacKay, J | 1 |
| Shahi, M | 3 |
| Foale, RA | 3 |
| Nicolaides, A | 1 |
| Poulter, NR | 3 |
| Sever, PS | 3 |
| Thom, SA | 3 |
| Neuvonen, PJ | 1 |
| Suhonen, R | 1 |
| Kailasam, MT | 1 |
| Parmer, RJ | 1 |
| Cervenka, JH | 1 |
| Wu, RA | 1 |
| Ziegler, MG | 1 |
| Kennedy, BP | 1 |
| Adegbile, IA | 1 |
| O'Connor, DT | 1 |
| Garde, E | 1 |
| Jørgensen, HS | 1 |
| Olsen, TS | 1 |
| Lassen, NA | 1 |
| Goldberg, A | 2 |
| Sweet, C | 1 |
| Dobrindt, R | 1 |
| Aulehner, R | 2 |
| Lydtin, H | 2 |
| O'Callaghan, CJ | 1 |
| Krum, H | 1 |
| Conway, EL | 1 |
| Lam, W | 1 |
| Skiba, MA | 1 |
| Howes, LG | 1 |
| Louis, WJ | 1 |
| Draaijer, P | 1 |
| Kool, MJ | 1 |
| van Bortel, LM | 1 |
| Nieman, F | 1 |
| van Hooff, JP | 1 |
| Leunissen, KM | 1 |
| Landahl, S | 2 |
| Thulin, T | 2 |
| Almkvist, H | 1 |
| Berglund, L | 1 |
| Björnsson, T | 1 |
| Fagher, B | 2 |
| Henningsen, N | 1 |
| Honkavaara, M | 1 |
| Naukkarinen, V | 1 |
| Nordenström, P | 1 |
| Sillanpää, J | 1 |
| Siewert-Delle, A | 1 |
| Ljungman, S | 1 |
| Hartford, M | 1 |
| Wikstrand, J | 1 |
| Wade, JR | 1 |
| Sambol, NC | 1 |
| Jennings, GL | 2 |
| Sudhir, K | 2 |
| Laufer, E | 1 |
| Korner, P | 1 |
| Reid, C | 1 |
| Høegholm, A | 2 |
| Wiinberg, N | 2 |
| Rasmussen, E | 2 |
| Nielsen, PE | 2 |
| Schoemaker, RC | 1 |
| van Houwelingen, HC | 1 |
| Kjellström, T | 2 |
| Blychert, E | 8 |
| Lindgärde, F | 2 |
| Hojo, Y | 2 |
| Ebata, H | 2 |
| Kawasaki, K | 2 |
| Tsuruya, Y | 2 |
| Ikeda, U | 2 |
| Nishinaga, M | 2 |
| Natsume, T | 2 |
| Ishida, H | 1 |
| Shimada, K | 2 |
| Lindqvist, M | 1 |
| Kahan, T | 1 |
| Melcher, A | 1 |
| Hjemdahl, P | 1 |
| Janssen, BJ | 1 |
| Oosting, J | 1 |
| Tyssen, CM | 1 |
| Struyker-Boudier, HA | 1 |
| Weber, MA | 2 |
| Faison, EP | 1 |
| Lipschutz, K | 1 |
| Shapiro, DA | 1 |
| Nelson, EB | 1 |
| Irvin, JD | 1 |
| Morgan, T | 3 |
| Hoffmann, J | 2 |
| Jönsson, L | 1 |
| Borgholst, O | 1 |
| Ekblad, G | 1 |
| Engstrand, C | 1 |
| Grundestam, I | 1 |
| Lindh, A | 1 |
| Watts, RW | 3 |
| Dufek, A | 1 |
| Wing, LM | 4 |
| Russell, AE | 3 |
| Tonkin, AL | 3 |
| Bune, AJ | 3 |
| West, MJ | 3 |
| Chalmers, JP | 3 |
| Hammond, JJ | 2 |
| Cutler, SA | 2 |
| Asmar, RG | 1 |
| Benetos, A | 1 |
| Chaouche-Teyara, K | 1 |
| Raveau-Landon, CM | 1 |
| Safar, ME | 1 |
| Carruthers, SG | 1 |
| Vint-Reed, C | 1 |
| Ozdemir, O | 2 |
| Erbas, B | 2 |
| Ugur, O | 2 |
| Varoglu, E | 2 |
| Erbengi, G | 1 |
| Bekdik, C | 1 |
| Oram, E | 2 |
| Shionoiri, H | 1 |
| Takizawa, T | 1 |
| Ohyama, Y | 1 |
| Ishii, J | 1 |
| Katayama, S | 1 |
| Nagasawa, T | 1 |
| Kitamoto, K | 1 |
| Nagasawa, K | 1 |
| Hariya, Y | 1 |
| Sato, R | 1 |
| Grabowski, M | 1 |
| Ryding, E | 1 |
| Elmqvist, D | 1 |
| Johansson, BB | 1 |
| Chou, TZ | 1 |
| Lee, KW | 1 |
| Ding, YA | 1 |
| Omvik, P | 2 |
| Lund-Johansen, P | 4 |
| Pasaoglu, I | 1 |
| Koray, Z | 1 |
| Yorgancioglu, C | 1 |
| Hazan, E | 1 |
| Bekdik, CF | 1 |
| Gradman, AH | 4 |
| Walton, T | 1 |
| Symes, LR | 1 |
| Shamiss, A | 3 |
| Peleg, E | 1 |
| Rosenthal, T | 4 |
| Ezra, D | 1 |
| Kendall, MJ | 1 |
| Roth, D | 1 |
| Gordon, RD | 1 |
| Klemm, SA | 1 |
| Tunny, TJ | 1 |
| Wicks, JR | 1 |
| Elmfeldt, DB | 2 |
| Chan, JC | 2 |
| Critchley, JA | 2 |
| Lappe, JT | 1 |
| Raskin, SJ | 1 |
| Snavely, D | 2 |
| Little, WC | 1 |
| Cheng, CP | 1 |
| Elvelin, L | 2 |
| Nordlander, M | 7 |
| Rivas-Cabañero, L | 1 |
| Rodríguez-Barbero, A | 1 |
| Macías-Núñez, JF | 1 |
| López-Novoa, JM | 1 |
| Morgan, O | 2 |
| Carroll, J | 2 |
| Zevin, D | 1 |
| Levi, J | 1 |
| Landry, FJ | 1 |
| Horwhat, JD | 1 |
| Tomich, D | 1 |
| Pinski, L | 1 |
| McGrath, BP | 3 |
| Schulman, DS | 1 |
| Flores, AR | 1 |
| Tugoen, J | 1 |
| Dianzumba, S | 1 |
| Reichek, N | 1 |
| Pannarale, G | 1 |
| Puddu, PE | 1 |
| Monti, F | 1 |
| Irace, L | 1 |
| Bentivoglio, M | 1 |
| Collauto, F | 1 |
| Barsotti, A | 1 |
| Corea, L | 1 |
| Trevi, G | 1 |
| Campa, PP | 1 |
| Jacono, A | 1 |
| Lapidus, L | 2 |
| Gustin, G | 1 |
| White, WB | 2 |
| Taylor, S | 1 |
| Daragjati, C | 1 |
| Sowers, JR | 1 |
| Raman, BB | 1 |
| Afonso, LC | 1 |
| Bedford-Rice, K | 1 |
| Standley, PR | 1 |
| Ambrosi, P | 1 |
| Bertucci, B | 1 |
| Bertault-Péres, P | 1 |
| Métras, D | 1 |
| Plaschke, M | 1 |
| Podjarny, E | 1 |
| Korzets, Z | 1 |
| Bernheim, J | 1 |
| Nussinovitch, N | 1 |
| Grossman, E | 1 |
| Katz, A | 1 |
| Rachima, C | 1 |
| Nakajima, Y | 1 |
| Yamamoto, K | 1 |
| Shimada, S | 1 |
| Kotaki, H | 1 |
| Sawada, Y | 1 |
| Iga, T | 1 |
| Nalbantgil, I | 1 |
| Onder, R | 1 |
| Killiçcioglu, B | 1 |
| Boydak, B | 1 |
| Terzioglu, E | 1 |
| Yilmaz, H | 1 |
| McGrath, K | 1 |
| Batlouni, M | 1 |
| Leite Luna, R | 1 |
| Castro, I | 1 |
| Silveira Sbissa, A | 1 |
| Armaganijan, D | 1 |
| Chaves Junior, Hde C | 1 |
| Nobre, F | 1 |
| Pereira da Cunha, C | 1 |
| van Ree, JW | 1 |
| van der Pol, GA | 1 |
| Poisson, P | 1 |
| Bauer, B | 2 |
| Schueler, E | 1 |
| Dees, A | 1 |
| Kremer Hovinga, T | 1 |
| Breed, JG | 1 |
| Verstappen, VM | 1 |
| Puister, SM | 1 |
| Meems, L | 1 |
| Cutler, NR | 1 |
| Davis, PJ | 1 |
| Robbins, JA | 1 |
| Weiss, RJ | 1 |
| Wood, BC | 1 |
| Tomlinson, B | 1 |
| Chan, TY | 1 |
| Cockram, CS | 1 |
| Ledingham, JM | 1 |
| Phelan, EL | 1 |
| Cross, MA | 1 |
| Laverty, R | 1 |
| Welin, L | 1 |
| Niklasson, A | 1 |
| Olsson, G | 1 |
| Fasce, E | 1 |
| Peña, L | 1 |
| Fasce, M | 1 |
| Mervaala, EM | 3 |
| Teräväinen, TL | 3 |
| Malmberg, L | 3 |
| Laakso, J | 3 |
| Vapaatalo, H | 3 |
| Karppanen, H | 3 |
| Fagan, TC | 1 |
| Pörsti, I | 1 |
| Casele, HL | 1 |
| Windley, KC | 1 |
| Prieto, JA | 1 |
| Gratton, R | 1 |
| Laifer, SA | 1 |
| Park, S | 1 |
| McCune, SA | 1 |
| Radin, MJ | 1 |
| Hoepf, TM | 1 |
| Hensley, J | 1 |
| Hohl, CM | 1 |
| Altschuld, RA | 1 |
| Chern, MS | 2 |
| Lin, FC | 3 |
| Wu, D | 3 |
| Zimlichman, R | 1 |
| Schwartz, J | 1 |
| Tobar, R | 1 |
| Navarro, JF | 1 |
| García-Pérez, J | 1 |
| Rodríguez-Pérez, JC | 1 |
| Videbaek, LM | 1 |
| Jacobsen, IA | 1 |
| Bonaduce, D | 2 |
| Canonico, V | 2 |
| Petretta, M | 2 |
| Forgione, L | 1 |
| Ianniciello, A | 1 |
| Cavallaro, V | 1 |
| Bertocchi, F | 1 |
| Rengo, F | 1 |
| Mallion, JM | 3 |
| Dahan, R | 1 |
| Boutelant, S | 1 |
| Benkritly, A | 3 |
| Baguet, JP | 2 |
| Noir-Clerc, M | 1 |
| Kolloch, RE | 1 |
| Rahn, KH | 1 |
| Francischetti, A | 1 |
| Ono, H | 1 |
| Frohlich, ED | 2 |
| Halling, K | 1 |
| Rydén-Bergsten, T | 1 |
| Fletcher, A | 1 |
| Rodríguez Moreno, C | 1 |
| Karonen, T | 1 |
| Stubb, S | 1 |
| Keski-Oja, J | 1 |
| Bicchi, M | 1 |
| Vedovini, G | 1 |
| Cappelli, R | 1 |
| Arrigucci, S | 1 |
| Righi, GA | 1 |
| Forconi, S | 1 |
| Kaplan, RC | 1 |
| Psaty, BM | 1 |
| Kriesel, D | 1 |
| Heckbert, SR | 1 |
| Smith, NL | 1 |
| Gillett, C | 1 |
| Golston, AG | 1 |
| Lefebvre, J | 1 |
| Poirier, L | 1 |
| Archambault, F | 1 |
| Jewell, D | 1 |
| Reed, CV | 1 |
| Lacourcière, Y | 1 |
| McClennen, W | 1 |
| Wilson, T | 1 |
| Ostergren, J | 3 |
| Isaksson, H | 2 |
| Brodin, U | 1 |
| Schwan, A | 2 |
| Ohman, KP | 2 |
| Risler, T | 1 |
| Bohm, R | 1 |
| Wetzchewald, D | 2 |
| Nast, HP | 1 |
| Koch, HH | 1 |
| Stein, G | 1 |
| Erley, CM | 1 |
| Lindeberg, S | 1 |
| Vyssoulis, GP | 1 |
| Trikas, AG | 1 |
| Paleologos, AA | 1 |
| Toutouza, MG | 1 |
| Toutouzas, PK | 1 |
| Cohen, A | 1 |
| Bregman, B | 1 |
| Agabiti Rosei, E | 1 |
| Williams, B | 1 |
| Dubourg, O | 1 |
| Clairefond, P | 1 |
| Brudi, P | 1 |
| Gosse, P | 1 |
| Guéret, P | 1 |
| Reuter, MK | 1 |
| Lorenz, H | 1 |
| Verho, P | 1 |
| Smith, N | 1 |
| Degen, A | 1 |
| Verho, M | 1 |
| Gueyffier, F | 1 |
| Boissel, JP | 1 |
| Parving, HH | 1 |
| Hoglund, C | 1 |
| Hutchinson, HG | 1 |
| Herpin, D | 1 |
| Tremel, F | 1 |
| Ni, Z | 1 |
| Andersson, F | 1 |
| Kartman, B | 1 |
| Andersson, OK | 5 |
| Evans, MF | 1 |
| Schaefer, RM | 1 |
| Aldons, PM | 1 |
| Burgess, ED | 1 |
| Tilvis, R | 1 |
| Girerd, X | 1 |
| Singh, GP | 1 |
| Rehn, L | 1 |
| Vidt, DG | 1 |
| Pohl, MA | 1 |
| Ylitalo, A | 1 |
| Airaksinen, KE | 1 |
| Sellin, L | 1 |
| Huikuri, HV | 1 |
| Klein, G | 1 |
| Zhu, X | 1 |
| Lu, G | 1 |
| Ou, S | 1 |
| Wesseling, H | 1 |
| Madrid, A | 1 |
| Mickiewicz, M | 1 |
| Spinelli, L | 1 |
| Marciano, F | 1 |
| Vetrano, A | 1 |
| Signorini, A | 1 |
| Elliott, WJ | 2 |
| Montoro, R | 2 |
| Smith, D | 1 |
| Leibowitz, M | 1 |
| Hwang, C | 1 |
| Schleman, M | 1 |
| Zannad, F | 1 |
| Boivin, JM | 1 |
| Hung, MJ | 1 |
| Cherng, WJ | 1 |
| Wang, CH | 1 |
| Hung, KC | 1 |
| Hsieh, IC | 1 |
| Wen, MS | 1 |
| Susic, D | 1 |
| Varagic, J | 1 |
| Fink, KS | 1 |
| Ellsworth, A | 1 |
| Detry, JM | 1 |
| Safar, M | 1 |
| Taverner, D | 1 |
| Marley, J | 1 |
| Massaro, J | 1 |
| Anguita Sánchez, M | 1 |
| Jones, DW | 1 |
| Miller, ME | 1 |
| Wofford, MR | 1 |
| Anderson, DC | 1 |
| Cameron, ME | 1 |
| Willoughby, DL | 1 |
| Adair, CT | 1 |
| King, NS | 1 |
| De Rosa, ML | 1 |
| Giordano, A | 1 |
| Della Guardia, D | 1 |
| Maddaluno, G | 1 |
| Lionetti, F | 1 |
| Marsicani, N | 1 |
| Vigorito, C | 1 |
| Vaile, JC | 1 |
| Jordan, PJ | 1 |
| Stallard, TJ | 2 |
| Littler, WA | 6 |
| Haria, M | 1 |
| Markham, A | 1 |
| Skrabal, F | 1 |
| Zuhair, HA | 1 |
| Abd El-Fattah, AA | 1 |
| El-Sayed, MI | 1 |
| Ram, CV | 1 |
| Clay, DR | 1 |
| Bourg, MP | 1 |
| Lawrence, DB | 1 |
| Parra, D | 1 |
| Beckey, NP | 1 |
| Korman, L | 1 |
| Sheehy, O | 1 |
| LeLorier, J | 1 |
| Rogan, JW | 1 |
| Lyszkiewicz, DA | 1 |
| Blowey, D | 1 |
| Khattak, S | 1 |
| Arbus, GS | 1 |
| Koren, G | 1 |
| Bulpitt, CJ | 1 |
| Fischberg, GM | 1 |
| Lozano, E | 1 |
| Rajamani, K | 1 |
| Ameriso, S | 1 |
| Fisher, MJ | 1 |
| Ariff, B | 1 |
| Wasan, B | 1 |
| Chapman, N | 1 |
| Lehrl, S | 1 |
| Grässel, E | 1 |
| Eicke, C | 1 |
| Paterna, S | 1 |
| Di Pasquale, P | 1 |
| Parrinello, G | 1 |
| Tuttolomondo, A | 1 |
| Follone, G | 1 |
| Cardinale, A | 1 |
| Ortoleva, A | 1 |
| Giambanco, F | 1 |
| Abruzzese, G | 1 |
| Colomba, D | 1 |
| Bologna, P | 1 |
| Fernández, P | 1 |
| Giubilato, A | 1 |
| Valdes, L | 1 |
| Albano, V | 1 |
| Licata, G | 1 |
| Corradi, L | 1 |
| Malalamani, GD | 1 |
| McLay, JS | 1 |
| MacDonald, TM | 1 |
| Elliott, HL | 1 |
| Nyström, FH | 1 |
| Oparil, S | 1 |
| Aurup, P | 1 |
| Meyer, FP | 1 |
| Hilleman, DE | 1 |
| Reyes, AP | 1 |
| Wurdeman, RL | 1 |
| Faulkner, M | 1 |
| Lopes, AA | 1 |
| Andrade, J | 1 |
| Noblat, AC | 1 |
| Silveira, MA | 1 |
| Black, HR | 1 |
| Strom, JA | 1 |
| Liebson, PR | 1 |
| Hwang, CT | 1 |
| Ruff, DA | 1 |
| DeQuattro, V | 2 |
| Zhang, D | 1 |
| Schleman, MM | 1 |
| Klibaner, MI | 1 |
| Ol'binskaia, LI | 1 |
| Khapaev, BA | 1 |
| Zheleznykh, EA | 1 |
| Dernellis, J | 1 |
| Panaretou, M | 1 |
| Wilson, J | 1 |
| Orchard, MA | 1 |
| Prentice, CR | 1 |
| Lees, AD | 1 |
| Baig, MW | 1 |
| Perrins, EJ | 1 |
| Davies, JA | 1 |
| Kon, SP | 1 |
| Tan, HW | 1 |
| Chua, CT | 1 |
| Ong, ML | 1 |
| Kamsiah, J | 1 |
| Maheendran, KK | 1 |
| Ponniah, CA | 1 |
| Tariq, AR | 1 |
| Mahendran, T | 1 |
| Jensen, HA | 1 |
| Todd, PA | 1 |
| Faulds, D | 1 |
| Edgar, B | 8 |
| Farr, C | 1 |
| Inoue, T | 1 |
| Omosu, M | 1 |
| Hayashi, S | 1 |
| Sakaguchi, S | 1 |
| Nakao, K | 1 |
| Inukai, T | 1 |
| Odagiri, N | 1 |
| Ono, T | 1 |
| Holliwell, DL | 1 |
| Klaus, D | 1 |
| Garanin, G | 1 |
| Lohr, E | 1 |
| Frisén, M | 1 |
| Karlsson, O | 2 |
| Rydén, L | 4 |
| Jones, E | 1 |
| Jungmann, E | 2 |
| Schumm-Draeger, PM | 2 |
| Scheuermann, EH | 2 |
| Usadel, KH | 1 |
| Havu, N | 1 |
| Bailey, DG | 2 |
| Spence, JD | 2 |
| Munoz, C | 1 |
| Arnold, JM | 2 |
| Frewin, DB | 1 |
| Aldons, P | 1 |
| Wilson, LL | 1 |
| O'Sullivan, EF | 1 |
| Wyndham, RN | 1 |
| Karrasch, J | 1 |
| Agar, J | 1 |
| Singh, BB | 1 |
| Jackson, B | 5 |
| Atkins, PF | 1 |
| Dahlöf, C | 2 |
| Campbell, LM | 1 |
| Cowen, KJ | 1 |
| Cranfield, FR | 1 |
| Goves, JR | 5 |
| Jones, DF | 1 |
| Lees, CT | 3 |
| Richardson, PD | 4 |
| Teal, JA | 1 |
| Timerick, SJ | 2 |
| Granérus, G | 6 |
| Flygt, G | 3 |
| Kennerfalk, A | 1 |
| Lundborg, P | 3 |
| Wallander, MA | 2 |
| Capewell, S | 4 |
| Collier, A | 3 |
| Matthews, D | 2 |
| Collier, R | 2 |
| Hajducka, C | 3 |
| Clarke, BF | 2 |
| Muir, AL | 7 |
| Nilsson-Ehle, P | 1 |
| Thomas, P | 1 |
| Sheridan, DJ | 1 |
| Volkmann, R | 1 |
| Wysocki, M | 1 |
| Reid, JL | 1 |
| Wester, A | 2 |
| Brun, J | 1 |
| Fröberg, L | 1 |
| Kronmann, P | 1 |
| Olsson, LB | 1 |
| Skoog, P | 1 |
| Tygesen, G | 1 |
| Scherstén, B | 1 |
| Tibblin, G | 1 |
| Hart, W | 1 |
| Westberg, B | 4 |
| Lorimer, AR | 4 |
| Pringle, SD | 1 |
| Mulder, AW | 2 |
| Lassen, E | 1 |
| Ahlstrøm, F | 1 |
| Bøgeskov-Jensen, I | 1 |
| Frimodt-Møller, J | 1 |
| Nielsen, MR | 1 |
| Wickers-Nielsen, N | 1 |
| Winkel, O | 2 |
| Weissel, M | 1 |
| Stanek, B | 1 |
| Leary, WP | 1 |
| Maharaj, B | 1 |
| Savonitto, S | 2 |
| Bevilacqua, M | 1 |
| Chebat, E | 1 |
| Vago, T | 1 |
| Bertora, P | 1 |
| Baldi, G | 1 |
| Renesto, E | 1 |
| Peruzzi, E | 1 |
| Sardina, M | 1 |
| Norbiato, G | 1 |
| Koenig, W | 3 |
| Binner, L | 3 |
| Gabrielsen, F | 1 |
| Sund, M | 3 |
| Rosenthal, J | 3 |
| Hombach, V | 3 |
| Hwang, YS | 1 |
| Yen, HW | 1 |
| Wong, EC | 1 |
| Hehr, R | 2 |
| Yedinak, KC | 1 |
| Lopez, LM | 1 |
| Buur, T | 1 |
| Larsson, R | 3 |
| Regårdh, CG | 5 |
| Aberg, J | 2 |
| Nickelsen, T | 1 |
| Schöffling, K | 1 |
| Ibsen, H | 2 |
| Fariello, R | 2 |
| Boni, E | 2 |
| Corda, L | 2 |
| Cantalamessa, A | 2 |
| Zaninelli, A | 2 |
| Pollavini, G | 3 |
| Alicandri, C | 2 |
| Muiesan, G | 2 |
| Ernst, E | 1 |
| Dimenäs, E | 1 |
| Svärdsudd, K | 1 |
| Di Somma, S | 1 |
| Liguori, V | 1 |
| Petitto, M | 1 |
| Cavallotti, G | 2 |
| de Divitiis, O | 1 |
| Wathen, CG | 5 |
| Hannan, WJ | 2 |
| Strauer, BE | 1 |
| Jeffrey, RF | 1 |
| Brown, J | 1 |
| Lee, MR | 1 |
| Cerasola, G | 2 |
| Cottone, S | 2 |
| Nardi, E | 1 |
| Fulantelli, MA | 1 |
| Carone, MB | 2 |
| D'Ignoto, G | 2 |
| Woo, BY | 1 |
| Yeoh, TK | 1 |
| Tan, AT | 1 |
| Schmitz, A | 1 |
| Pedersen, MM | 1 |
| Mogensen, CE | 1 |
| Karlberg, BE | 1 |
| Gelin, A | 2 |
| Lundgren, H | 1 |
| Bengtsson, L | 1 |
| Lindsjö, MK | 1 |
| Danielsson, B | 1 |
| Bengtsson, U | 1 |
| Hardlund, JH | 1 |
| Sjöström, PA | 1 |
| Moberg, L | 3 |
| Crozier, IG | 1 |
| Ikram, H | 1 |
| Nicholls, MG | 1 |
| Low, CJ | 1 |
| Bossini, A | 1 |
| Di Veroli, C | 1 |
| Cagli, V | 1 |
| Wingstrand, K | 1 |
| Lidman, K | 1 |
| Nyborg, NC | 1 |
| Byg-Hansen, J | 1 |
| Ludden, CT | 1 |
| Adkins, E | 1 |
| Seymour, AA | 1 |
| Emmert, S | 1 |
| Ribeiro, LG | 1 |
| Julius, S | 1 |
| Westerling, S | 2 |
| Sjögren, E | 4 |
| Katzman, PL | 9 |
| Hulthén, UL | 8 |
| Hökfelt, B | 7 |
| Hamilton, DV | 1 |
| Barnes, PC | 1 |
| Bowles, RM | 1 |
| Rajaratnam, DV | 1 |
| Comerford, MB | 1 |
| Ginks, WR | 1 |
| Ginks, SE | 1 |
| Grabau, WJ | 1 |
| Malcolm, JP | 1 |
| Horton, R | 2 |
| Thalén, P | 2 |
| Cubela, R | 1 |
| Debrevi, L | 1 |
| Whitty, M | 1 |
| Johnston, CI | 2 |
| Chalmers, J | 1 |
| Wing, L | 1 |
| West, M | 1 |
| Bune, A | 1 |
| Johnston, C | 1 |
| McGrath, B | 1 |
| Mashford, ML | 1 |
| Heath, W | 1 |
| Westwood, B | 1 |
| Gudbrandsson, T | 1 |
| Hellsing, T | 1 |
| Kullman, S | 1 |
| Kuylenstierna, J | 1 |
| Leppert, J | 1 |
| Möller, B | 1 |
| Skogström, K | 1 |
| Svensson, A | 1 |
| Liedholm, H | 1 |
| Melander, A | 1 |
| Cambell, LM | 1 |
| Ross, JR | 2 |
| McCullagh, A | 1 |
| Barnes, P | 1 |
| Lesbre, JP | 1 |
| Witchitz, S | 1 |
| Andrejak, M | 1 |
| Morand, P | 1 |
| Raveau-Landon, C | 1 |
| Bengtsson-Hasselgren, B | 1 |
| Rönn, O | 3 |
| Lok, H | 1 |
| Bayliff, CD | 1 |
| Porcellati, C | 1 |
| Verdecchia, P | 1 |
| Gatteschi, C | 1 |
| Benemio, G | 1 |
| Guerrieri, M | 1 |
| Boldrini, F | 1 |
| Abelardo, NS | 1 |
| Ramos, EF | 1 |
| Mendoza, VL | 1 |
| Sulit, YQ | 1 |
| Mitchell, MJ | 1 |
| Bruce, A | 1 |
| Langton, D | 1 |
| Matthews, PG | 1 |
| Syme, S | 1 |
| Treloar, K | 1 |
| McNeil, JJ | 1 |
| Bruner, CA | 1 |
| Webb, RC | 1 |
| Thorén, P | 1 |
| Westling, H | 1 |
| Skarphedinsson, JO | 1 |
| Leonetti, G | 3 |
| Gradnik, R | 3 |
| Terzoli, L | 3 |
| Fruscio, M | 2 |
| Rupoli, L | 3 |
| Sampieri, L | 2 |
| MacLeod, D | 2 |
| Tucker, L | 2 |
| Forret, EA | 2 |
| Hill, TW | 2 |
| Hansson, BG | 1 |
| Lyngstam, G | 1 |
| Lyngstam, O | 1 |
| Thilén, U | 1 |
| Collste, P | 3 |
| Danielsson, M | 1 |
| Feleke, E | 1 |
| Westermann, B | 1 |
| Houtzagers, JJ | 1 |
| Meulesteen, P | 1 |
| Gibson, J | 1 |
| Borgmästars, H | 1 |
| Forsén, B | 1 |
| Tuomilehto, J | 1 |
| Hellebø, R | 1 |
| Walle, PO | 1 |
| Nielsen, HM | 1 |
| Nielsen, E | 1 |
| Steiness, E | 1 |
| Bengtsson, B | 2 |
| Sluiter, HE | 3 |
| Mangano, MT | 1 |
| Pinto, A | 1 |
| Saltiel, E | 1 |
| Ellrodt, AG | 1 |
| Monk, JP | 1 |
| Langley, MS | 1 |
| Ekeroth, M | 1 |
| Chow, J | 1 |
| Groom, P | 1 |
| Simpson, RJ | 1 |
| Singh, B | 1 |
| Ward, DE | 2 |
| Peers, E | 1 |
| Carle, WK | 1 |
| Latta, D | 1 |
| Lough, JR | 1 |
| Pender, J | 1 |
| Sefton, S | 1 |
| Peers, EM | 1 |
| Von Schenck, H | 1 |
| Smith, U | 1 |
| Freeling, P | 2 |
| Davis, RH | 2 |
| Burton, RH | 2 |
| Orme-Smith, EA | 1 |
| Graham-Evans, JN | 1 |
| Orne-Smith, EA | 1 |
| Osborne, CJ | 1 |
| Krönig, B | 1 |
| Lijnen, P | 2 |
| Fagard, R | 3 |
| Staessen, J | 3 |
| Moerman, E | 2 |
| De Schaepdryver, A | 1 |
| Amery, A | 3 |
| Harrington, K | 1 |
| Fitzgerald, P | 1 |
| O'Donnell, P | 1 |
| Hill, KW | 1 |
| O'Brien, E | 1 |
| O'Malley, K | 1 |
| Nordborg, C | 3 |
| Gabrielsson, M | 1 |
| Larsson, M | 1 |
| Lernfelt, B | 1 |
| Smith, SA | 2 |
| Mace, PJ | 3 |
| Björck, S | 2 |
| Nyberg, G | 2 |
| Huysman, FT | 1 |
| Thien, TA | 2 |
| Koene, RA | 2 |
| Friberg, P | 2 |
| Wåhlander, H | 1 |
| Hardebo, JE | 1 |
| Kåhrström, J | 1 |
| Samuelsson, O | 1 |
| Maclean, D | 1 |
| Mitchell, ET | 1 |
| Readman, AS | 1 |
| Lindsjö, M | 1 |
| Mörlin, B | 1 |
| McAlpine, HM | 2 |
| Rae, AP | 1 |
| Simpson, IA | 1 |
| Barbour, MP | 1 |
| Lawrie, TD | 2 |
| Clement, DL | 1 |
| De Pue, NY | 1 |
| Huysmans, FT | 1 |
| Walker, ID | 1 |
| Davidson, JF | 1 |
| DiBona, GF | 1 |
| Raner, S | 1 |
| Boselli, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Randomized, Open-label, Parallel-group Clinical Study to Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for the Treatment of Patients With Mild-to-Moderate Hypertension[NCT01520285] | Phase 4 | 281 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| An Multicenter Study to Evaluate the Efficacy and Safety of a 5 Week Therapy With the Combination of Valsartan 160 mg Plus Amlodipine 10 mg in Hypertensive Patients Not Adequately Responding to a 5 Week Therapy With Ramipril 5 mg and Felodipine 5 mg[NCT00367939] | Phase 3 | 132 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Felodipine Event Reduction Study[NCT01136863] | 9,800 participants (Actual) | Interventional | 1998-04-30 | Completed | |||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| Effects of Transcutaneous Nervous Electric Stimulation (TENS) and Interferential Electrical Stimulation (IES) on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients[NCT03258489] | 60 participants (Actual) | Interventional | 2018-07-20 | Completed | |||
| [NCT00005332] | 0 participants | Observational | 1991-09-30 | Completed | |||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
24 reviews available for felodipine and Blood Pressure, High
| Article | Year |
|---|---|
Pharmacology, Efficacy and Safety of Felodipine with a Focus on Hypertension and Angina Pectoris.
Topics: Angina Pectoris; Animals; Antihypertensive Agents; Calcium Channel Blockers; Felodipine; Humans; Hyp | 2015 |
Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 1995 |
[Calcium antagonists: on the way to expanding the indications].
Topics: Atherosclerosis; Calcium; Calcium Channel Blockers; Chronic Disease; Felodipine; Humans; Hypertensio | 2010 |
Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; D | 2005 |
A review of calcium channel antagonists in the treatment of pediatric hypertension.
Topics: Amiodarone; Calcium Channel Blockers; Child; Felodipine; Humans; Hypertension; Isradipine; Nicardipi | 2006 |
Treatment of hypertension with felodipine in patients with concomitant diseases.
Topics: Disease; Felodipine; Humans; Hypertension | 1993 |
Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension.
Topics: Angina Pectoris; Animals; Drug Interactions; Felodipine; Heart Failure; Hemodynamics; Humans; Hypert | 1993 |
Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol.
Topics: Dose-Response Relationship, Drug; Drug Combinations; Felodipine; Humans; Hypertension; Metoprolol | 1995 |
Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine.
Topics: Amlodipine; Calcium Channel Blockers; Coronary Disease; Felodipine; Heart Failure; Hemodynamics; Hum | 1995 |
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension.
Topics: Drug Therapy, Combination; Felodipine; Hemodynamics; Humans; Hypertension; Kidney; Metoprolol; Quali | 2000 |
Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.
Topics: Angina Pectoris; Cardiomegaly; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Interact | 1992 |
Plasma concentration--effect relationships for felodipine: a meta analysis.
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Blood Pressure; Felodipine; Female; Humans; Hyper | 1992 |
Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients.
Topics: Aging; Felodipine; Hemodynamics; Humans; Hypertension; Treatment Outcome | 1992 |
Vascular selectivity of felodipine: clinical experience.
Topics: Animals; Felodipine; Heart; Humans; Hypertension; Muscle, Smooth, Vascular; Organ Specificity; Vascu | 1990 |
Hemodynamic effects of felodipine in hypertension: a review.
Topics: Animals; Felodipine; Hemodynamics; Humans; Hypertension | 1990 |
Dose-plasma concentration--effect relationship of felodipine in essential hypertension: a review.
Topics: Animals; Dose-Response Relationship, Drug; Felodipine; Humans; Hypertension | 1990 |
A review of the antihypertensive effects of felodipine alone or in combination.
Topics: Animals; Drug Therapy, Combination; Felodipine; Humans; Hypertension | 1990 |
The safety of felodipine.
Topics: Animals; Felodipine; Humans; Hypertension | 1990 |
Felodipine: a new dihydropyridine calcium-channel antagonist.
Topics: Angina Pectoris; Animals; Blood Pressure; Double-Blind Method; Felodipine; Heart Failure; Humans; Hy | 1991 |
Felodipine in hypertension--a review.
Topics: Blood Pressure; Drug Tolerance; Felodipine; Heart; Hemodynamics; Humans; Hypertension; Kidney; Nitre | 1987 |
Comparison of felodipine extended release and conventional tablets in essential hypertension using ambulatory blood pressure monitoring.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Met | 1989 |
Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.
Topics: Felodipine; Humans; Hypertension; Metabolic Clearance Rate; Nitrendipine | 1988 |
Aspects on the benefit-risk balance of felodipine in hypertension.
Topics: Antihypertensive Agents; Felodipine; Humans; Hypertension; Nitrendipine; Risk Factors | 1987 |
241 trials available for felodipine and Blood Pressure, High
| Article | Year |
|---|---|
Efficacy of felodipine and enalapril in the treatment of essential hypertension with coronary artery disease and the effect on levels of Salusin-β, Apelin, and PON1 gene expression in patients.
Topics: Apelin; Aryldialkylphosphatase; Blood Pressure; Coronary Artery Disease; Enalapril; Essential Hypert | 2022 |
The effect of combined antihypertensive treatment (felodipine with either irbesartan or metoprolol) on erectile function: a randomized controlled trial.
Topics: Adult; Antihypertensive Agents; Biphenyl Compounds; Drug Therapy, Combination; Erectile Dysfunction; | 2013 |
[Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension].
Topics: Antihypertensive Agents; Dihydropyridines; Double-Blind Method; Essential Hypertension; Felodipine; | 2013 |
The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Anti | 2014 |
Lercanidipine hydrochloride versus felodipine sustained-release for mild-to-moderate hypertension: a multi-center, randomized clinical trial.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Delayed-Action Preparations; Dihydropyridines; Fel | 2015 |
Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambula | 2016 |
Effects of lercanidipine hydrochloride versus felodipine sustained-release on day-to-day home blood pressure variability.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Delayed | 2016 |
Effect and tolerability of felodipine ER (Feloten) in the treatment of hypertension assessed by office blood pressure and home blood pressure.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Clinical Trials as T | 2008 |
Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2008 |
[Structural-functional properties of the vascular wall in hypertensive patients with coronary heart disease: effects of felodipin and perindopril].
Topics: Antihypertensive Agents; Arteries; Endothelium, Vascular; Felodipine; Humans; Hypertension; Middle A | 2009 |
[Impact of antihypertensive medication timing on degree and stability of blood pressure lowering in patients with essential hypertension].
Topics: Antihypertensive Agents; Blood Pressure; Drug Administration Schedule; Drug Therapy, Combination; Fe | 2009 |
Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study.
Topics: Age Factors; Aged; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; C | 2010 |
Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; De | 2010 |
[Effect between felodipine plus irbesartan and felodipine plus metoprolol regimen on the sexual function in young and middle-aged women with hypertension].
Topics: Adolescent; Adult; Antihypertensive Agents; Biphenyl Compounds; Felodipine; Female; Humans; Hyperten | 2010 |
[Therapeutic effect on essential hypertension treated with combined therapy of acupuncture and medication].
Topics: Acupuncture Therapy; Adult; Aged; Blood Pressure; Combined Modality Therapy; E-Selectin; Felodipine; | 2010 |
Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Felodip | 2011 |
Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Glucose; Blood Pressure; Calcium Channel | 2011 |
The effect of metoprolol alone and combined metoprolol-felodipin on the digital microcirculation of patients with primary Raynaud's syndrome.
Topics: Adult; Drug Therapy, Combination; Felodipine; Female; Fingers; Humans; Hyperemia; Hypertension; Lase | 2011 |
Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension.
Topics: Adolescent; Adult; Antihypertensive Agents; Biphenyl Compounds; Felodipine; Female; Humans; Hyperten | 2012 |
[Calcium channels blocker felodipin in the treatment of patients with arterial hypertension and chronic cardial failure with preserved cardiac output].
Topics: Blood Pressure; Calcium Channel Blockers; Cardiac Output; Chronic Disease; Diagnosis, Differential; | 2011 |
Antihypertensive effect of low-frequency transcutaneous electrical nerve stimulation (TENS) in comparison with drug treatment.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure Determination; Calcium Channel Blockers; Cross- | 2012 |
Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: is adding drugs always beneficial?
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; China; Double-Blind Method; | 2012 |
Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Delayed-Actio | 2002 |
Different drug classes have variable effects on blood pressure depending on the time of day.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circ | 2003 |
Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril.
Topics: Antihypertensive Agents; Biomarkers; Blood Pressure; Data Interpretation, Statistical; Enalapril; Fe | 2002 |
Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension.
Topics: Antihypertensive Agents; Baroreflex; Blood Pressure; Dihydropyridines; Double-Blind Method; Felodipi | 2003 |
Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium Channel Blockers; Cost-Benefit Analy | 2003 |
Clinical trial of extended-release felodipine in pediatric essential hypertension.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Child; Delayed-Action Preparations; Felodipine; | 2003 |
[The effect of analysed hypotensive drugs on certain metabolic parameters].
Topics: Adult; Antihypertensive Agents; Diabetes Mellitus, Type 2; Felodipine; Female; Humans; Hyperlipidemi | 2003 |
The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Calcium Channel Blockers; Diastole; Dilt | 2004 |
[Efficacy and tolerability of felodipine based antihypertensive therapy in hospitalized patients with hypertension].
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Drug Therapy, Combination; Felodipine; Fema | 2004 |
Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients.
Topics: Aged; Antihypertensive Agents; Felodipine; Female; Humans; Hypertension; Insulin Resistance; Leptin; | 2005 |
Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 2005 |
The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Ch | 2005 |
Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients: amlodipine versus felodipine extended release.
Topics: Adult; Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Blood Pressure; Body Wei | 2006 |
Initiation of hypertension treatment with a fixed-dose combination or its monocomponents -- does it really matter?
Topics: Antihypertensive Agents; Drug Therapy, Combination; Felodipine; Female; Humans; Hypertension; Male; | 2006 |
Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Brac | 2006 |
A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT).
Topics: Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antih | 2006 |
Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Topics: Adult; Aged; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutane | 2007 |
[The FEVER (Felodipine EVEnt Reduction) trial; a randomised, double-blind, placebo-controlled trial in Chinese hypertensive patients].
Topics: Aged; Calcium Channel Blockers; China; Diuretics; Double-Blind Method; Felodipine; Female; Humans; H | 2007 |
[Efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination therapy in the treatment of mild to moderate essential hypertension in China].
Topics: Adult; Aged; Antihypertensive Agents; China; Delayed-Action Preparations; Drug Therapy, Combination; | 2007 |
Differential effects of felodipine and nifedipine on 24-h blood pressure and left ventricular mass.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 1995 |
Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension.
Topics: Aldosterone; Analysis of Variance; Autonomic Nervous System; Baroreflex; Calcium Channel Blockers; C | 1995 |
Efficacy and safety of losartan.
Topics: Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Dose-R | 1995 |
Antihypertensive treatment with felodipine but not with a diuretic reduces episodes of myocardial ischaemia in elderly patients with hypertension.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Felodipine; Female; Hemodyn | 1994 |
Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients.
Topics: Blood Pressure; Captopril; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Double-Blind Me | 1994 |
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Conver | 1995 |
Vascular compliance in sodium-sensitive and sodium-resistant borderline hypertensive patients.
Topics: Adult; Blood Pressure; Blood Vessels; Compliance; Diet, Sodium-Restricted; Echocardiography, Doppler | 1995 |
[Good quality of life of older patients with hypertension. Equally good effect of felodipine and hydrochlorothiazide].
Topics: Aged; Double-Blind Method; Felodipine; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Qual | 1995 |
Efficacy and tolerability of felodipine ER and diltiazem SR as monotherapy in primary hypertension: a double-blind randomized study.
Topics: Blood Pressure; Delayed-Action Preparations; Diltiazem; Double-Blind Method; Felodipine; Female; Hea | 1994 |
Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with beta-blockade.
Topics: Adrenergic beta-Antagonists; Aged; Albuminuria; Blood Pressure; Drug Therapy, Combination; Felodipin | 1995 |
Felodipine population dose-response and concentration-response relationships in patients with essential hypertension.
Topics: Adult; Aged; Aging; Algorithms; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Metho | 1995 |
Assessment of effects of two anti-hypertensive regimens on overall cardiovascular risk.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cardiovascular Diseases; Cholesterol; Diuretics; Drug Thera | 1995 |
Comparative effects of amlodipine and felodipine ER on office and ambulatory blood pressure in patients with mild to moderate hypertension. Danish Multicentre Group.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; | 1995 |
The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Angiotensin-Converting Enzym | 1994 |
Short-term effects of felodipine in hypertensive type II diabetic males on sulfonylurea treatment.
Topics: Aged; Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Felo | 1994 |
Extended-release felodipine in patients with mild to moderate hypertension. Felodipine ER Dose-Response Study Group.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Blood Pressure; Delayed-Action Preparations | 1994 |
Interaction of indomethacin with felodipine and enalapril.
Topics: Arthritis, Rheumatoid; Blood Pressure; Drug Interactions; Enalapril; Felodipine; Female; Humans; Hyp | 1993 |
Antihypertensive efficacy and tolerability of a new once-daily felodipine-metoprolol combination compared with each component alone. The Swedish/UK Study Group.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Delayed-Action Preparations; Doub | 1993 |
Comparison of a felodipine-metoprolol combination tablet vs each component alone as antihypertensive therapy. The German Multicentre Study Group.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Fe | 1993 |
Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Delayed-Action Preparations; Doub | 1993 |
Comparison of felodipine and enalapril monotherapy in essential hypertension.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Blood Pressure; Double-Blind Method; Drug Administrat | 1993 |
The Hypertension Optimal Treatment Study (the HOT Study).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Clinical Protocols; Felodipine; Fe | 1993 |
Mono- and combination therapy with felodipine or enalapril in elderly patients with systolic hypertension.
Topics: Aged; Aged, 80 and over; Blood Pressure; Drug Combinations; Enalapril; Felodipine; Female; Heart Rat | 1994 |
Felodipine, metoprolol and their combination compared with placebo in isolated systolic hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Blood Pressure; Double-Blind Method; Drug Combinations; Felodipine; Female; | 1994 |
A comparison of isradipine and felodipine in Australian patients with hypertension: focus on ankle oedema. The Physician's Study Group.
Topics: Adolescent; Adult; Aged; Ankle; Blood Pressure; Double-Blind Method; Drug Tolerance; Edema; Enalapri | 1993 |
Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension.
Topics: Adult; Aged; Brachial Artery; Carotid Arteries; Double-Blind Method; Felodipine; Female; Hemodynamic | 1993 |
Antihypertensive effect and tolerability of felodipine extended release (ER) tablets in comparison with felodipine plain tablets (PT) and placebo in hypertensives on a diuretic. Canadian Study Group.
Topics: Adult; Aged; Blood Pressure; Body Weight; Canada; Delayed-Action Preparations; Double-Blind Method; | 1993 |
Effect of felodipine-ER on blood pressure, platelet function, and rheological properties in hypertension.
Topics: 6-Ketoprostaglandin F1 alpha; Blood Platelets; Blood Pressure; Blood Viscosity; Calcium; Cyclic AMP; | 1993 |
A multicenter comparison of isradipine and felodipine in the treatment of mild-to-moderate hypertension. The Physician's Study Group.
Topics: Adult; Ankle; Double-Blind Method; Drug Therapy, Combination; Edema; Enalapril; Felodipine; Female; | 1993 |
The role of atrial natriuretic peptide in the diuretic effect of Ca2+ entry blockers.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Calcium Channel Blockers; Diure | 1993 |
Office and ambulatory blood pressure: a comparison between amlodipine and felodipine ER. Danish Multicentre Group.
Topics: Adult; Aged; Amlodipine; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Delayed-Ac | 1995 |
[Initial results of the HOT-study in Switzerland (hypertension optimal treatment)].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1995 |
Effects of felodipine, metoprolol and their combination on blood pressure at rest and during exercise and on volume regulatory hormones in hypertensive patients.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Double-Blind Method; Drug Thera | 1995 |
Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Calcium Channel Blockers; Dela | 1995 |
Effect of dose on trough peak ratio of antihypertensive drugs in elderly hypertensive males.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cross-Over | 1995 |
Twenty-four-hour blood pressure monitoring during treatment with extended-release felodipine versus slow-release nifedipine: cross-over study.
Topics: Adolescent; Adult; Aged; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cross-Over | 1995 |
Felodipine as an alternative to more expensive calcium antagonists in mild to moderate hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diltiazem; Drug Costs; Felo | 1996 |
Clinical equivalence of two tablet formulations of felodipine. A placebo-controlled study of 24-hour blood pressure control and tolerability.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Chemistry, Pharmaceutical; Cro | 1995 |
Twenty-four-hour antihypertensive efficacy of felodipine 10 mg extended-release: the Italian inter-university study.
Topics: Adult; Aged; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cross-Over Studies; De | 1996 |
Antihypertensive drugs and glucose metabolism: a comparison between a diuretic and felodipine, a new calcium antagonist, when added to a beta-blocker in non-diabetic hypertensive women.
Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Cross-Over Studies; Diuretics; Drug The | 1994 |
A study of the efficacy of felodipine given once or twice daily in the management of elderly hypertensive patients.
Topics: Aged; Aged, 80 and over; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Felo | 1996 |
Felodipine or hydrochlorothiazide/triamterene for treatment of hypertension in the elderly: effects on blood pressure, hypertensive heart disease, metabolic and hormonal parameters.
Topics: Aged; Aged, 80 and over; Blood Pressure; Calcium Channel Blockers; Diuretics; Double-Blind Method; D | 1996 |
Hypertension optimal treatment: the Israeli HOT Study Group. Hypertension Optimal Treatment.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Therapy, Co | 1996 |
The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Drug Administration Schedule; Felodipine; Female; H | 1996 |
Left ventricular hypertrophy and QT dispersion in hypertension.
Topics: Adult; Antihypertensive Agents; Echocardiography; Electrocardiography; Felodipine; Female; Hemodynam | 1996 |
[Multicenter comparative study of felodipine-ER and nifedipine-OROS in the treatment of mild-to-moderate arterial hypertension].
Topics: Adult; Aged; Analysis of Variance; Chi-Square Distribution; Drug Tolerance; Felodipine; Female; Hear | 1996 |
Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life.
Topics: Aged; Aged, 80 and over; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Felodipine; | 1996 |
Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy.
Topics: Adult; Aged; Antihypertensive Agents; Calcium Channel Blockers; Double-Blind Method; Drug Therapy, C | 1996 |
Calcium antagonists, a useful additional therapy in treatment resistant hypertension: comparison of felodipine ER and nifedipine Retard by 24-h ambulatory blood pressure monitoring.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Double | 1997 |
Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Delayed-Action Preparations | 1997 |
Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Ca | 1997 |
[Felodipine in the treatment of essential arterial hypertension in elderly patients].
Topics: Aged; Aged, 80 and over; Blood Pressure; Calcium Channel Blockers; Felodipine; Female; Heart Rate; H | 1996 |
Blood pressure reduction and tolerability of felodipine ER in older and younger hypertensive patients. The Felodipine ER in the Elderly versus Young Working Group.
Topics: Adult; Aged; Calcium Channel Blockers; Double-Blind Method; Drug Tolerance; Felodipine; Heart Rate; | 1997 |
Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Calcium Channel Blockers; Felodipine; Female; Hu | 1997 |
Rest and effort hemodynamic responses during prolonged treatment with felodipine, 24-h blood pressure monitoring, and echocardiographic changes.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Echoca | 1997 |
The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium Channel Blockers; Cardiovascular Dis | 1997 |
Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients.
Topics: Adult; Amlodipine; Antihypertensive Agents; Area Under Curve; Blood Pressure; Cross-Over Studies; De | 1997 |
Twenty-four-hour blood pressure monitoring during treatment with extended-release felodipine versus slow-release nifedipine in elderly patients with mild to moderate hypertension: a randomized, double-blind, cross-over study.
Topics: Aged; Aged, 80 and over; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bloc | 1997 |
[Long-term clinical tolerance of antihypertensive treatment during the HOT study. Groupe français de l'etude HOT].
Topics: Antihypertensive Agents; Aspirin; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; | 1997 |
[New therapeutic principle in the management of hypertension].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calc | 1996 |
[The Hypertension Optimal Treatment (HOT) study: results of 12-month therapy related to age].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 1998 |
Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study.
Topics: Affect; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Ankle; Blood Pressure; Ca | 1997 |
Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bloc | 1998 |
Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group.
Topics: Aged; Aged, 80 and over; Delayed-Action Preparations; Diuretics; Double-Blind Method; Drug Administr | 1998 |
Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium | 1998 |
A comparison of the antihypertensive efficacy and safety of felodipine IV and nifedipine IV in patients with hypertensive crisis or emergency not responding to oral nifedipine.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Emergencies; Fel | 1998 |
Significance of blood pressure levels achieved with felodipine anti-hypertensive treatment on cardiovascular structure and function changes.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Echocardiography; Felodipin | 1998 |
Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
Topics: Adolescent; Adult; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Calcium Channel Bloc | 1998 |
Effects of felodipine ER, a dihydropyridine calcium antagonist, on blood pressure and serum lipids.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Felodipine; Female; | 1998 |
A comparison of nisoldipine coat-core and felodipine in the treatment of mild-to-moderate hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Edema; Felodipine; Female; Humans; Hypert | 1998 |
[The Hypertension Optimal Treatment Study: efficacy and tolerability on the 36th month].
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Felodipine; Female | 1998 |
Do intensive blood pressure lowering and low-dose ASA help our hypertensive patients?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1998 |
Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group.
Topics: Aged; Amlodipine; Antihypertensive Agents; Delayed-Action Preparations; Dizziness; Double-Blind Meth | 1998 |
Improved efficacy with maintained tolerability in the treatment of primary hypertension. Comparison between the felodipine-metoprolol combination tablet and monotherapy with enalapril. Swedish Multicentre Group.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium | 1999 |
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
Effects of combination antihypertensive therapy on baroreflex sensitivity and heart rate variability in systemic hypertension.
Topics: Aged; Antihypertensive Agents; Baroreflex; Blood Pressure; Double-Blind Method; Drug Therapy, Combin | 1999 |
Combination therapy with felodipine and metoprolol compared with captopril and hydrochlorothiazide. German MC Study Group.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Captopril; Double-Blind Method; Drug Therapy, Com | 1998 |
[Effects of plendil on serum oxygen free radicals and insulin resistance in patients with essential hypertension].
Topics: Calcium Channel Blockers; Delayed-Action Preparations; Felodipine; Female; Humans; Hypertension; Ins | 1998 |
The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
[Lowering of diastolic blood pressure < or = 90 mmHg should not be attempted, except in type 2 diabetics; the 'Hypertension optimal treatment' (HOT) trial].
Topics: Adult; Aged; Aspirin; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Me | 1999 |
Comparison of verapamil versus felodipine on heart rate variability in hypertensive patients.
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Delayed-Action Preparations; Felodipine; Female; Hea | 1999 |
Comparison of two strategies for intensifying antihypertensive treatment: low-dose combination (enalapril + felodipine ER) versus increased dose of monotherapy (enalapril). LEVEL (Lexxel vs Enalapril) Study Group.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Dose-Respo | 1999 |
Comparison of clinical efficacy and adverse effects between extended-release felodipine and slow-release diltiazem in patients with isolated systolic hypertension.
Topics: Adult; Aged; Calcium Channel Blockers; Diltiazem; Felodipine; Female; Humans; Hypertension; Male; Mi | 1999 |
Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension. Lorraine General Physician Investigators Group.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug The | 1999 |
Comparison of antihypertensive efficacy and tolerability of losartan and extended-release felodipine in patients with mild to moderate hypertension.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Delayed-Action Preparations; Felodipine; | 1999 |
[Effect of intensive antihypertensive treatment and of aspirin in a low dose in the hypertensive. The HOT (Hypertension Optimal Treatment) study].
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Dose-Response Relationship, Drug; Double- | 1999 |
Felodipine-metoprolol combination tablet: a valuable option to initiate antihypertensive therapy?
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood P | 1999 |
Cross-over comparison of nifedipine Oros and felodipine extended release with blind 24 h ambulatory blood pressure assessments.
Topics: Adolescent; Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; | 1999 |
Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Body Mass Index; Calcium Chan | 1999 |
The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 1999 |
Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension.
Topics: Aged; Antihypertensive Agents; Chi-Square Distribution; Chlorthalidone; Drug Therapy, Combination; E | 1999 |
[A critical analysis of the Hypertension Optimal Treatment (HOT) Study (appeared in Lancet 1998; 351: 1755-1762)].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
Patterns of amlodipine and felodipine use in an elderly Quebec population.
Topics: Aged; Amlodipine; Antihypertensive Agents; Felodipine; Female; Humans; Hypertension; Male; Patient C | 2000 |
A randomized prospective crossover trial of amlodipine in pediatric hypertension.
Topics: Adolescent; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulato | 2000 |
The effect of lowering blood pressure on quality of life.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug | 2000 |
[Effectiveness of felodipine in hypertensive patients with mild cerebral cognition disorders in a randomized double-blind study].
Topics: Aged; Amiloride; Blood Viscosity; Brain; Cognition Disorders; Dementia; Double-Blind Method; Drug Th | 2000 |
[Cognition disorders and dementia--new end-organ damage in hypertension].
Topics: Aged; Amiloride; Cognition Disorders; Dementia; Double-Blind Method; Felodipine; Humans; Hydrochloro | 2000 |
Comparison of the effects of felodipine and cilazapril on exercise performance in patients with mild to moderate hypertension. A crossover study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cilazap | 2000 |
Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydrop | 2000 |
The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Cross-Over Studies; Delayed-Action | 2000 |
Less difference between office and ambulatory blood pressure in women than in men both before and during antihypertensive treatment.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Blood Pressure Monitoring, | 2000 |
Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug Ther | 2001 |
Reduction in diastolic blood pressure and cardiovascular mortality in nondiabetic hypertensive patients. A reanalysis of the HOT study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetic | 2001 |
One-year study of felodipine or placebo for stage 1 isolated systolic hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Echocardiography; Felodipine; Fe | 2001 |
[Prospects of use of the combined preparation logimax in patients with essential hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Calcium Channel Blockers; Delayed | 2002 |
A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2002 |
Once daily felodipine monotherapy in mild to moderate hypertension.
Topics: Adult; Aged; Blood Pressure; Felodipine; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged | 1992 |
Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group.
Topics: Adult; Aged; Aging; Blood Pressure; Delayed-Action Preparations; Dipeptides; Felodipine; Female; Hum | 1992 |
Felodipine pharmacokinetics and plasma concentration vs effect relationships.
Topics: Absorption; Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Biological Availabili | 1992 |
Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.
Topics: Angina Pectoris; Cardiomegaly; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Interact | 1992 |
[The Hypertension Optimal Treatment Study. Background information].
Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Drug Therapy, Combination; Felodipine; Female | 1992 |
Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy.
Topics: Adult; Aged; Analysis of Variance; Cardiomegaly; Double-Blind Method; Drug Therapy, Combination; Fel | 1992 |
Regression of left ventricular hypertrophy during long-term antihypertensive treatment--a comparison between felodipine and the combination of felodipine and metoprolol.
Topics: Adult; Analysis of Variance; Blood Pressure; Cardiomegaly; Double-Blind Method; Drug Therapy, Combin | 1992 |
Twenty-four hour blood pressure profiles in hypertensive patients following various formulations and dosage regimens of felodipine.
Topics: Aged; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule | 1992 |
Comparison and interaction of low dose felodipine and enalapril in the treatment of essential hypertension in elderly subjects.
Topics: Aged; Aging; Blood Pressure; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Dru | 1992 |
Hemodynamic comparisons of enalapril and felodipine and their combination.
Topics: Aged; Blood Pressure; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Enalapril; | 1992 |
Interaction of citrus juices with felodipine and nifedipine.
Topics: Biological Availability; Blood Pressure; Citrus; Drug Interactions; Evaluation Studies as Topic; Fel | 1991 |
Felodipine in combination with a beta-adrenoceptor blocker as an effective substitute for triple therapy in severe hypertension. The Australian Felodipine Multicentre Study Group.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Drug Therapy, Combination; Drug Tolerance; Fel | 1991 |
Plasma concentration-effect relationships of intravenous and extended-release oral felodipine in hypertensive patients.
Topics: Adult; Aged; Biological Availability; Blood Pressure; Delayed-Action Preparations; Double-Blind Meth | 1990 |
Felodipine-ER once daily as monotherapy in hypertension.
Topics: Administration, Oral; Aged; Delayed-Action Preparations; Diastole; Dose-Response Relationship, Drug; | 1990 |
Long-term treatment of hypertension with felodipine.
Topics: Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Felodipine; Heart Rate; Humans; Hype | 1990 |
Felodipine in type II diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Felodipine; Female; Glucose Tol | 1990 |
Felodipine does not affect plasma lipoprotein concentrations. Swedish MC Study Group.
Topics: Adult; Cholesterol; Double-Blind Method; Felodipine; Humans; Hypertension; Lipoproteins; Randomized | 1990 |
The efficacy of different felodipine formulations: a comparison using 24-h blood pressure monitoring.
Topics: Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Felodipine; Female; Humans; Hypert | 1990 |
Felodipine monotherapy vs. placebo: a dose-response study in hypertension. Binational MC Study Group in U.K. and Holland.
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Felodipine; Humans; Hypertension; Mid | 1990 |
Optimal felodipine dose when combined with metoprolol in arterial hypertension: a Swedish multicenter study within primary health care. Swedish General Practitioner Felodipine Study Group.
Topics: Adult; Aged; Blood Pressure; Body Weight; Delayed-Action Preparations; Double-Blind Method; Drug The | 1990 |
Felodipine extended-release tablets once daily are equivalent to plain tablets twice daily in treating hypertension. Dutch Hospital Multicentre Group.
Topics: Adult; Aged; Blood Pressure; Body Weight; Delayed-Action Preparations; Felodipine; Female; Heart Rat | 1990 |
Antihypertensive effects of felodipine once daily given as monotherapy to elderly patients: a placebo comparison. Binational MC Study Group (U.K. and Holland).
Topics: Aged; Aged, 80 and over; Blood Pressure; Felodipine; Humans; Hypertension; Middle Aged | 1990 |
A comparison of felodipine and nitrendipine in the treatment of hypertension.
Topics: Blood Pressure; Double-Blind Method; Felodipine; Heart Rate; Humans; Hypertension; Nitrendipine; Ran | 1990 |
Felodipine is more effective than hydrochlorothiazide when added to a beta-blocker in treating elderly hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Body Weight; Double-Blind Method; Drug Therapy, C | 1990 |
Comparison of felodipine and hydrochlorothiazide for the treatment of mild to moderate hypertension in black Africans.
Topics: Adult; Africa; Black People; Blood Pressure; Double-Blind Method; Felodipine; Female; Heart Rate; Hu | 1990 |
Comparison of felodipine with nifedipine as additions to metoprolol in the treatment of hypertension. U.K. Multicentre Hospital Group.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Felodipine; Heart Rate; | 1990 |
Antihypertensive efficacy and tolerability of a fixed combination of metoprolol and felodipine in comparison with the individual substances in monotherapy. The Swedish/United Kingdom Study Group.
Topics: Adult; Aged; Blood Pressure; Body Weight; Double-Blind Method; Drug Therapy, Combination; Electrocar | 1990 |
Beta-adrenergic receptors and reflex tachycardia after single and repeated felodipine administration in essential hypertension.
Topics: Adult; Blood Pressure; Catecholamines; Down-Regulation; Drug Administration Schedule; Felodipine; Fe | 1991 |
Catecholamines and the renin-angiotensin-aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Catecholamines; Delayed-Action Preparations; Double-Blind | 1991 |
Comparison of once daily felodipine 10 mg ER and hydrochlorothiazide 25 mg in the treatment of mild to moderate hypertension.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; | 1991 |
Felodipine: a new dihydropyridine calcium-channel antagonist.
Topics: Angina Pectoris; Animals; Blood Pressure; Double-Blind Method; Felodipine; Heart Failure; Humans; Hy | 1991 |
Response of patients to enalapril, felodipine and their combination.
Topics: Aged; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Enalapril; Felodipine; Female; | 1991 |
Pharmacokinetics of felodipine in chronic hemodialysis patients.
Topics: Administration, Oral; Aged; Blood Pressure; Felodipine; Female; Half-Life; Humans; Hypertension; Inj | 1991 |
The efficacy and tolerability of long-term felodipine treatment in hypertension. The Scandinavian Multicenter Group.
Topics: Adrenergic beta-Antagonists; Adult; Ankle; Blood Pressure; Body Weight; Double-Blind Method; Drug Ad | 1990 |
Felodipine extended release in mild to moderate hypertension.
Topics: Adult; Aged; Delayed-Action Preparations; Double-Blind Method; Felodipine; Female; Heart Rate; Human | 1991 |
Extended release felodipine in essential hypertension. Variations in blood pressure during whole-day continuous ambulatory recording.
Topics: Adult; Blood Pressure; Blood Pressure Determination; Delayed-Action Preparations; Exercise; Felodipi | 1991 |
Felodipine in the treatment of hypertensive type II diabetics: effect on glucose homeostasis.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Metho | 1991 |
Felodipine once daily in elderly hypertensives. Binational MC Study Group (United Kingdom and Netherlands).
Topics: Aged; Aging; Blood Pressure; Delayed-Action Preparations; Felodipine; Humans; Hypertension | 1991 |
Effects of felodipine ER and hydrochlorothiazide on blood rheology in essential hypertension--a randomized, double-blind, crossover study.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combina | 1991 |
Aspects of quality of life on treatment with felodipine.
Topics: Adult; Aged; Analysis of Variance; Dose-Response Relationship, Drug; Double-Blind Method; Drug Thera | 1991 |
Hemodynamic interactions between diuretics and calcium antagonists in the treatment of hypertensive patients.
Topics: Adult; Diuretics; Drug Interactions; Drug Therapy, Combination; Felodipine; Female; Hemodynamics; Hu | 1990 |
Effects of felodipine on atrial natriuretic peptide in hypertensive non-insulin dependent diabetes mellitus.
Topics: Aged; Atrial Natriuretic Factor; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Felo | 1990 |
Felodipine as monotherapy in Asian patients with mild to moderate hypertension.
Topics: Adult; Aged; Asian People; Blood Pressure; Clinical Trials as Topic; Felodipine; Female; Heart Rate; | 1990 |
Effects of felodipine on urinary albumin excretion and metabolic control in hypertensive non-insulin-dependent diabetics.
Topics: Aged; Albuminuria; Blood Pressure; C-Peptide; Delayed-Action Preparations; Diabetes Mellitus, Type 2 | 1990 |
Antihypertensive drugs and glucose metabolism: comparison between a diuretic, a beta-blocker and felodipine, a new calcium antagonist in subjects with arterial hypertension and diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Double-Blind Method; Felodipine; Female; Glucose Tolerance T | 1990 |
Twenty-four hour profile of the hypotensive action of felodipine in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Circadian Rhythm; Double-Blind Method; Felodipine; Female; Heart Rate; | 1990 |
Control of blood pressure in hypertensive patients with felodipine extended release or nifedipine retard.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Drug Evaluation; Felo | 1990 |
Felodipine ER formulation in the treatment of mild hypertension: efficacy and tolerability vs placebo.
Topics: Adult; Aged; Blood Pressure; Dosage Forms; Drug Tolerance; Felodipine; Heart Rate; Humans; Hypertens | 1990 |
Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.
Topics: Adult; Biological Availability; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Fe | 1990 |
Antihypertensive effects and pharmacokinetics of felodipine combined with a beta-blocker and a diuretic.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind | 1987 |
Catecholamines, renin-angiotensin-aldosterone, and cardiovascular response during exercise following acute and long-term calcium antagonism with felodipine in essential hypertension.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Epinephrine; Felodipine; Heart | 1987 |
Monotherapy with felodipine, a new calcium antagonist, in mild and moderate hypertension.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Fel | 1987 |
Felodipine compared to prazosin as additional therapy to a beta-blocking drug.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Felodipine; Female; Humans; Hy | 1987 |
Antihypertensive effect of felodipine or hydralazine when added to beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Doub | 1988 |
A placebo-controlled dose-response study of felodipine extended release in hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Body Weight; Calcium Channel Blockers; Clinical Trials as Topic; Dose-R | 1989 |
A dose-finding, placebo-controlled study on extended-release felodipine once daily in treatment of hypertension.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Felodipine; Female; Heart Rate; Humans; Hy | 1989 |
[Treatment of essential hypertension with felodipine or atenolol as first line therapy. Comparative double-blind randomized study].
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Felodipine; Female | 1989 |
A trial of the calcium antagonist felodipine in hypertensive type 2 diabetic patients.
Topics: Apolipoproteins; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Creatinine; Diabetes Melli | 1989 |
Felodipine in elderly hypertensives. Dutch GP Multicentre Study Group.
Topics: Aged; Blood Pressure; Felodipine; Female; Heart Rate; Humans; Hypertension; Male; Random Allocation; | 1989 |
Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild-to-moderate hypertension.
Topics: Adult; Aged; Ambulatory Care; Analysis of Variance; Blood Pressure Determination; Delayed-Action Pre | 1989 |
A comparison of felodipine and nifedipine as monotherapies for the treatment of mild to moderate hypertension.
Topics: Adult; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Felodipine; Femal | 1989 |
Cardiovascular-risk reduction: initial diuretic therapy compared with calcium-antagonist (felodipine) therapy for primary hypertension.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Cholesterol; Clinica | 1989 |
Comparison of felodipine extended release and conventional tablets in essential hypertension using ambulatory blood pressure monitoring.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Met | 1989 |
Felodipine can replace minoxidil in the treatment of refractory hypertension.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Felodipine; Humans; Hypertension; Male; Middle | 1985 |
Antihypertensive effects of felodipine compared with placebo.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Diuretics; Drug T | 1985 |
Antihypertensive effect of felodipine combined with beta-blockade. A comparison between 2 and 3 daily dosages.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clin | 1985 |
Felodipine in comparison with prazosin in hypertensive patients inadequately controlled on beta-blockade.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Felodipine; Femal | 1985 |
Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension. Cooperative Study Group.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Felodipine; Female; Humans; Hydralazine; | 1986 |
Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials a | 1987 |
Felodipine versus hydrochlorothiazide as an addition to a beta-blocker in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Fel | 1987 |
Felodipine, a new calcium antagonist, as monotherapy in mild or moderate hypertension. Cooperative study group.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clinical Trials as T | 1987 |
Clinical evaluation of felodipine in hypertensive patients previously treated with a triple drug regimen.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Felodipine; Humans; | 1987 |
A dose-response study of felodipine in patients remaining hypertensive on a beta blocker. Canadian Felodipine Study Group.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Dose-Response Relati | 1987 |
Hormonal and blood pressure responses to tilting in beta-blocked essential hypertension treated with felodipine or prazosin.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Antihypertensive Agents; Blood Pressure; C | 1987 |
Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials a | 1987 |
Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Meth | 1988 |
Effects of the calcium antagonist felodipine on the sympathetic and renin-angiotensin-aldosterone systems in essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Catecholamines; Clinical Trials as Topic; Double-Bli | 1988 |
A double-blind comparison of felodipine and hydrochlorothiazide added to metoprolol to control hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dizziness; Double-Bl | 1988 |
A comparison of felodipine and propranolol as additions to hydrochlorothiazide in the treatment of hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1988 |
Glucose tolerance in hypertensive patients during treatment with the calcium antagonist, felodipine.
Topics: Blood Glucose; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Meth | 1987 |
Control of hypertension in elderly patients with felodipine and metoprolol: a double-blind, placebo-controlled clinical trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Felodi | 1987 |
The use of felodipine in the treatment of severe hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Electrocardi | 1987 |
Hypertension in the elderly. Its diagnosis in general practice and treatment with felodipine and metoprolol.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-B | 1987 |
Felodipine versus Moduretic. A double-blind parallel-group multicentre study.
Topics: Adult; Amiloride; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Me | 1987 |
Short and long term treatment of essential hypertension with felodipine as monotherapy.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Felodipine; Female; Humans | 1987 |
Felodipine monotherapy in systolic hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Felodipi | 1987 |
Comparison of antihypertensive effect and pharmacokinetics of conventional and extended release felodipine tablets in patients with arterial hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations; Felodipine; Female; Humans; Hy | 1987 |
Treatment of essential hypertension with felodipine in combination with a diuretic.
Topics: Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Diuretics; Double-Blind Method; | 1986 |
Felodipine, blood pressure, and cardiovascular reflexes in hypertensive humans.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Felodipine; Female; Heart Rate; Humans; Hypertension | 1986 |
Comparative trial of felodipine and nifedipine in refractory hypertension.
Topics: Aged; Ankle; Antihypertensive Agents; Blood Pressure; Body Weight; Calcium Channel Blockers; Clinica | 1985 |
Effects of felodipine on rest and exercise heart rate and blood pressure in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Bendroflumethiazide; Blood Pressure; Clinical Trials as Topic; Doubl | 1985 |
Felodipine in hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Felodipine; Female; Heart | 1985 |
Acute diuretic/natriuretic properties of felodipine in man.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Diuresis; Felodipine; Female; Heart Rate; Huma | 1985 |
159 other studies available for felodipine and Blood Pressure, High
| Article | Year |
|---|---|
Insights into Dissolution and Solution Chemistry of Multidrug Formulations of Antihypertensive Drugs.
Topics: Antihypertensive Agents; Chemistry, Pharmaceutical; Crystallization; Drug Combinations; Drug Compoun | 2020 |
Appraisal of Felodipine Nanocrystals for Solubility Enhancement and Pharmacodynamic Parameters on Cadmium Chloride Induced Hypertension in Rats.
Topics: Animals; Biological Availability; Cadmium Chloride; Felodipine; Hypertension; Nanoparticles; Particl | 2022 |
Influence of 3 calcium channel blockers on gingival overgrowth in a population of severe refractory hypertensive patients.
Topics: Adult; Aged; Amlodipine; Brazil; Calcium Channel Blockers; Felodipine; Female; Gingival Overgrowth; | 2018 |
Calcium Antagonists Use and Its Association with Lower Urinary Tract Symptoms: A Cross-Sectional Study.
Topics: Aged; Calcium Channel Blockers; Cross-Sectional Studies; Dihydropyridines; Felodipine; Female; Human | 2013 |
Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design.
Topics: Absorption; Administration, Oral; Angina, Unstable; Animals; Antihypertensive Agents; Cardiotonic Ag | 2014 |
Complications associated with End Stage Renal Disease.
Topics: Ceftazidime; Diabetes Mellitus, Type 2; Diabetic Foot; Diabetic Nephropathies; Diabetic Neuropathies | 2015 |
Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cohort Studies; Dihyd | 2017 |
[Efficacy of long acting calcium antagonist felodipine in smoking women with essential arterial hypertension].
Topics: Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Delayed-Action Preparations; Dose-Resp | 2008 |
[The use of felodipine in ambulatory practice: assessment of clinical efficacy and compliance in patients with arterial hypertension].
Topics: Ambulatory Care; Blood Pressure; Calcium Channel Blockers; Felodipine; Female; Follow-Up Studies; Hu | 2009 |
[Curative effects on mild to moderate primary hypertension and influence on pulse wave velocity of slow releasing felodipine].
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Felodipine; Heart Rate; Humans; Hypertensi | 2008 |
Felodipine-induced eruptive telangiectasia following mastectomy and radiotherapy.
Topics: Breast Neoplasms; Calcium Channel Blockers; Felodipine; Female; Humans; Hypertension; Mastectomy; Mi | 2010 |
Blockade of calcium channels and AT1 receptor prevents the hypertensive effect of calcilytic NPS 2143 in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Calcium Channel Blockers; Calcium | 2010 |
Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats.
Topics: Aldosterone; Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Felodipine; | 2010 |
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Calcium Channel Blockers; Carcinoma, He | 2011 |
[Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt].
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carbazoles; Carvedil | 2010 |
Effects of antihypertensive therapy on female sexual dysfunction: clinically meaningful?
Topics: Antihypertensive Agents; Biphenyl Compounds; Felodipine; Female; Humans; Hypertension; Metoprolol; O | 2012 |
The effect of transcutaneous electrical nerve stimulation on blood pressure.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Felodipine; Female; Humans; Hypertension; Male; T | 2013 |
Hypertension.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Felodipine; Female; Humans; Hypertension; Male; T | 2013 |
Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR.
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pr | 2002 |
[Dangerous duo: hypertension and pre-diabetes--the underestimated risk].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type | 2003 |
A comparative analysis of amlodipine and felodipine in a military outpatient population: efficacy, outcomes, and cost considerations.
Topics: Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; | 2003 |
Calcium channel blockers (felodipine) and pediatric essential hypertension.
Topics: Adolescent; Blood Pressure; Calcium Channel Blockers; Child; Child Welfare; Diastole; Dose-Response | 2003 |
Evaluation of a therapeutic conversion from amlodipine to felodipine.
Topics: Aged; Amlodipine; Blood Pressure; Data Collection; Drug Evaluation; Felodipine; Heart Rate; Humans; | 2003 |
[The effect and mechanism of felodipine and valsartan on a novel salt-sensitive hypertensive rat induced by sensory denervation].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Felodipine; Hypertension; Male; Rats; Rats, Wistar | 2005 |
Dihydropyridines, felodipine, and PHARMAC.
Topics: Angina Pectoris; Calcium Channel Blockers; Dihydropyridines; Drug Approval; Drug Industry; Felodipin | 2005 |
More heat to support aggressive blood pressure lowering: the FEVER study.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Felodipine; Humans; Hy | 2005 |
Hypertensive urgency.
Topics: Aged; Antihypertensive Agents; Blood Pressure Determination; Clonidine; Felodipine; Female; Humans; | 2006 |
CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blo | 2006 |
FEVER study: a trial further supporting the concept of a blood pressure-independent stroke protective effect by dihydropyridines.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Felodipine; Female; Heart Rate; Hum | 2006 |
The effect of ionizing radiation of 1,4-dihydropyridine derivatives in the solid state.
Topics: Calcium Channel Blockers; Dihydropyridines; Electron Spin Resonance Spectroscopy; Felodipine; Gamma | 2007 |
Comparison in vitro felodipine release rate from the original versus generic product with controlled release of the drug.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Czech Republic; Data Interpretation, Statistical; | 2007 |
Effects of extended-release felodipine on endothelial vasoactive substances in patients with essential hypertension.
Topics: Angiotensin II; Colorimetry; Delayed-Action Preparations; Endothelins; Endothelium, Vascular; Epopro | 2008 |
Felodipine, an arteriolar dilator with pronounced antihypertensive effect.
Topics: Antihypertensive Agents; Arterioles; Blood Pressure; Felodipine; Humans; Hypertension; Kidney; Male; | 1983 |
Regression of structural cardiovascular changes by antihypertensive therapy in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Cardiovascular System; Circadian Rhy | 1984 |
Short-term effects of felodipine, a new dihydropyridine, in hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Evaluation; Felodipi | 1984 |
Evidence that the increased calcium sensitivity of resistance vessels in spontaneously hypertensive rats is an intrinsic defect of their vascular smooth muscle.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium; Disease Models, Animal; Felodipine; Hyper | 1981 |
The effects of antihypertensive therapy on carotid vascular structure in man.
Topics: Adult; Aged; Carotid Arteries; Drug Therapy, Combination; Felodipine; Female; Humans; Hypertension; | 1995 |
Itraconazole interacts with felodipine.
Topics: Drug Interactions; Felodipine; Female; Humans; Hypertension; Itraconazole; Middle Aged | 1995 |
[Reducing hypertension may worsen symptoms of acute apoplexy].
Topics: Acute Disease; Aged; Cerebrovascular Disorders; Diltiazem; Felodipine; Humans; Hypertension; Male; R | 1995 |
Repeated measures for two within-subject factors: analysis and missing data solutions.
Topics: Algorithms; Analysis of Variance; Computer Simulation; Drug Therapy; Felodipine; Humans; Hypertensio | 1994 |
Altered levels of erythrocyte calcium-binding proteins in essential hypertensives with genetic predisposition: correlation with ambulatory blood pressure.
Topics: Aging; Ambulatory Care; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Cytos | 1994 |
Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension.
Topics: Calcium Channel Blockers; Drug Administration Schedule; Felodipine; Hemodynamics; Humans; Hypertensi | 1994 |
Time-dependent efficacy of antihypertensive agents in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Circadian Rhythm; Clonidine; Felodipine | 1993 |
Scintigraphic evaluation of the short- and long-term renal effects of oral felodipine using technetium-99m-mercaptoacetyl triglycine.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Felodipine; Female; Heart Rate; Humans; Hypertens | 1993 |
Felodipine therapy may not alter glucose and lipid metabolism in hypertensives. Felodipine Multicenter Prospective Study Group in Japan.
Topics: Analysis of Variance; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Blood Glucose; Blood P | 1994 |
Alterations in cytosolic calcium-binding proteins that increase felodipine fluorescence in spontaneously hypertensive rats.
Topics: Animals; Brain; Calcium-Binding Proteins; Cytosol; Electrophoresis, Polyacrylamide Gel; Felodipine; | 1993 |
Cerebral blood flow in patients with severe hypertension, and acute and chronic effects of felodipine.
Topics: Adult; Aged; Blood Pressure; Cerebrovascular Circulation; Felodipine; Female; Heart Rate; Humans; Hy | 1993 |
Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.
Topics: Adult; Amlodipine; Antihypertensive Agents; Benzeneacetamides; Carbazoles; Carvedilol; Diet, Sodium- | 1993 |
Short- and long-term effects of felodipine on circulating endothelin and atrial natriuretic peptide levels in essential hypertension.
Topics: Adult; Aged; Atrial Natriuretic Factor; Blood Pressure; Endothelins; Felodipine; Female; Humans; Hyp | 1993 |
Effect of felodipine on systemic hemodynamics of spontaneous mild-hypertensive aged rats.
Topics: Aging; Animals; Blood Pressure; Cardiac Output; Cerebrovascular Circulation; Felodipine; Female; Hem | 1995 |
Antihypertensive treatment in hypertensive patients with normal left ventricular mass is associated with left ventricular remodeling and improved diastolic function.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diastole; Echocardiography; Exercise Test; Felodi | 1996 |
Clinical outcome of a mandatory formulary switch for dihydropyridine calcium channel blocker therapy at a Veteran's Administration Medical Center.
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Connecticut; Felodipine; Female; Formularies, Hospit | 1996 |
Effects of antihypertensive therapy on platelet cytosolic calcium responses to low density lipoprotein cholesterol.
Topics: Aged; Aged, 80 and over; Blood Platelets; Calcium; Cholesterol, LDL; Cytosol; Diltiazem; Drug Therap | 1996 |
Felodipine in hypertensive heart transplant recipients.
Topics: Blood Pressure; Calcium Channel Blockers; Creatinine; Cyclosporine; Felodipine; Follow-Up Studies; H | 1996 |
Efficacy of low felodipine dose monotherapy in mild-to-moderate hypertension: a comparison between office and ambulatory blood pressure monitoring.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Ca | 1996 |
Felodipine in the treatment of severe refractory hypertension.
Topics: Adolescent; Adult; Aged; Blood Pressure; Calcium Channel Blockers; Diastole; Felodipine; Female; Hum | 1996 |
In vitro-in vivo correlation of pharmacodynamics of felodipine in essential hypertensive patients based on an ion-channel binding model.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Felodipine; Humans; Hypertension; Male; Nitrend | 1996 |
Effect of felodipine treatment and withdrawal on blood pressure and cardiovascular structure in New Zealand genetically hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Cardiovascular System; Felodipine; H | 1995 |
Overview of the safety of felodipine based on clinical trials in patients with hypertension.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular Disorders; Double-Blind Method; F | 1997 |
Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Blockers; Drug Th | 1997 |
Cardiovascular and renal effects of the combination of felodipine and metoprolol during a high-salt and a moderate-salt diet in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Calcium Channel Blockers; Drug Therapy, Combin | 1997 |
Felodipine use in pregnancy. Report of three cases.
Topics: Adult; Calcium Channel Blockers; Felodipine; Female; Follow-Up Studies; Humans; Hypertension; Infant | 1997 |
Verapamil accelerates the transition to heart failure in obese, hypertensive, female SHHF/Mcc-fa(cp) rats.
Topics: Animals; Blood Pressure; Brain; Calcium Channel Blockers; Felodipine; Female; Heart; Heart Failure; | 1997 |
Felodipine as monotherapy and associated with enalapril for essential hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Drug Th | 1997 |
Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pre | 1998 |
Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME.
Topics: Animals; Antihypertensive Agents; Arterioles; Drug Therapy, Combination; Enalapril; Enzyme Inhibitor | 1998 |
[Calcium antagonists and their impact on coronary risk].
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; | 1998 |
Truncal telangiectases coinciding with felodipine.
Topics: Aged; Back; Calcium Channel Blockers; Felodipine; Female; Humans; Hypertension; Skin Diseases; Telan | 1998 |
Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension.
Topics: Aged; Analysis of Variance; Blood Pressure; Blood Volume; Calcium Channel Blockers; Diastole; Felodi | 1998 |
Replacing short-acting nifedipine with alternative medications at a large health maintenance organization.
Topics: Aged; Calcium Channel Blockers; Cohort Studies; Delayed-Action Preparations; Drug Utilization; Felod | 1998 |
[Misleading interpretation of a study on blood pressure].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Felodipine; Humans; Hypertension; Randomized Cont | 1998 |
Hypertension Optimal Treatment (HOT) trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 1998 |
Hypertension Optimal Treatment (HOT) trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium | 1998 |
[New discoveries on target blood pressure and ACE inhibitors. Swedish guidelines on hypertension are still correct].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Bloc | 1998 |
Nitric oxide metabolism in erythropoietin-induced hypertension: effect of calcium channel blockade.
Topics: Animals; Blood Pressure; Blotting, Western; Calcium; Calcium Channel Blockers; Drug Interactions; Er | 1998 |
Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Cost-Benefit Analysis; Drug Combinations; Enalapril; Felodipin | 1998 |
Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Body Weight; Calc | 1999 |
Antihypertensive treatment and CHD in the elderly.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 1999 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
The effects of acute and chronic dihydropyridine calcium antagonist therapy on baroreflex sensitivity: a re-analysis using the sequence method.
Topics: Adult; Baroreflex; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; | 2000 |
Pumpkin-seed oil modulates the effect of felodipine and captopril in spontaneously hypertensive rats.
Topics: Animals; Antioxidants; Blood Pressure; Captopril; Cucurbitaceae; Dose-Response Relationship, Drug; F | 2000 |
The Hypertension Optimal Treatment Trial: a precursor for lowering the target blood pressure level.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Felodipine; Humans; Hype | 1999 |
Outcomes of an amlodipine-to-felodipine therapeutic interchange program.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chi-Square Distribution; Confidence Intervals; Felodipine | 2000 |
Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Diltiazem; Felodipine; Female; Humans; Hyperte | 2000 |
Stroke precipitated by moderate blood pressure reduction.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Emergency Treatment; Felodipine; Female; Humans; Hyp | 2000 |
Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy.
Topics: Adult; Antihypertensive Agents; Bendroflumethiazide; Blood Pressure; Cardiac Output; Echocardiograph | 2000 |
[Felodipine in hypertensive patients with mild encephalopathies].
Topics: Aged; Cognition Disorders; Dementia, Vascular; Double-Blind Method; Felodipine; Humans; Hypertension | 2001 |
Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Calcium Channel Bloc | 2001 |
Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism.
Topics: Adult; Blood Pressure; Case-Control Studies; Felodipine; Female; Hemodynamics; Hormone Replacement T | 2002 |
Treatment of hypertension induces a fall in platelet basal cytoplasmic calcium concentration without influencing platelet aggregation.
Topics: Adult; Aged; Basal Metabolism; Blood Platelets; Blood Pressure; Calcium; Cytoplasm; Drug Therapy, Co | 1992 |
[Antihypertensive effect of felodipine, a new calcium antagonist].
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Di | 1992 |
[Long-term antihypertensive therapy of diabetic patients with felodipine. Effects of treatment on blood pressure and kidney function parameters].
Topics: Blood Pressure; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Felodi | 1992 |
Effects of chronic felodipine treatment on renal function and morphology in SHR.
Topics: Animals; Blood Pressure; Creatinine; Drug Synergism; Felodipine; Female; Glomerulosclerosis, Focal S | 1992 |
Vascular selectivity of calcium antagonists: importance for the management of hypertension. Proceedings of the Third International Symposium on Felodipine. Rome, Italy, October 17-18, 1988.
Topics: Animals; Calcium Channel Blockers; Felodipine; Hemodynamics; Humans; Hypertension | 1990 |
Long-term effects of felodipine on blood pressure and renal hemodynamics in severe hypertension.
Topics: Adult; Aged; Blood Pressure; Felodipine; Female; Glomerular Filtration Rate; Humans; Hypertension; K | 1990 |
Felodipine safety evaluation: adverse event pattern.
Topics: Delayed-Action Preparations; Felodipine; Humans; Hypertension | 1990 |
Hemodynamic and long-term renal effects of felodipine in severely hypertensive patients.
Topics: Adult; Blood Pressure; Felodipine; Glomerular Filtration Rate; Hemodynamics; Humans; Hypertension; K | 1990 |
Chronic hemodynamic effects of tiapamil and felodipine in essential hypertension at rest and during exercise.
Topics: Adult; Blood Pressure; Blood Volume; Body Weight; Cardiac Output; Exercise; Felodipine; Heart Rate; | 1990 |
Hemodynamic effects of the vascular selective calcium antagonist felodipine in patients with impaired left ventricular function.
Topics: Coronary Disease; Felodipine; Heart Failure; Hemodynamics; Humans; Hypertension; Myocardial Contract | 1992 |
Efficacy of once-daily felodipine monotherapy in systemic hypertension.
Topics: Adult; Blood Pressure; Circadian Rhythm; Delayed-Action Preparations; Felodipine; Female; Heart Rate | 1992 |
[Long-term antihypertensive treatment in diabetes mellitus. Results with the calcium antagonist felodipine].
Topics: Adult; Aged; Blood Pressure; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Felodipine; Femal | 1991 |
Felodipine--another calcium-channel blocker for hypertension.
Topics: Drug Interactions; Felodipine; Humans; Hypertension | 1991 |
[Circadian pressure variability and pressure peaks during treatment of mild to moderate essential hypertension with felodipine].
Topics: Adult; Blood Pressure; Circadian Rhythm; Exercise; Exercise Test; Felodipine; Female; Humans; Hypert | 1990 |
The haemodynamic effects of long term felodipine therapy in previously untreated essential hypertension.
Topics: Adult; Aged; Blood Pressure; Cardiovascular System; Creatinine; Drug Administration Schedule; Felodi | 1990 |
Significance of coronary circulation in hypertensive heart disease for development and prevention of heart failure.
Topics: Adult; Animals; Cardiac Output, Low; Cardiomegaly; Coronary Circulation; Coronary Disease; Coronary | 1990 |
Reversal of cardiac hypertrophy and left ventricular function with the calcium antagonist felodipine in hypertensive patients.
Topics: Adult; Calcium; Cardiomegaly; Echocardiography; Felodipine; Female; Humans; Hypertension; Male; Midd | 1990 |
Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function.
Topics: Adult; Aged; Biological Availability; Blood Pressure; Felodipine; Female; Furosemide; Glomerular Fil | 1990 |
Felodipine in the treatment of patients with severe hypertension and impaired renal function.
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Felodipine | 1990 |
Central hemodynamics and 24-hour blood pressure in obstructive sleep apnea syndrome: effects of corrective surgery.
Topics: Adult; Ambulatory Care; Blood Pressure; Blood Pressure Monitors; Cardiac Output; Felodipine; Heart R | 1990 |
Effect of felodipine on resistance vessels from spontaneously hypertensive and normotensive rats.
Topics: Animals; Calcium; Felodipine; Hypertension; Muscle Contraction; Nifedipine; Norepinephrine; Rats; Ra | 1985 |
Enalapril in experimental hypertension and acute heart failure: comparison with calcium channel blockers.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; D | 1986 |
Discussion on the search for an ideal vasodilator: a hemodynamic perspective.
Topics: Antihypertensive Agents; Felodipine; Hemodynamics; Humans; Hypertension; Nitrendipine; Vascular Resi | 1987 |
Baroreflex control of heart rate and renin release in SHR following administration of felodipine, an antihypertensive Ca2+ antagonist.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Felodipine; Heart Rate; Hypertension; Metoprolol; | 1987 |
Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Diabetes Mellitus, Expe | 1987 |
Haemodynamic effects and pharmacokinetics of felodipine at rest and during exercise in hypertensive patients treated with metoprolol or atenolol.
Topics: Aged; Atenolol; Blood Pressure; Calcium Channel Blockers; Exercise; Exercise Test; Felodipine; Femal | 1989 |
Ethanol enhances the hemodynamic effects of felodipine.
Topics: Adult; Biological Availability; Blood Pressure; Drug Synergism; Ethanol; Felodipine; Heart Rate; Hem | 1989 |
Effect of felodipine on blood pressure and vascular reactivity in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Felodipine; Hypertension; Muscle Contraction; Mus | 1989 |
Effect of the calcium antagonists felodipine and nimodipine on cortical blood flow in the spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Cerebral Cortex; Felodipine; Homeostasis; Hydrogen; Hypertension; Male; Nim | 1989 |
Renal and antihypertensive effects of felodipine in hypertensive patients.
Topics: Adult; Blood Pressure; Diuresis; Felodipine; Female; Heart Rate; Humans; Hypertension; Kidney; Male; | 1985 |
Long term experience of felodipine in combination with beta-blockade and diuretics in refractory hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Alkaline Phosphatase; Antihypertensive Agents; Aspartate A | 1985 |
Felodipine in combination with a beta-blocker and a diuretic in chronic treatment of patients with refractory primary hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Therapy | 1987 |
Pharmacokinetics and haemodynamics of felodipine in hypertensive patients treated concomitantly with a beta-blocker.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Drug Therapy, Combination; Felodipine; H | 1987 |
Effects of felodipine on natriuresis, atrial natriuretic factor, the renin-angiotensin-aldosterone system, and blood pressure in essential hypertension.
Topics: Adult; Atrial Natriuretic Factor; Blood Pressure; Calcium Channel Blockers; Felodipine; Female; Huma | 1988 |
Effect of felodipine in refractory hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Felodipine; Female; Humans; Hypertension; Male; Midd | 1988 |
The effects of combining felodipine and metoprolol in moderate to severe hypertension--a one year study.
Topics: Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination; Felodipine; Female; Humans; Hyperte | 1988 |
Unchanged insulin secretion and glucose tolerance but increased insulin clearance during long-term calcium antagonism with felodipine in essential hypertension.
Topics: Adult; Blood Glucose; C-Peptide; Calcium Channel Blockers; Felodipine; Homeostasis; Humans; Hyperten | 1987 |
Glucoregulatory hormone response to insulin-induced hypoglycaemia following long-term calcium antagonism with felodipine in patients with essential hypertension.
Topics: Adult; Blood Glucose; Calcium Channel Blockers; Epinephrine; Felodipine; Glucagon; Growth Hormone; H | 1987 |
Effects of felodipine and metoprolol on blood pressure, plasma renin, angiotensin II, aldosterone and catecholamines in hypertensive patients.
Topics: Adult; Aldosterone; Angiotensin II; Antihypertensive Agents; Blood Pressure; Catecholamines; Electro | 1987 |
Baroreflex control of renin release in spontaneously hypertensive rats after administration of felodipine.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Felodipine; Hypertension; Male; Nitrendipine; Pres | 1987 |
Glucose tolerance and secretion and clearance of insulin during long term felodipine treatment.
Topics: Adult; Antihypertensive Agents; C-Peptide; Felodipine; Glucagon; Glucose Tolerance Test; Humans; Hyp | 1987 |
Calcium antagonism with felodipine in essential hypertension. Effects on cardiovascular and renal function, the sympathetic and the renin-angiotensin-aldosterone systems, glucose tolerance and glucoregulatory hormones.
Topics: Adult; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Exercise Test; Felodipine; Glucagon; | 1987 |
Influence of antihypertensive treatment on basal cerebral arteries in spontaneously hypertensive rats. A morphometric study.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cerebral Arteries; Drug Therapy, Combination; Felo | 1988 |
Renal effects of acute and long-term treatment with felodipine in essential hypertension.
Topics: Adult; Felodipine; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Nitr | 1988 |
Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects.
Topics: Adult; Age Factors; Aged; Blood Pressure; Felodipine; Female; Humans; Hypertension; Kidney; Liver; L | 1988 |
Felodipine monotherapy in hypertension.
Topics: Antihypertensive Agents; Felodipine; Humans; Hypertension; Nitrendipine | 1987 |
Clinical evaluation of felodipine in patients with refractory hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Drug Resistance; Felodipine; Female; Glomerula | 1987 |
Antihypertensive and biochemical effects of the dihydropyridine felodipine in the long term treatment of moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Chemical Analysis; Blood Pressure; Drug Ther | 1987 |
Pharmacokinetics and haemodynamics of felodipine as monotherapy in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Felodipine; Hemodynamics; Humans; Hypertension; Male | 1987 |
Effect of long term felodipine treatment on renal vascular tone, glomerular filtration rate and renal tubular function in essential hypertension.
Topics: Antihypertensive Agents; Felodipine; Glomerular Filtration Rate; Humans; Hypertension; Kidney Tubule | 1987 |
Renal effects of felodipine in hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Diuresis; Felodipine; Glomerular Filtration Rate; Humans; H | 1987 |
Structural and functional adaptations within the myocardium and coronary vessels after antihypertensive therapy in spontaneously hypertensive rats.
Topics: Animals; Coronary Circulation; Coronary Vessels; Felodipine; Hypertension; Metoprolol; Myocardium; N | 1986 |
Does sympathectomy or antihypertensive treatment affect the morphometry of basal cerebral arteries in spontaneously hypertensive rats?
Topics: Age Factors; Animals; Blood Pressure; Cerebral Arteries; Felodipine; Ganglia, Sympathetic; Hypertens | 1986 |
The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Antihypertensive Agents; Catecholamines; Felodipine; Heart Rate; | 1986 |
Acute haemodynamic and humoral responses to felodipine and metoprolol in mild hypertension.
Topics: Adult; Aldosterone; Antihypertensive Agents; Calcium Channel Blockers; Catecholamines; Drug Therapy, | 1987 |
The use of Doppler echocardiography to assess the acute haemodynamic response to felodipine and metoprolol in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Cardiac Output; Echocardiography; Felodipine; Hemodynamics; Humans; | 1987 |
The influence of antihypertensive treatment on the renal arterial structure in spontaneously hypertensive rats. A morphometric study.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Felodipine; Heart Rate; Hypertension; Male; Metopr | 1987 |
Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Felodipine; Heart Rate; Hemodynamics; Humans; | 1987 |
Influence of long-term antihypertensive therapy on cardiac function, coronary flow and myocardial oxygen consumption in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Coronary Circulation; Felodipine; Heart; Heart Rat | 1986 |
Felodipine compared to nifedipine as "third-line drug" in resistant hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Drug Evaluation; Drug Resistance; Felodipine; | 1986 |
Felodipine. A calcium-inhibiting vasodilator in refractory hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Felodipine; Female; | 1985 |
Effects of felodipine on resistance and capacitance vessels in patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Vessels; Electrocardiography; | 1985 |
Effect of felodipine and metoprolol on muscle and skin arteries in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Felodipine; Female; Heart Rate; Humans; Hypere | 1985 |
Haemodynamic effects of intravenous felodipine in normotensive and hypertensive subjects.
Topics: Adolescent; Adult; Antihypertensive Agents; Blood Pressure; Felodipine; Female; Heart Rate; Hemodyna | 1985 |
Felodipine as an alternative to minoxidil in severe refractory hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Drug Resistance; Felodipine; Humans; Hypertension; Male; Mi | 1985 |
Acute haemodynamic and platelet effects of felodipine in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Blood Coagulation; Blood Platelets; Blood Pressure; Felodipine; Fema | 1985 |
Effects of felodipine on renal function in animals.
Topics: Animals; Antihypertensive Agents; Dogs; Felodipine; Glomerular Filtration Rate; Hemodynamics; Hydral | 1985 |
Antihypertensive and water and sodium balance effects of felodipine, a new vasodilating calcium antagonist, in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Creatinine; Felodipine; Fe | 1985 |
Renal effects of felodipine in hypertensive patients with reduced renal function.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Felodipine; Female; Glomerular Filtration Rate | 1985 |
Haemodynamic effects of short and long term administration of felodipine in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Cardiac Output; Coronary Circulation; Drug Administration Schedule | 1985 |